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ABSTRACT 
 
This thesis summarizes an investigation of antimicrobial resistance (AMR) and 
antimicrobial use (AMU) in cow-calf herds. The specific objectives of this project were 
to describe common reasons for treatment and the types of antimicrobials used in cow-
calf herds, to describe the frequency of AMR in generic fecal Escherichia coli isolated 
from various age groups commonly found on cow-calf farms, to determine risk factors 
associated with the occurrence of AMR, and finally to investigate the underlying 
molecular mechanisms of AMR in cow-calf herds. At least 86% of the herds treated one 
or more calves or cows during the study period; however, the overall proportion of both 
calves and cows reported as treated was less than 14% for calves and 3% for cows.  The 
majority of antimicrobials reported as used in cow-calf operations were for individual 
therapeutic use rather than prophylaxis, metaphylaxis, or growth promotion. Injectable 
formulations were the most commonly reported method of antimicrobial administration 
on cow-calf farms. Cow-calf herds in Wetern Canada are not a significant reservoir for 
resistance to antimicrobials classified as very important to human medicine such as 
ciprofloxacin and ceftiofur. The three most common resistances detected were to 
tetracycline, sulphamethoxazole, and streptomycin regardless of age group. Young 
calves sampled in the spring of the year were more likely to be shedding AMR E. coli 
than older calves sampled in the fall of the year or than cows sampled in the spring of 
the year. The cow-calf pair relationship was not an important factor in transfer of AMR 
from the individual cow to her calf, but the presence of AMR in the general cow herd 
was associated with AMR in the calf population.  The potential importance of co-
selection for AMR at the molecular level was demonstrated by both the risk factor 
iv 
analysis and the molecular work. Phenotypic resistance to streptomycin, tetracycline, 
and sulphamethoxazole were each associated with the presence of resistance genes from 
all six families of antimicrobials examined in this study. Several statistically significant 
associations were also detected between the resistance genes considered. No significant 
associations were detected between any of the AMR phenotypes or genotypes and the 
STEC virulence factors stx1, stx2 and eae. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
 
Antimicrobial resistance (AMR) is a growing public health concern. The spread of 
AMR and the appearance of multiple antimicrobial resistant pathogenic bacteria have 
been recognized by the World Health Organization (WHO) as serious problems that can 
complicate medical treatment of bacterial infections (WHO, 2001). The increase in the 
number of antimicrobial resistant pathogens in human medicine has raised both public 
and scientific interest, and some of this concern has focussed on antimicrobial use 
(AMU) in livestock production.  
 
Most AMR in human pathogens is attributable to the selection pressure from AMU 
in people (Thompson, 2000). However, the volume of antimicrobials used in food 
animal production has led to concerns in the public, regulatory and scientific arenas that 
AMU in food animals could contribute to the AMR problem by creating a reservoir of 
resistant bacteria (Bailar and Travers, 2002, O’Connor et al., 2002; Schroeder et al., 
2002). For human health, the transfer of such resistance to zoonotic enteropathogens is 
of primary interest, but the transfer of resistance to animal pathogens and the associated 
subsequent loss of therapeutic options for veterinary medicine is also an important 
concern.  
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At this time, AMR is not a major clinical problem in veterinary medicine in Canada; 
however, the impact of AMR in human medicine and the occurrence of AMR as a 
veterinary problem in other parts of the world indicate that this is a real possibility 
(McEwen, 2002). The use of antimicrobial drugs in animal agriculture is essential for 
maintaining and improving animal health and welfare through disease treatment, 
increasing carcass quality, and enhancing the economic efficiency of growth and 
production. If the livestock industry loses efficacious antimicrobials because of 
resistance development or limited access because of tighter regulations, the 
consequences and costs to the industry would be substantial.  
 
1.2 Investigative approach 
 
Although there is a growing amount of literature on AMR, no information is 
currently available regarding AMR or AMU in cow-calf herds in western Canada. The 
cow-calf industry is a vital and important part of the agricultural economy in all parts of 
Canada, but particularly in Saskatchewan and Alberta. These two provinces are home to 
more than 65% of the beef cow, breeding heifer and calf populations in Canada 
(Statistics Canada, Accessed July 25, 2006; 
http://www.40.statcan.ca/101/cst01/prim50a.htm). A better understanding of AMR and 
AMU patterns in this population is essential to develop a baseline of data to determine 
the need for future monitoring in the Canadian cow-calf industry. 
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This investigation was undertaken to provide initial data on AMR and AMU in cow-
calf herds in order to describe common reasons for treatment and the types of 
antimicrobials used on cow-calf farms, to describe the amount of AMR in various age 
groups commonly found on cow-calf farms, to determine risk factors associated with 
AMR development, and finally to investigate the underlying molecular mechanisms of 
AMR in cow-calf herds. 
 
This project represented a collaborative research initiative undertaken to address the 
presence of and risk factors for AMR in western Canadian cow-calf herds. The Western 
College of Veterinary Medicine, the Public Health Agency of Canada, and Alberta 
Agriculture worked together to address this important question. The primary hypothesis 
of this dissertation was that AMR in fecal generic Escherichia coli isolates collected 
from cow-calf herds would be relatively less prevalent than from other food-animal 
species because these animals are extensively managed as compared with most other 
livestock commodities. A secondary hypothesis was that although use and resistance 
would likely be associated with each other, routine AMU would be relatively 
uncommon in most cow-calf operations. The final hypothesis examined in this study 
was that the statistical associations between AMR genes present in the E.coli isolates 
would likely support evidence of co-selection of unrelated resistance genes and 
virulence factors of interest. 
 
The specific objectives of this investigation were; 
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1. To describe the frequency of treatment with antimicrobials, common reasons for 
AMU, and the types of antimicrobials used in western Canadian cow-calf herds. 
2. To describe AMR in calves from western Canadian cow-calf herds in the spring 
and fall of 2002 using commensal E. coli as an indicator organism. 
3. To describe AMR in cows and cow-calf pairs from western Canadian beef herds 
in the spring using commensal E. coli as an indicator organism. 
4. To investigate farm level management practices associated with AMR in 
commensal E. coli isolates collected from calves during the 2002 calving season 
on beef herds in western Canada. 
5. To measure the associations between antimicrobial resistant phenotypes and 
resistance genes in commensal E. coli isolates obtained from cattle in cow-calf 
herds to understand the potential for co-selection and genetic linkages.  
6. To describe the associations between genetic determinants of antimicrobial 
resistance in commensal E. coli isolates obtained from cattle in cow-calf herds 
to understand the potential for coselection and genetic linkages.  
7. To investigate whether either AMR phenotype or genotype are associated with 
the presence of the virulence genes stx1, stx2 and eae in commensal E. coli 
isolates from cattle in cow-calf herds.  
 
The participating cow-calf producers from across Alberta and Saskatchewan were 
also involved in a multifaceted survey of risk factors affecting cattle productivity and 
health. Private veterinary clinics were approached and asked to participate. Within each 
practice herds were identified and enrolled based on selection criteria which considered 
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factors such as herd size, animal identification, existing calving records, animal 
handling facilities sufficient for pregnancy testing and bull evaluation, and a 
relationship with a local veterinary clinic. Only herds using a winter/spring calving 
season were enrolled in the study. Participating herds were visited regularly by one of 
six study veterinarians to collect samples and data, and to monitor the quality and 
consistency of on-farm records. Data on AMU were collected using both individual 
animal treatment records and a standardized questionnaire. 
 
In a first step of this study (Chapter 2), the literature on AMR and AMU were 
reviewed and gaps in the existing literature were identified as they relate to the 
objectives of this thesis. Reported reasons for antimicrobial treatment and potential risk 
factors for treatment in both cows and calves were examined in Chapter 3. The 
prevalence of AMR and the importance of individual animal determinants of AMR 
status was then described in Chapters 4 and 5 by investigating the extent of AMR in 
young calves, calves at weaning, and cows. The role of the cow-calf pair relationship in 
the transfer of resistance was also explored in Chapter 5. In Chapter 6, the importance 
of herd-level risk factors associated with AMR in calves born and sampled in the spring 
of 2002 was investigated. The molecular aspects of AMR were then considered in a 
sub-set of isolates. The association between AMR phenotype and genotype was initially 
assessed (Chapter 7) and then the relationship between AMR genes was examined 
(Chapter 8). The genetic aspect of this project provided an opportunity to explore the 
potential for co-selection of AMR determinants in these isolates. As a final part of the 
molecular investigation, Chapter 9 examined the virulence factors stx1, stx2 and eae and 
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their relationship to either the AMR phenotype or genotype because of the potential 
public health impact. Finally, Chapter 10 summarizes the new information generated by 
and the limitations of this field study, it also provides suggestions for further research.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Introduction 
 
Antimicrobial resistance (AMR) is an important issue facing both human and 
veterinary medicine. The primary concern in veterinary medicine is not treatment 
failure as a result of AMR, but that the use of antimicrobials in food animal production 
could promote the development of resistance in people. The debate about the role of 
agriculture in the distribution and magnitude of AMR in people has been on going since 
before the release of the Swann report in 1969 (Prescott, 2000).  
 
There is a tremendous amount of literature on AMR and antimicrobial use (AMU) in 
both human and veterinary medicine. This is not intended to be an exhaustive review of 
these subjects, but rather to provide readers that are not intimately involved in this area 
of research with sufficient background to understand the following thesis and to 
recognize that AMR is a complex issue which still requires more research. The issues 
summarized included: detection methods for AMR, how AMR is transferred, how some 
key antimicrobials exert their effect and how bacteria combat these antimicrobials, 
AMR and virulence factors, the challenges of collecting and reporting AMU 
information, and AMU/AMR in livestock with a particular focus on the beef cattle 
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industry. The review will focus on AMR in fecal Escherichia coli (E.coli) in cattle 
unless otherwise stated.  
 
Standard search engines such as Agricola, CAB abstracts, and Ovid MEDLINE as 
well as non-scientific search engines including ‘google’ were used for literature 
searches. Search terms included, but were not limited to, combinations of: 
antimicrobial, antibiotic, use, exposure, treatment, susceptibility, resistance, Escherichia 
coli, bovine, cattle, cow-calf, herd, and farm. Cited references were examined for 
additional resources. An English language restriction was used.  
 
2.2. Antimicrobial resistance (AMR)  
 
Antimicrobial resistance is a form of natural selection and is an expected 
phenomenon (McDermott et al., 2002). Resistant micro-organisms were present long 
before the introduction of antimicrobials, and resistance was probably a defense 
mechanism used by antibiotic-producing organisms to protect themselves (Smith, 1967, 
Dancer et al., 1997). Therefore in the presence of an antimicrobial, the bacteria that 
possess an effective resistance trait will survive and those that do not will be eliminated. 
In an environment with long-term antimicrobial exposure, the proportion of resistant 
bacteria will increase over time (McDermott et al., 2002).  
 
Levy (1998) described five basic principles of AMR. First, given sufficient time and 
use of an antimicrobial, resistance will develop in a susceptible organism. Resistant 
organisms have been identified for all types of antimicrobials. Second, AMR is 
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progressive and can be monitored by studying changes in minimum inhibitory 
concentrations. Third, bacteria resistant to one antimicrobial are more apt to become 
resistant to others. Fourth, once resistance appears, it is likely to decline slowly, if at all. 
Fifth, the use of antimicrobials in one individual affects others in the surrounding 
environment.  
 
2.2.1. Definitions 
 
To ensure clarity, definitions of the key terminology used throughout this project 
have been provided. An antibiotic is a substance that is produced by a microorganism 
and at low concentrations inhibits or kills other microorganisms (Prescott, 2000, 
Guardabassi and Courvalin, 2006). An antimicrobial includes any substance of natural, 
semisynthethic, or synthethetic origin that kills or inhibits the growth of a 
microorganism, but causes little or no damage to the host (Prescott, 2000, Guardabassi 
and Courvalin, 2006). Although the two terms differ in their precise definition, 
antimicrobial is often used synonymously with antibiotic (Prescott, 2000). 
Antimicrobial was the term used throughout this thesis.  
 
Resistance can be a result of an intrinsic mechanism that prevents the bacteria from 
being destroyed by an antimicrobial, or it can be acquired through chromosomal 
mutation or the exchange of genetic material. Bacteria that are intrinsically resistant 
lack the structural or functional cellular mechanisms that are required for the 
antimicrobial to act (Prescott, 2000, Guardabassi and Courvalin, 2006). Intrinsic 
resistance is a genus or species specific property of bacteria (Schwarz et al., 2006). 
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Acquired resistance can develop and be transferred in susceptible organisms as a result 
of mutation, horizontal acquisition of foreign genetic material, or a combination of these 
processes (Catry et al., 2003, Guardabassi and Courvalin, 2006). The focus of this 
review and thesis is on acquired resistance. Additional information on the mechanisms 
of acquired resistance development and spread are provided later on in this review. 
 
2.3. Susceptibility testing 
 
Susceptibility testing is used to guide therapy and to generate surveillance data (Potz 
et al., 2004). Susceptibility is determined by growth inhibition and not the killing of 
bacterium (Walker, 2000). The results can be reported quantitatively or qualitatively. 
Qualitative results are reported as susceptible, intermediate, or resistant, while 
quantitative results provide a minimum inhibitory concentration (MIC) in µg/ml or 
mg/ml. The MIC is defined as the lowest concentration of drug required to inhibit 
growth of an organism using a standardized test (Jorgensen, 2004) and can be 
monitored to determine if a population is shifting towards increasing resistance 
(Walker, 2000).  
 
Practitioners often require a clinically relevant category derived from applying 
interpretative breakpoints to the MIC information (Craig, 1993, MacGowan and Wise, 
2001). Interpretive breakpoints allow for susceptible, intermediate, and resistant 
categorization of isolates. The break point for susceptibility is the recommended dosage 
of an antimicrobial that inhibits the bacterium’s growth (Walker, 2000). Breakpoints for 
resistance represent concentrations that cannot be achieved by normal dosing, and 
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intermediate breakpoints are those which fall between susceptible and resistant (Walker, 
2000).  
 
Laboratory assessment of susceptibility and resistance is not necessarily equivalent 
to clinical susceptibility and resistance. Clinically (or in vivo) a strain is considered 
resistant if it survives therapy (Guardabassi and Courvalin, 2006). Clinical resistance 
can vary depending on the dosage, mode of drug administration, distribution of the 
drug, and the immune status of the patient (Guardabassi and Courvalin, 2006). Clinical 
breakpoints indicate the MIC that will reflect the probability of treatment success given 
a specified dosing schedule (Mouton, 2002). Clinical breakpoints are set not only based 
on the MICs, but also in vivo parameters such as pharmacokinetics and 
pharmacodynamics of the drug as well as with correlation of the MICs with the clinical 
outcome (Guardabassi and Courvalin, 2006). Factors such as bacterial distribution in 
the host, sub-MIC effects, postantibiotic effects, protein binding, and variations in drug 
concentration in the blood can all affect in vivo susceptibility (Jorgensen, 2004) and 
determination of the clinical breakpoint. An excellent overview of approaches that can 
be used to calculate clinical breakpoints is provided by Mouton (2002).  
 
Breakpoints can also be considered from a microbiological (in vitro) rather than a 
clinical point of view. Microbiological breakpoints are based on MICs for a bacterial 
species with resistance at the higher MICs when compared to the distribution of the 
normal susceptible population (Guardabassi and Courvalin, 2006). Microbiological 
resistance is determined by comparison of two or more strains under identical 
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conditions (Guardabassi and Courvalin, 2006). These breakpoints are useful for 
surveillance and for identifying emerging resistance (Guardabassi and Courvalin, 2006).  
 
Microbiological breakpoints are used to detect organisms that do no belong to the 
natural bacterial population. These organisms have acquired resistance and may 
represent an emerging resistant strain (Mouton, 2002). The microbiological breakpoint 
criteria do not consider drug pharmacokinetic properties in individual patients (Dudley 
and Ambrose, 2000, Mouton, 2002).  
 
Breakpoints are generally derived from human isolates (Walker, 2000). The 
pharmacokinetic data collected from human populations may differ significantly from 
that derived from animals; therefore, what may be an appropriate breakpoint for human 
isolates may not be the same for animal isolates. Since human breakpoints do not 
reliably predict clinical outcomes when applied to veterinary pathogens, the National 
Committee for Clinical Laboratory Standards (NCCLS) have developed a veterinary 
specific antimicrobial susceptibility criteria (NCCLS, 2000).  
 
There are other challenges associated with the reporting of breakpoints and AMR. 
Resistance can only be assessed by comparing the strains of the same species or genus 
(Guardabassi and Courvalin, 2006). For example, ampicillin has an MIC breakpoint of 
128 µg/ml for E. coli sp. but for Streptococcus agalacttiae the MIC is 0.12 µg/ml 
(Prince and Neu, 1983). Breakpoints may also vary between countries (MacGowan and 
Wise, 2001, Mouton, 2002, Jorgensen, 2004) depending on the agency setting the 
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breakpoints and the methodologies used. Therefore, when comparing susceptibility 
results between different organism and countries one must keep in mind what the 
susceptible, intermediate, and resistant breakpoints are for each respective organism or 
country. Despite these limitations, susceptibility breakpoints can provide a reference for 
clinical efficacy (Jorgensen, 2004) and for surveillance purposes. 
 
2.3.1. Phenotype susceptibility testing methods   
 
The primary methods used for susceptibility testing are agar disc diffusion, broth 
microdilution, agar dilution, broth macrodilution, and E-test. Since agar diffusion and 
broth microdilution are the two principal methodologies used in veterinary medicine 
(Brooks et al., 2003), this discussion will focus on these tests and some of their 
advantages and disadvantages.  
 
Agar disc diffusion is based on diffusion of an antimicrobial agent from a 
commercially prepared disc placed on an agar surface inoculated with a standardized 
growth medium that has been seeded with approximately 1.0 x 108 colony forming units 
of pure culture (Prescott, 2000). At the same time that the inoculum is growing, the 
antimicrobial agent is diffusing from the disc. If the organism is susceptible to the 
antimicrobial, a zone of growth inhibition is created around the disc. The larger the zone 
of inhibition, the more susceptible the organism is to the antimicrobial.  
 
Agar disc diffusion techniques provide qualitative data, are flexible and low cost. 
However, the results of disc diffusion will vary unless the inoculum density, the agar 
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thickness and the incubation are carefully controlled (Potz et al., 2004). Veterinary 
specific antimicrobial disks are available for antimicrobials such as ceftiofur, 
enrofloxacin, and tilmicosin (Watts and Lindeman, 2006). Agar disc diffusion 
breakpoints are derived from the relationship between the zones of inhibition to the 
MIC (Craig, 2000).  
 
Agar dilution is the gold standard, but it and broth macrodilution are often too 
cumbersome for routine use and so are often replaced with broth microdilution (Walker, 
2000). Broth microdilution involves using a microplate that contains antimicrobial 
agents of known concentration in progressive two fold dilutions that encompass similar 
concentrations to those obtained in serum and tissue at recommended doses (Walker, 
2000). To perform broth microdilution, a bacterial suspension is made from an 
overnight culture of a single randomly selected isolate, diluted to turbidity comparable 
to a 0.5 McFarland standard (Walker, 2000). This is further diluted so that the final 
concentration of bacteria per well is 5 x 104 colony forming units (Walker, 2000). The 
plates are then incubated for 16-20 hours (Walker, 2000). The minimum inhibitory 
concentration is recorded as the lowest concentration of antimicrobial that completely 
inhibits growth.  
 
Broth microdilution and agar dilution both provide MICs by exposing the organism 
to a series of twofold log dilutions of the antimicrobial of interest (Jorgensen, 2004). 
These are the preferred methods of surveillance systems (Watts and Lindeman, 2006) 
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because they can demonstrate trends in MICs over time. Broth microdilution can be 
highly automated and, therefore, is capable of handling large volumes of samples.  
 
The disadvantage is that broth microdilution utilizes MIC panels that are often 
inflexible as to the dilution and the antimicrobials available on a specified panel. 
Custom plates can be designed, but they are often cost prohibitive for many 
laboratories. Another limitation is that because only a few (1-10) isolates/sample are 
selected for testing and MICs may fail to identify minority strains present in a complex 
polyclonal population unless a large number of isolates are investigated (Hedges et al., 
1977, Humphrey et al., 2002). Also, under selective pressure of antimicrobial treatment, 
such minority species, if expressing a suitable phenotype, may be capable of dominating 
the microflora and potentially giving rise to sub-clinical or even clinical disease (Linton 
et al., 1978). As such random isolate selection may fail to fully describe the clinical 
importance AMR of any given bacterial population. 
 
2.4. Molecular aspects of antimicrobial resistance  
 
The phenotype provides an indication of the susceptibility of the organism and its 
potential impact clinically, but it does not indicate the genes present or the underlying 
mechanism for resistance. The genotype on the other hand does not imply whether a 
strain is sensitive or not to a specific antimicrobial, but it demonstrates the diversity and 
distribution of resistance genes (Aarts et al., 2006). Because each methodology provides 
different information, considering both the phenotype and genotype will provide a more 
complete understanding AMR.  
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Bacteria are very proficient at sharing the genetic information necessary to survive in 
the presence of antimicrobials (McDermot et al., 2002). The ability to readily exchange 
genes increases the possibility for the spread of AMR determinants from commensal 
organisms to pathogens (Salyers and Cuevas, 1997). Even transient passage of an 
ingested resistant organism through the intestinal tract can result in the transfer of 
resistant genes to resident microflora, which can then serve as a reservoir for pathogenic 
bacteria (McDermott et al., 2002).  
 
2.4.1. How bacteria acquire resistance 
 
There are two major ways that susceptible bacteria acquire AMR, mutation or 
horizontal gene transfer. 
 
2.4.1.1. Mutation 
 
Mutation is the spontaneous change in the genome from susceptible to resistant, 
usually during replication (Catry et al., 2003). Chromosomal mutations often result in 
structural changes to the bacterial cell wall and subsequent resistance development 
(Prescott, 2000, Guardabassi and Courvalin, 2006). They may lead to dramatic 
resistance development or to slower more gradual resistance development depending on 
the antimicrobial agent affected (Prescott, 2000, Guardabassi and Courvalin, 2006). 
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Mutants may be disadvantaged compared to the parent and, therefore, be less able to 
survive in the population in the absence of the selective pressure of an antimicrobial 
(Prescott, 2000). Alternatively, mutants maybe as viable as the parent and may persist in 
the population with or without selective pressure from AMU (Prescott, 2000). 
Mutational events happen at high frequencies for drugs such as streptomycin, nalidixic 
acid, and rifampin; whereas, the mutation frequency to erythromycin are lower and 
almost non-existent for vancomycin and polymixin B (Prescott, 2000).  
 
2.4.1.2. Horizontal transfer of resistance 
 
The horizontal transfer of resistance genes from donor to recipient bacteria is a 
second method through which bacteria can acquire resistance. The three primary 
methods for horizontal resistance gene transfer are transformation, transduction, and 
conjugation (Schwarz and Chaslus Dancla, 2001).  
 
Transformation is the uptake of naked bacterial DNA from the environment by an 
acceptor bacteria (Prescott, 2000, Schwarz and Chaslus-Dancla, 2001). It is a critically 
important method of gene transfer (Prescott, 2000) in vitro but less important in vivo 
(Schwarz et al., 2006). Transformation generally occurs between closely related genera 
and may result in gene recombination producing new forms of resistance genes 
(Prescott, 2000). This method of resistance transfer is particularly important in bacteria 
species such as Streptococcus spp. and Neisseria spp. that have a high frequency of 
natural transformation (Prescott, 2000).  
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Transduction is the transfer of resistant genes via a bacterial virus or phage (Prescott, 
2000, Schwarz and Chaslus-Dancla, 2001). It is thought to be a relatively unimportant 
method of resistance transfer because of the specificity of bacteriophages (Prescott, 
2000) and the limited amount of space for DNA to be packaged into the phage 
(Schwarz et al., 2006). Occasionally, resistance plasmids can be accidentally packed up 
into phage heads during phage assembly and subsequently be able to infect new cells by 
injecting plasmid DNA into a recipient cell (Schwarz et al., 2006). Neither 
transformation nor transduction requires a viable donor cell or a link between donor and 
recipient (Guardabassi and Courvalin, 2006).  
 
Conjugation is the transfer of resistance genes from a resistant organism to a 
sensitive organism through a protein channel (Bennett, 1995, Prescott, 2000, Schwarz 
and Chaslus-Dancla, 2001). Gene transfer in conjugation allows the spread of mobile 
genetic elements such as plasmids, transposons, or integron/gene cassettes (Hall and 
Collins, 1995, Bennett, 1999, Schwarz and Chaslus-Dancla, 2001). These elements can 
possess multiple AMR genes and may be responsible for the rapid dissemination of 
genes among different bacteria (Kruse and Sorun, 1994, Salyers and Cuevas, 1997, 
Sandvang et al., 1997). Linked clusters of AMR on a single mobile element can also 
aggregate in such a way that antimicrobials of a different class or even non-
antimicrobial substances like heavy metals or disinfectants can select for AMR bacteria 
(Recchia and Hall, 1997, Salyers et al., 2004). Exchange of resistance genes between 
pathogens and non-pathogens or between gram-positive and negative bacteria has also 
been documented (Prescott, 2000, Salyers et al., 2004).  
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2.4.1.2.1 Mobile genetic elements 
 
As stated above the acquisition of genetic elements such as plasmids, transposons, or 
integrons/gene cassettes are a critical part of horizontal transfer of AMR. These 
elements vary considerably from each other in regard to their carriage of resistance, 
their replication and transmission. 
 
Plasmids are extra-chromosomal circular DNA which can replicate independently, 
but synchronously with chromosomal DNA (Prescott, 2000, Schwarz et al., 2006). 
When resistance is transferred as a result of plasmids, a copy of the plasmid is always 
retained by the parent (Prescott, 2000). Most plasmids carry the gene required for 
conjugation, but not all do, in these cases plasmids can be mobilized by using the 
conjugal apparatus of other self-transmissible plasmids within the cell (Prescott, 2000).  
 
Plasmids can code for resistance to between one and ten different antimicrobials 
(multiple AMR) (Prescott, 2000). Multi-resistant plasmids are often the result of 
interplasmidic recombination, integration of transposons, or insertion of gene cassettes 
(Schwarz et al., 2006). All resistance genes on a multi-resistant plasmid are transferred 
when the plasmid is transferred, whether there is selective pressure for all of the 
resistance genes on the plasmid or for just one of the resistance genes (Schwarz et al., 
2006). Plasmids can act as vectors for transposons and integrons/gene cassettes 
(Bennett, 1995). 
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Transposons (jumping genes) are short sequences of DNA that can move from 
plasmid to plasmid, or from plasmid to chromosome and vice versa (Prescott, 2000). 
Transposons do not possess replication systems and must be incorporated into 
chromosomal DNA or plasmids (Schwarz et al., 2006). Unlike plasmids, no copy of the 
transposon remains within the original cell as the transposon moves between the donor 
and recipient (Prescott, 2000). All transposons can move and integrate into foreign 
DNA by nonhomologous recombination, which permits the same transposon to be 
found in the genome or plasmids of highly unrelated organisms (Prescott, 2000).  
 
Integrons are a mobile element often found on plasmids and are distinct from 
transposons (Prescott, 2000). They are a site specific recombination system that 
contains an integrase enzyme, a gene-capture site, and a captured gene or genes 
(Prescott, 2000). The genes are present as mobile gene cassettes that represent small 
mobile elements that contain only a single resistance gene and a specific recombination 
site (Recchia and Hall, 1995, Nandi et al., 2004). The recombination site allows 
mobility when they are recognized by site-specific integrases, which catalyze 
integration of the cassettes at specific sites within the integron thereby permitting 
integrons containing multiple resistance gene cassettes (Prescott, 2000).  
 
Gene expression of an integron is dependent on various factors including promoter 
strength, gene copy number, the relative distance of the gene cassette from the 
promoter, and the presence of additional internal promotors (Matinez-Freijo et al., 1998, 
Martinez-Freijo et al., 1999). Expression is usually mediated via a common promoter 
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situated upstream (5’-end) of the gene cassettes, rather than through individual promoter 
copies (Matinez-Freijo et al., 1998). Higher levels of gene expression can be achieved if 
a second promoter is included adjacent to the first, or if the gene in question is included 
as multiple copies (Matinez-Freijo et al., 1998). The relative distance between a gene 
cassette and the promoter plays a significant role regarding expression; proximal genes 
tend to be expressed more effectively than distal genes (Matinez-Freijo et al., 1998). As 
a result, distal genes may have very little effect on the susceptibility of the host 
bacterium to relevant antimicrobials (Matinez-Freijo et al., 1998, Matinez-Freijo et al., 
1999). Integron carriage of resistance gene cassettes by the host bacterium was also 
found to be dependent on the environment that the host organism found itself in, with 
the loss of integron borne resistance genes in the absence of antimicrobial selective 
pressure (Rosser and Young, 1999). 
 
2.5. How antimicrobials exert their effect 
 
Antimicrobials by definition are substances that inhibit the growth of or kill micro-
organisms with little or no damage to the host. The three main mechanisms of action for 
antimicrobials to achieve this goal are: inhibition of cell wall synthesis, inhibition of 
protein synthesis, and inhibition of DNA synthesis. In addition to these three targets 
antimicrobials may also have an indirect method of action by blocking folic acid 
synthesis and subsequently inhibiting nucleic acid development. 
 
The cell wall acts as a mechanical means of protection, as a surface for proteins and 
appendages for cell adhesion, for motility, host infection, and horizontal gene transfer 
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(Guardabassi and Courvalin, 2006). In gram positive bacteria, the cell wall is thick and 
composed of multiple layers of cross linked glycan and peptide strands crossed by 
molecules of teichoic and teichuronic acids. In gram negative bacteria the peptidoglycan 
wall is thinner and is surrounded by a lipopolysaccharide (Guardabassi and Courvalin, 
2006). The lipopolysaccharide layer, in gram negative bacteria, decreases permeability 
and therefore affects the uptake of certain antimicrobials such as glycopeptides 
(Guardabassi and Courvalin, 2006). 
 
The main phases of cell wall synthesis are: the cytoplasmic phase, where the 
peptioglycan layers are formed; the membrane phase, where the muramyl pentapeptide 
is bound and then transferred to the cell membrane; and the extracytoplasmic phase, 
where there is crosslinkage (van Heijenoort, 2001). Antimicrobials may exert their 
effect at any one of these points of cell wall synthesis ultimately leading to the 
destruction of the cell. The antimicrobials that act primarily on the cell wall include the 
beta-lactams and the glycopeptides. 
 
Protein synthesis is essential for bacterial survival. It starts with transcription of 
DNA into mRNA and ends with mRNA translation and translocation (Guardabassi and 
Courvalin, 2006). Antimicrobials most frequently target translation when the bacterial 
ribosome reads the mRNA and translates it into amino acid sequences (Guardabassi and 
Courvalin, 2006). Drugs that act on this step generally bind to specific sites on the 
ribosome and destroy its functionality (Guardabassi and Courvalin, 2006). Ribosomes 
are comprised of two subunits, a small 30S subunit and a large 50S subunit 
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(Guardabassi and Courvalin, 2006). Drugs which target the 30S subunit include 
aminoglycosides, sepctinomycin, and tetracyclines, while chloramphenicol, 
pleuromutilins, and oxazolidones target the 50S subunit (Guardabassi and Courvalin, 
2006). 
 
Bacterial DNA synthesis permits the replication of the bacterial chromosome during 
cell division, and RNA synthesis allows gene expression and protein synthesis by 
transcription of DNA into RNA (Guardabassi and Courvalin, 2006). Quinolones target 
two enzymes involved in the early stages of this process including topoisomerase II or 
DNA gyrase and topoisomerase IV, and exert their effect through interaction with the 
enzyme bound DNA complex (Guardabassi and Courvalin, 2006). Novobiocin also acts 
on the above two enzymes, but its mechanism of action is through competitive 
inhibition of ATP by attaching to ATP binding sites; whereas, rifamycins inhibit protein 
transcription of DNA into mRNA (Guardabassi and Courvalin, 2006). 
 
An additional way that antimicrobials can exert their effect is through the inhibition 
of nucleic acid synthesis. Sulphonamides and diaminopyramidines (e.g. trimethoprim) 
have an indirect inhibitory affect on nucleic acid synthesis by blocking various stages of 
folic acid synthesis (Guardabassi and Courvalin, 2006). Sulfonamides competitively 
inhibit p-aminobenzoate (PABA) modification into dihydrofolate. 
Diamionopyramidines competitively inhibit dihydrofolate reductase actively preventing 
dihydrofolic acid reduction into treahydrofolic acid (Guardabassi and Courvalin, 2006)  
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2.6. How bacteria fight back against antimicrobials  
 
Resistance to the same antimicrobial can be mediated by several different 
mechanisms. Additionally, the same resistance gene or mechanism of resistance maybe 
found in a wide variety of bacteria or limited to certain bacterial species or genera 
(Schwarz et al., 2006).  
 
The mechanisms that organisms may develop to protect themselves from 
antimicrobials, and thus become resistant, are often classified into five main categories. 
These categories include enzymatic inactivation or modification of antimicrobials, 
impermeability of the bacterial cell wall or membrane, active expulsion of the drug by 
cell efflux pump, alteration of target receptors, and drug trapping or titration. 
 
1. Enzymatic inactivation or modification of antimicrobials. This is the main 
mechanism of resistance to beta-lactams, aminoglycosides, and phenicols 
(Guardabassi and Courvalin, 2006). Drug inactivating enzymes are generally 
associated with mobile genetic elements. Some of the most clinically important 
enzymes are the beta-lactamases. These enzymes hydrolyze the beta-lactam ring 
of penicillins, cephalosporins, and carbapenems preventing them from binding 
to the active serine site of the penicillin binding proteins (cell wall 
transpeptidases) and impede cell wall synthesis (Guardabassi and Courvalin, 
2006). The other clinically important enzymes are the aminoglycoside 
modifiying enzymes that catalyze the transfer of an acetyl group (N-
acetyltransferases), a phosphoryl group (O-phosphotransferases), or a nucleotide 
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(O-nucleotidyltransferases) to the amino or hydroxyl group of the 
aminoglycoside molecule. The end result is a chemically modified drug that has 
poor binding to the ribosomes and is subsequently not taken up by the cell 
(Wright, 1999). 
2. Impermeability of the bacterial cell wall or membrane. Hydrophyllic drugs enter 
gram negative bacterial cell wall through porins, while hydrophobic drugs enter 
through the phospholipid layer (Guardabassi and Courvalin, 2006). Any change 
in porins can confer resistance (Guardabassi and Courvalin, 2006). Lack of 
aminoglycoside activity in anaerobes is a result of reduced drug uptake.  
3. Active expulsion of the drug by cell efflux pump. Efflux pumps are proteins that 
reduce the concentration of the drug in the cytoplasm thereby limiting access of 
the drug to its target (Guardabassi and Courvalin, 2006). There are two major 
types of antimicrobial efflux pumps (Guardabassi and Courvalin, 2006). The 
first type of efflux pump acts on specific drugs. Drug pumps are an important 
mechanism for tetracycline resistance especially in gram negative bacteria, but 
can also confer resistance to phenicols (Guardabassi and Courvalin, 2006). 
Specific drug pumps are associated with mobile genetic elements (Butaye et al., 
2003). The second type of efflux pump creates multiple drug resistance. This 
pump is frequently encoded by the chromosome and is divided into ATP binding 
cassette transporters or secondary drug transporters depending on their source of 
energy (Putman et al., 2000). The secondary drug transporters are the pumps 
that account for most of the resistance to multiple antimicrobial agents. 
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4. Alteration of target receptors. Resistance by alteration or protection of drug 
receptors has been reported for tetracycline and or quinolones (Guardabassi and 
Courvalin, 2006).  
5. Drug trapping or titration can be accomplished by several venues and the 
consequence is reduced free drug at the target site (titration). For example, the 
chromosomal mutations responsible for the overproduction of PABA, the target 
of sulphonamides and diamionpyrimidines (dihydrofolate reductase), have been 
reported in several bacteria (Guardabassi and Courvalin, 2006).  
 
2.6.1. Primary mechanisms of antimicrobial resistance development of six 
antimicrobials important in cow-calf herds 
 
Schwarz et al. (2006) provide a good over view of the mechanisms and spread of 
bacterial resistance to nine classes of antimicrobial agents that play a major role in 
veterinary medicine, as well as for glycopeptides and streptogramins which are 
important in human medicine. Brief descriptions of the primary mechanisms for AMR 
development of six antimicrobial classes commonly used in cow-calf operations are 
provided here. 
 
2.6.1.1. Beta-lactams 
 
Resistance to beta-lactam antimicrobials is mainly due to inactivation by beta 
lactamases (Livermore, 1995) and decreased ability to bind to penicillin-binding 
proteins (Georgeopapadakou, 1993). However, beta-lactam resistance may also be a 
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result of decreased uptake of the drug due to permeability barriers or increased efflux 
via multidrug transporters (Paulson et al., 1996, Quintiliani et al., 1999). The 
inactivation of beta-lactams is primarily due to the cleavage of the amino bond in the 
beta-lactam ring by a beta lactamase enzyme (Bush et al., 1995, Livermore, 1995, Bush, 
2001, Wiegand, 2003). Genes encoding beta-lactamases are located on either plasmids 
or the bacterial chromosome (Aarts et al., 2006). Examples of specific gene variants for 
the beta-lactamase family in gram negative bacteria include ampC, tem, shv, oxa and 
ctx-M (Aarts et al., 2006). Extended spectrum beta-lactamases that play an important 
role in human medicine have also been described (Bradford, 2001), as have the AMR 
genes for methicillin resistant Staphylococcus aures (Aarts et al., 2006).  
 
2.6.1.2. Tetracyclines 
 
Tetracycline resistance is almost always a result of the uptake of new genes (Chopra 
and Roberts, 2001). There are 23 efflux genes (which code for energy dependent efflux 
of tetracyclines), 11 ribosomal protection genes (which code for protein that protects 
bacterial ribosomes), 3 genes that code for enzymes that modify and inactivate 
tetracycline, and 1 gene that has an unknown mechanism (Schwarz et al., 2006). 
Currently only the first two mechanisms are important in bacteria of veterinary 
importance.  
 
The efflux resistance genes tetA, tetB, tetC, tetD and tetH are most wide spread in 
gram negative bacteria and are located on transposons (Allmeier et al., 1992, Chalmers 
et al., 2000, Lawley et al., 2000) and plasmids (Schwarz et al., 2006). The tetB gene 
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confers resistance to both tetracycline and minocylcine, but not to the new glycyclines, 
while the other efflux proteins confer resistance only to tetracycline (Chalmers et al., 
2000, Chopra and Roberts, 2001). Resistance to minocycline and glycyclines are 
relevant as they are newer drugs that play a role in human medicine. The methodologies 
utilized to identify these different tet resistance genes have been described elsewhere 
(Frech and Schwarz, 2000, Kehrenberg et al., 2001, Aminov et al., 2001, Ng et al., 
2001, Guerra et al., 2004, van Hoek et al., 2005). 
 
Ribosomal protection genes are a second important way for tetracycline resistance 
development. They are of gram positive origin but can also be found in gram negative 
genera (Schwarz et al., 2006). An example of a ribosomal protection gene is the tetM 
gene which has a wide range of hosts and is located on a conjugative transposon 
(Flannagan et al., 1994, Chopra and Roberts, 2001, , Salyers et al., 1995).  
 
Other less well described mechanisms of tetracycline resistance include enzymatic 
inactivation, 16S rRNA mutation, other mutations, and multidrug transporters (Schwarz 
et al, 2006). 
 
2.6.1.3. Quinolones and Fluorquinolones 
 
Quinolones and fluoroquinolones are potent inhibitors of bacterial DNA replication 
(Schwarz et al., 2006). The two major mechanisms of resistance development to 
fluorquinolone antimicrobials are point mutations and decreased intracellular 
accumulation (Schwarz et al., 2006). Several recent reviews deal with the molecular 
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basis and epidemiology of quinolone resistance in E. coli and Salmonella spp. of animal 
origin (Drlica and Zhao, 1997, Everett and Piddock, 1998, Hooper, 1999, Bager and 
Helmuth, 2001, Cloeckaert and Chaslus-Dancla, 2001, Webber and Piddock, 2001, 
Ruiz, 2003).  
 
Briefly, point mutations in the target genes gyrA and gyrB coding for DNA gyrase 
and or for parC and parE coding for DNA topoismerase IV are frequent in quinolone 
and fluoroquinolone resistance (Schwarz et al., 2006). Detection of these point 
mutations in the region of the gyrA, gyrB, or parC and parE genes can be accomplished 
through PCR (Aarts et al., 2006) while microarrays have been used to assess mutlidrug 
efflux systems. Resistance genes associated with multidrug efflux pumps vary 
depending on the organism involved (Schwarz et al., 2006) and they may lead to high 
levels of resistance to quinolones and other antimicrobials where multidrug efflux 
pumps and decreased membrane permeability are involved (Lee et al., 2000). Quinolone 
and fluorquinolone resistance can also result from interaction between different 
resistance mechanisms, decreased drug uptake and DNA gyrase protection (Schwarz et 
al., 2006) 
 
2.6.1.4. Aminoglycosides and Aminocyclitols 
 
The main mechanism for aminoglycoside resistance is enzymatic inactivation (Shaw 
et al., 1993, Mingeot-Leclercq et al., 1999), but reduced uptake and chromosomal 
mutations conferring high levels of resistance to streptomycin have also been described 
(Quintiliani et al., 1999). Aminoglycoside resistance is mediated by more that 50 
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aminoglycoside modifying enzymes that are classified as either aminoglycoside 
acetyltransferases (aac), aminoglycoside andenyltransferases (aad or ant), and 
aminoglycoside phosphotransferases (aph) (Shaw et al., 1993, Mingeot-Leclercq et al., 
1999, Aarts et al., 2006). Most aac, ant and aph genes are located on mobile genetic 
elements such as plasmids, transposons, or gene cassettes (Shaw et al., 1993, Recchia 
and Hall, 1995, Davies and Wright, 1997, Mingeot-Leclercq et al., 1999, Wright, 1999, 
Sandvang and Aarestrup, 2000,). The modifications of aminoglycosides and 
aminocyclitols by inactivating enzymes have been described in detail in various reviews 
(Shaw et al., 1993, Davies and Wright, 1997). 
 
2.6.1.5. Chloramphenicol and Florfenicol 
 
Both enzymatic and non-enzymatic chloramphenicol and florfenicol resistance genes 
have been described (Aarts et al., 2006), but enzymatic inactivation is the predominant 
method (Shaw, 1983, Murray and Shaw, 1997, Schwarz et al., 2004) of resistance 
development. Enzymatic resistance genes are primarily encoding acetyltranfereases and 
are the cat genes (Aarts et al., 2006). Non-enzymatic gene coding of chloramphenicol 
and florfenicol include the cml genes on transposon TN1696 and the floR gene (Aarts et 
al., 2006). Efflux systems conferring resistance to chloramphenicol alone or in 
combination with florfenicol (Schwarz et al., 2004), permeability barriers, and 
multidrug transporters (Paulsen et al., 1996, Schwarz et al., 2004) as well as other minor 
mechanisms of resistance have also been identified for this class of antimicrobials 
(Schwarz et al., 2006). Details on different genes and mechanisms for phenicol 
resistance are available (Schwarz et al., 2004) 
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2.6.1.6. Sulphonamides and Trimethoprim  
 
Sulphonamides and trimethoprim are competitive inhibitors of different enzymatic 
steps in folate metabolism (Schwarz et al., 2006). Sulphonamide resistance can result 
from chromosomal mutations in the dihydropteroate synthase (folP) gene or by 
acquisition of resistant dihydropteroate synthase genes (sul genes) (Aarts et al., 2006, 
Schwarz et al., 2006). Three sul genes have been described in gram negative bacteria 
(Swedberg and Skold, 1980, Radstrom and Swedberg, 1988, Aarts et al., 2006). The 
sulI gene is associated with class 1 integrons and, therefore, is often linked to other 
genes. It is spread in gram negative species as part of transposons or as conjugative 
plasmids (Sundstrom et al., 1988). The sulII gene often occurs with streptomycin 
resistance genes strA and strB on conjugative or nonconjugative plasmids (Radstrom 
and Swedberg, 1988, Kehrenberg and Schwarz, 2004), while the sulIII gene can be 
found on conjugative plasmids (Perreten and Boerlin, 2003) 
 
Trimethoprim resistance is primarily mediated by acquisition of dfr gene encoding 
resistant dihydrofolate reductase (Aarts et al., 2006, Schwarz et al., 2006). Transferable 
trimethoprim resistance has been identified in a variety of gram negative bacteria and 
several of these genes are part of plasmids, transposons, or gene cassettes (Recchia and 
Hall, 1995, Skold, 2001, Ito et al., 2004). Other potential mechanisms of trimethoprim 
resistance for some bacteria include permeability barriers and efflux pumps (Kohler et 
al., 1996, Huovinen, 2001) and dhfr and folate auxotrophy (Quintiliani et al., 1999). 
Mutations in chromosomal genes have also been observed (Huovinen, 2001). 
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2.6.2. Co-resistance and cross resistance 
 
The development of AMR is a complex process and the speed with which it develops 
depends on the bacteria involved, the selective pressure, and the availability and 
transferability of resistance genes (Schwarz et al., 2006). Recent studies have shown 
that the majority of multiple resistant phenotypes are obtained by the acquisition of 
external genes that may provide resistance to an entire class of antimicrobials (White 
and McDermott, 2002). When there is the selection of multiple AMR genes when one 
gene is selected this is called co-selection. 
 
Co-resistance is the coexistence of several different mechanisms including genes or 
mutations which allow bacteria of the same strain to be resistant to a variety of related 
or non-related substances simultaneously (Weldhagen, 2004, Guardabassi and 
Courvalin, 2006). Beta-lactamase genes that are situated on the class 1 integron can be 
used to provide four examples of co-resistance. Co-resistance can occur when beta-
lactamase genes on class 1 integrons are found with genes to quaternary ammonium 
compounds and sulphonamides (sulI) that classically occur at the distal 3’-end (Poirel et 
al., 2000, Poirel et al. 2001, Dubois et al., 2002). A second example is the common co-
existence of aminoglycoside encoded gene cassettes with beta-lacatamase gene 
cassettes on integron structures (Weldhagen, 2004). A third example is cat-type and 
clm-type gene cassettes co-existing on class 1 integrons with class A and class B beta-
lacatamase genes (Weldhagen, 2004). Finally, a fourth example is the occurrence of sul-
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gene types and the dhfrI/dhfr-gene types occurring together on class 1 integrons in 
conjunction with class A beta-lactamase bla gene cassettes (Weldhagen, 2004).  
 
Cross resistance is a single biochemical mechanism in which resistance to one drug 
is associated with resistance to another drug of the same or different class (Guardabassi 
and Courvalin, 2006). For example, despite differences in their chemical structure cross 
resistance to macrolides, lincosamides, and beta-streptogramins can result from the 
methylation of a single adenine residue in 50S rRNA (Guardabassi and Courvalin, 
2006). When the biochemical mechanism is drug efflux then cross-resistance to several 
drugs may be observed (Courvalin and Tri-Cuot, 2001). Cross-resistance is common 
among macrolides and fluoroquinolones (Prescott, 2000).  
 
2.7. Escherichia coli (E. coli) as an indicator organism 
 
Many AMR studies have focused on organisms that are pathogenic to humans 
including: Salmonella spp. (Wray et al., 1991), Campylobacter spp. (Gaunt and 
Piddock, 1996), or Escherichia coli O157 (Meng et al., 1998). However, transmissible 
genetic elements encoding AMR can also be maintained in commensal bacteria (Shaw 
and Cabelli, 1980, Falagas and Siakavelllas, 2000). Resistance gene transmission from 
normally nonpathogenic species to more virulent organisms within the animal or human 
intestinal tract may be an important mechanism for acquiring clinically significant 
antimicrobial resistant organisms (Winokur et al., 2001). E. coli have developed a 
number of elaborate methods for acquiring and disseminating genetic determinants and, 
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therefore, may serve as an important reservoir for transmissible resistance (Neidhardt, 
1996).  
 
Commensal E. coli have been included in various surveillance programs and 
research projects as indicators of both selection pressure and the reservoir of resistance 
genes. The rationale for using E. coli includes: it is commonly found in avian and 
mammalian species and, therefore, a good benchmark for comparison between species 
and ecological niches; it is easy to grow; and there is the opportunity for the spread of 
transferable resistance. There is evidence that resistance transfer occurs in vivo between 
E. coli and other E. coli, other Enterobacteriacea, and other types of bacteria (Winokur 
et al., 2000, Winkokur et al., 2001). E. coli from fecal specimens also make good 
indicator organisms since they carry more resistance markers than any other 
Enterobacteriaceae species in the gut (Osterblad et al., 2000). Investigating AMR in 
generic E. coli from domestic species is, therefore, a practical way to improve the 
understanding of AMR ecology and the potential role of commensal microbiota of 
mammals as a reservoir for AMR.  
 
2.8. Shiga toxin producing E. coli and AMR 
 
Shiga toxin or verotoxin producing E. coli (STEC/VTEC) are the most important 
recently emerged group of foodborne pathogens (Remis et al., 1984, Karmali, 1989, 
Beutin et al., 1998, Paton and Paton, 1998, Beutin et al., 2002, Blanco et al., 2004, 
Mora et al., 2004,). Major STEC associated outbreaks have been experienced in 
Canada, Japan, the United Kingdom, and the United States (Karmali, M., 1989, Beutin 
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et al., 1998, Paton and Paton, 1998, Willshaw, et al., 2001, Beutin et al., 2002). In 
humans, these infections are associated with gastroenteritis that may be complicated by 
hemorrhagic colitis (HC) or hemolytic-uremic syndrome (HUS), which is a major cause 
of renal failure in children (Mora et al., 2004).  
 
STEC’s produce either one or two cytotoxins called Shiga toxins (stx1 and stx2) or 
verotoxins (vt1 and vt2) (Paton and Paton, 1998). Intimin is another virulence factor 
responsible for intimate attachment of STEC. It is encoded by chromosomal gene eae 
which is part of a large cluster of virulence genes on a pathogenicity island termed the 
locus for enterocyte effacement (LEE) (Kaper et al., 1998). STEC’s carrying the eae 
gene have been closely associated with HC and HUS (Karmali, 1989).  
 
Generally antimicrobials are not recommended for therapy of STEC infections 
because antimicrobials can lyse cell walls therefore releasing the toxins (Waterspiel et 
al., 1992, Wong et al., 2000). Additionally, antimicrobials are usually avoided because 
they can also cause increased expression of the toxins in vivo (Zhang et al., 2000). 
Despite the general practice of not using antimicrobials to treat STEC infections, there 
have been recent reports suggesting that AMR of STEC is on the rise (Gonzalez et al., 
1989, Farina et al., 1996, Meng et al., 1998, Galland et al., 2001, Willshaw et al., 2001, 
Schroeder et al., 2002,). 
 
Virulence genes are either located in chromosomal gene clusters (pathogenicity 
islands) or harbored in mobile accessory genetic elements such as plasmids and phages 
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(Groismann, 1996, Finlay and Falkow, 1997, Hacker et al., 1997). Resistance genes are 
also often associated with mobile DNA such as plasmids, transposons, and integrons 
(Jacoby, 1994, Tenover and Rasheed, 1998). Since AMR and virulence genes are 
carried in a similar fashion, it is possible that AMR and virulence genes could be linked 
and then co-selected (Martinez and Baquero, 2002). Therefore, reported increases in 
antimicrobial resistant STECs are of concern because AMU could potentially enhance 
the selection for bacteria carrying virulence genes. Antimicrobial use could ultimately 
accelerate the spread of virulence genes within bacterial populations and enhance the 
emergence of new pathogens or of pathogens with increased virulence potential 
(Boerlin et al., 2005). Finally, resistance genes may also be stabilized and fixed in 
pathogen populations by their linkage to virulence genes (Boerlin et al., 2005).  
 
Domestic ruminants especially cattle, sheep, and goats have been implicated as the 
primary reservoirs for STEC (Blanco et al., 1997, 2001, 2003, 2004). AMR from 
livestock and farms pose a potential risk to public health through direct contact with 
livestock or production environments, but also through AMR food-borne pathogens 
(van den Bogaard and Stobberingh, 2000, White et al., 2001). Non-pathogenic E. coli 
are also considered a problem because they can provide a pool of transferable resistance 
genes (Schmieger and Schicklmaier, 1999, Winokur et al., 2001).  
 
The current literature contains several articles describing AMR in STEC’s from a 
variety of populations (Blanco, 1989, Galland et al., 2001, Zhao et al., 2001, Gonzalez 
and Maidhof et al., 2002, Schroeder et al., 2002, Betteleheim et al., 2003, Mora et al., 
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2005). However, the current literature describing AMR in STEC does not always 
contain directly comparable information on the nature and extent of resistance in non-
STEC populations. The presence of AMR within a STEC positive isolate in the absence 
of additional information does not indicate whether or not STEC are more or less likely 
to be resistant to antimicrobials than non-STEC organisms, or conversely whether 
organisms that are antimicrobial resistant are more or less likely to contain virulence 
genes than organisms that are sensitive. This particular area needs more research to 
fully understand what is happening in STEC and non-STEC populations. 
 
2.9. Antimicrobial use: General considerations 
 
Different AMU regimen select for various resistance genes (Blake et al., 2003), and, 
therefore, use patterns of antimicrobial agents are expected to have some impact on the 
distribution of antimicrobial resistant phenotypes (McGowan and Gerding, 1996, 
Gaynes and Monnet, 1997, Aarestrup, 1999). Among the ramifications associated with 
such resistance gene selection are the degree of resistance conferred and the carriage of 
linked resistance determinants (Blake et al., 2003). Minimal antimicrobial exposure is 
necessary to select for continued persistence of resistance genes within enteric 
microflora (Blake et al., 2003). Persistence of AMR in bacteria is related to the 
persistence of antimicrobials. Therefore, short-term therapeutic treatment with 
antimicrobials generally do not produce bacteria that persist in the intestine, whereas 
prolonged AMU is more likely to be associated with persistence of resistant organisms 
after the drug is no longer administered (Prescott, 2000). As a result of the effect of 
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AMU on AMR, it is important to consider how AMR may be affected in a variety of 
production systems and livestock species with different AMU patterns and intensities. 
 
2.9.1. Reason for antimicrobial use in livestock 
 
Antimicrobial use in livestock production is necessary for the health and welfare of 
the animals. Method of administration and the volume of antimicrobial used will vary 
depending on the species of livestock, stage of production, and risk of disease. There 
are three primary reasons for AMU in food-producing animals: treatment of diseased 
animals, prevention and control of disease, and growth promotion.  
 
Prevention and control can be further divided into metaphylactic or prophylactic 
applications. Metaphylaxis is a disease control measure involving the mass medication 
of a group of animals to prevent the spread of disease when only a few individuals have 
been identified as infected. Prophylaxis is a preventative treatment of an animal or 
group of animals at a time when it may be more susceptible to infection. An example of 
prophylactic use of antimicrobials includes the treatment of dairy cows at the end of 
lactation. Antimicrobials are given at critical points in production to help prevent the 
development of disease. Prophylactic treatment may involve the entire group of animals 
or may be targeted towards specific high risk individuals depending on the animal 
species, the production system, and the disease condition.  
 
While there may be concern about the impact of metaphylactic and prophylactic 
treatment of groups of animals on the development of AMR, the bigger concern is the 
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use of antimicrobials for growth promotion. Growth promotion generally involves the 
use of antimicrobials licensed for this purpose. Generally antimicrobials used for 
growth promotion are provided at a sub-therapeutic dose (dose lower than those 
approved for therapeutic purposes) and are fed for a longer duration than antimicrobials 
used for prevention and control. It is the lower dose and the long duration of feeding of 
these antimicrobials which often causes concern about the development of AMR.  
 
Intensive livestock operations, such as feedlots, swine, or poultry operations, are 
often required to use the tools of prophylactic, metaphylactic, and growth promotant 
AMU in order to prevent disease and death, to ensure animal welfare, and for economic 
benefit. Cow-calf herds are generally managed more extensively and, therefore, these 
operations would be less likely to use antimicrobials in this way. In cow-calf herds the 
use of antimicrobials to prevent or control disease may be necessary in disease outbreak 
situations or in facilities with less than optimal management practices.  
 
2.9.2. Antimicrobial use and antimicrobial resistance 
 
The Canadian Veterinary Medical Association (CVMA) has taken a pro-active 
stance on AMR (CVMA, 2005) and makes several general recommendations. The first 
is that veterinarians, animal owners, and animal caretakers all share a responsibility for 
minimizing the use of antimicrobial drugs to conserve drug efficacy (CVMA, 2005). 
Veterinarians have a responsibility to educate staff, clients, and other animal handlers 
on the prudent use of antimicrobials and for ensuring such training occurs (CVMA, 
2005). The role of the veterinarian is to ensure that all users are aware of the appropriate 
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administration, handling, storage, disposal, and record keeping for antimicrobials 
(CVMA, 2005).  
 
The CVMA (2005) also recommends that veterinarians should continually update 
their knowledge of disease prevention, therapeutics, and of issues such as drug 
resistance trends to ensure the prudent use of antimicrobials. Implementation of 
preventative measures such as vaccination, biosecurity measures, good hygiene 
practices, and improved management may help prevent disease and, therefore, reduce 
the use of antimicrobials. Additionally, if the veterinarian understands resistance 
patterns that are emerging on a farm, they will be better able to make recommendations 
regarding antimicrobial treatment.  
 
Finally, the CVMA (2005) recommends that all antimicrobials even those not 
purchased directly through or on prescription from a veterinarian, should be used within 
the confines of a valid veterinarian-client-patient relationship. This should help ensure 
appropriate AMU because of the veterinarian’s understanding of farm management and 
disease status. With this knowledge, antimicrobial treatments can be designed to 
maximize therapeutic efficacy and minimize bacterial resistance.  
 
Both the structures and biochemical pathways within bacteria that determine 
antimicrobial availability within the microbe and the pharmacodynamic and 
pharmacokinetic properties of antimicrobials are complex (Aliabadi and Lees, 2000). 
Rational dosing of antimicrobials depends upon knowledge of physiology, anatomy, 
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pathology, and disease condition (Lees and Aliabadi, 2002). Resistance can result from 
both the selection of an inappropriate antimicrobial and from failure to optimize the 
dose level. For example, the dose interval is important for concentration-dependent 
antimicrobials and the duration of treatment is critical for time-dependent antimicrobials 
(Aliabadi and Lees, 2000). Pharmacokinetic variation may result from the animals’ 
disease status, age, and weight, or from non-biological factors such as route of 
administration, formulation, and drug interactions (Aliabadi and Lees, 2000). Through 
the optimization of the dosage schedule, the beneficial effects of treatment are 
maximized while the potential adverse effects are minimized (Aliabadi and Lees, 2000). 
While implementing the appropriate use of antimicrobials may limit AMR 
development, is it also important to recognize that even appropriate use can put 
selection pressure on the bacterial population and contribute to AMR.  
  
Producer access to over the counter (OTC) antimicrobials often results in AMU with 
little or no veterinary consultation (McEwen and Fedorka-Cray, 2002). These OTC 
drugs are made available to producers for purely practical reasons such as lack of access 
to a veterinarian (McEwen and Fedorka-Cray, 2002). This practice can result in 
inappropriate antimicrobial choices, dosing and treatment frequency and, therefore, may 
be a factor in AMR development. 
 
The continued availability of antimicrobials in veterinary medicine depends upon the 
profession’s ability to use these products wisely and find the balance between 
maximizing animal welfare and conserving antimicrobial efficacy (CVMA, 2005). By 
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increasing awareness about AMR and implementing prudent use recommendations 
veterinarians can promote long term efficacy and continued availability of 
antimicrobials.  
 
Probably one of the most important methods of avoiding resistance is ensuring that 
antimicrobials are selected and used appropriately. They should not be used as a 
substitute for poor hygiene or poor disease control. Ensuring that all individuals using 
antimicrobial are well informed about when, where, and how antimicrobials should be 
used is an important step in avoiding further resistance development. Emphasizing the 
importance of preventative health programs along with good management and hygiene 
practices on the farm will reduce the potential for disease and the need for AMU. 
Additionally, monitoring programs can also help illustrate changing resistance patterns 
over time to alert us to new or emerging resistance patterns. 
 
2.9.3. Challenges of antimicrobial use data collection 
 
Antimicrobial use data are difficult to collect and report for several reasons. 
National, regional, or even farm level data are scarce. On a national level, Denmark, 
Sweden, and Finland are currently the only countries where pharmaceutical companies 
have a legal obligation to supply data on antimicrobial sales (Schwarz and Chaslus-
Dancla, 2001). At the national level, AMU is reported as kilograms or tonnes of active 
ingredient sold. While these data provide the volume of antimicrobial used it does not 
allow for drug potentcy, assessment of how the antimicrobial was used and whether this 
use may affect AMR. Data on the species it was delivered to, the number of animals 
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exposed, the dose received, and the method of delivery are generally unavailable. End-
user data are, therefore, required in order to gain a better appreciation of how and why 
antimicrobials are being used in livestock production, but even end-user AMU data has 
serious limitations. 
 
Complete and accurate farm-level AMU records are difficult to obtain. Capture of 
use information can be expensive for the researcher and burdensome for the producer to 
accommodate especially during times of additional demands with limited resources. 
Under reporting is potentially a problem since producers are busy with day-to-day 
operations on the farm and, therefore, record keeping may be relatively low on the 
priority list. Subsequently treatment records may be forgotten or incomplete. Dunlop et 
al. (1998) reported a 35% under-reporting rate for AMU recorded by swine producers as 
compared to inventory and disappearance data collected by the researcher. A 
preliminary report of AMU in the Ontario beef industry, by Bair and McEwen, (2001) 
estimated average under reporting of AMU on farm was 40%. This estimate was based 
on treatment diaries and accounting of drug disappearance in both feedlots and cow-calf 
herds (Bair and McEwen, 2001). For cow-calf herds specifically, under reporting 
ranged from 1-86% with a mean of 24% (Bair and McEwen, 2001). Several reasons for 
under-reporting include: misunderstandings between researchers and producers, and 
lack of time during periods of increased work load such as in disease outbreak situations 
(Singer et al. 2006).  
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In addition to the challenges of collecting AMU data, there is no widely accepted 
method for quantifying AMU (Singer et al., 2006). Use can be reported in many ways 
including, but not limited to, total volume of drug in kilograms, defined daily doses 
(DDD) (Jensen et al. 2004), animal daily doses (ADD) (Jensen et al., 2004), or as 
animal-units per treatment days (Dunlop et al, 1998). While each of the above methods 
try to capture the true exposure of an animal to a antimicrobial, they all are limited. 
Debate still surrounds the best approach to reporting AMU information. Jensen et al. 
(2004) provide a good overview and highlight the major potential methods for reporting 
AMU and the associated limitations.  
 
Although there are several issues associated with AMU data capture and reporting 
there is international interest in developing surveillance systems for AMR and AMU 
that potentially includes farm-level or aggregate-level AMU data (Rosdahl and 
Pederson, 1998, Nicholls et al., 2001 and WHO 2001). In order to achieve a meaningful 
way to collect and report AMU data, international collaborative efforts are being made 
to overcome the issues surrounding AMU collection. For end-user compiled AMU data 
to be useful in surveillance systems, the following pieces of information need to be 
collected: total amount of antimicrobial used, indication for treatment, route of 
administration, dose and duration (Singer et al., 2006). 
 
2.10. Antimicrobial use and antimicrobial resistance in cow-calf herds 
 
Little information is available on AMU and AMR in cow-calf herds. In papers 
describing AMU (Bair and McEwen, 2001, Powell and Powell, 2001, Busani et al., 
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2004, Sayah et al., 2005) or AMR in healthy cattle it is often not differentiated as to 
what was the age and type of cattle sampled (Mercer et al., 1971, Schroeder et al., 2002, 
Kijima-Tanaka et al., 2003, Sayah et al., 2005, Lim et al., 2007). If the literature 
pertains to beef cattle specifically the samples collected are often at the abattoir rather 
than on farm (Van Donkersgoed et al., 2003, CIPARS, 2006, Aslam and Service, 2006, 
Rigobelo et al., 2006). While abattoir samples provide some insight into on farm 
prevalence they may not completely reflect AMR patterns on farm. Also, the ability to 
link on farm AMU with AMR is critical in order to be able to identify risk factors and 
the potential impact of certain farm management practices. 
 
The following review illustrates the limited amount of data that are available on cow-
calf AMU and AMR and the gaps that need to be filled. Additionally it highlights the 
effects of management practices, AMU, animal age, and potentially other host specific 
factors as they relate to AMR. 
 
2.10.1. Antimicrobial use  
 
Antimicrobial use is generally accepted to be an important factor for the selection of 
AMR bacteria (Aarestrup, 1999, van den Bogaard and Stobberingh, 2000, McEwen and 
Fedorka-Cray, 2002). Selective pressure for AMR can be affected by treatment 
formulation, dose, interval and duration (Catry et al., 2003). Since there can be diverse 
AMU practices within the livestock industry, describing AMR in one livestock class, 
species, or management system can not be considered to be representative of another.  
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Many studies have been initiated to investigate a potential link between AMU and 
subsequent AMR in animals and the development of resistance in people (Hummel et 
al., 1986, Endtz et al, 1991, Johnson et al., 1995, Bager et al., 1997, Aarestrup, 1999, 
Winokur et al., 2001, Swartz, 2002). Additionally, studies of commensal and 
pathogenic resistant bacteria have been conducted in a variety of livestock species in 
order to more fully understand the type and level of resistance that is present in 
livestock (Dargatz et al., 2003, Fiztgerald et al., 2003, Lanz et al., 2003, Bywater et al., 
2004, Khachatryan et al., 2004, Rajic et al., 2004, Hershberger et al., 2005). Many of 
these studies have focused on intensively reared livestock populations, such as feedlots, 
swine, and poultry operations, that may incorporate antimicrobials in feed for 
prophylactic, metaphylactic, or therapeutic reasons (McEwen and Fedorka-Cray, 2002).  
 
In addition to in feed AMU, the dairy or feedlot industry may also use antimicrobials 
prophylactically in a substantial proportion of individual animals. Between 75-90% of 
all dairy cattle receive prophylactic antimicrobials to prevent mastitis (Sishco et al., 
1993, USDA, 2003). Depending upon the size of the feedlot, the type of cattle placed 
and the bovine respiratory disease risk designation, anywhere between 16-19% of 
feedlot cattle in the United States (USDA, 1999) and 20-50% of feedlot animals in 
Canada receive prophylactic injectable antimicrobials on arrival for the control of 
bovine respiratory disease (Radostits OM, 2001, personal communication with Dr. 
Calvin Booker, FHMS, February 22, 2007). 
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In contrast to these more intensive livestock management systems, cattle in cow-calf 
herds in western Canada are primarily raised extensively and are, therefore, subjected to 
different management practices and antimicrobial exposures than livestock species that 
are raised more intensively. The typical production cycle for cows calving in the winter-
spring months of the year involves a period of confinement to pens or small pastures 
that enable producers to readily observe the cattle prior to and during the calving 
season. The duration and intensity of this confinement varies between farms and 
management systems. In many herds, cows that are due to calve are kept separate from 
cows that have already calved. Upon completion of the calving season and depending 
on grass accessibility, cow-calf pairs are then turned out of these more confined areas 
onto larger pastures. Cattle may be kept on these larger pastures into the fall and earlier 
winter depending on availability of feed and weather conditions. Calves are usually 
weaned in the fall, and at that time they may be sold or kept as replacement animals 
(Mathison, 1993).  
 
Because of management and environmental conditions, in-feed use of antimicrobials 
and routine injectable AMU in cow-calf herds is assumed to be less frequent than in 
other species. However, there are very limited data available to understand the selective 
pressures experienced in cow-calf herds. Four papers, two published and two un-
published, containing data on AMU in cattle were identified. In some cases it is not 
always clear whether the data provided pertains specifically to cow-calf herds, to beef 
cattle, or to cattle in general. This makes it very difficult to draw any conclusions about 
AMU practices within cow-calf herds.  
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A Michigan study of AMU in cattle collected information for 60 days prior to the 
administration of the questionnaire (Sayah et al., 2005). This study indicated that, 
during this time, no beef cattle were treated with any of the following drugs: 
streptomycin, trimethoprim-sulphamethoxazole, tetracycline, ampicillin, cloxacillin, or 
bacitracin (Sayah et al., 2005). The following drugs were used on 89 beef cattle 
reported as treated: enrofloxacin (2.5%), sulphamethazine (55.7%),  chlortetracycline 
(55.7%), oxytetracycline (16.5%), penicillin (2.5%),  ceftiofur (1.3%), and tilmicosin 
(27.9%)(Sayah et al., 2005). Dairy cattle on the other hand were treated differently 
(n=131) (Sayah et al., 2005) than the beef cattle. Streptomycin was used on 32.8%, 
sulphamethazine in 20.6%, trimethoprim-sulphamethoxazole in 1%, tetracycline, 
chlortetracycline and oxytetracycline in 12.7%, 21.4%, and 16.8% of the dairy cattle 
respectively (Sayah et al., 2005). Penicillin, ampicillin, cloxacillin, and ceftiofur were 
also used in 60.8%, 3.1%, 2.3%, and 19.9% of dairy cattle (Sayah et al., 2005).  
 
Bair and McEwen (2001) looked at AMU in the Ontario beef industry. This study 
included 16 feedlots and 13 cow-calf farms. The preliminary report indicated that 
oxytetracycline and tilmicosin were used prophylactically on 6/16 feedlots, whereas 
oxtetracycline or penicillin were used prophylactically on 3/13 cow-calf farms (Bair and 
McEwen, 2001). All feedlots used ionophore medication in the feed (Bair and McEwen, 
2001). Nine of 13 cow-calf herds used ionophores in feed (Bair and McEwen, 2001). 
No cow-calf herds used any other in-feed antimicrobials (Bair and McEwen, 2001). One 
feedlot and 1 cow-calf herd used water medication (Bair and McEwen, 2001). A sulpha 
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based drug was used in the feedlot and chlortetracycline was used in the cow-calf herd 
(Bair and McEwen, 2001). The most commonly used injectable drugs were: penicillin 
(45% of herds), florfenicol (35%), ceftiofur (17%), oxytetracycline (22%), tilmicosin 
(80%), and sulbactam-ampicillin (11%).  
 
A survey of Ontario beef producers’ attitudes about AMU was issued in 1999 
(Powell and Powell, 2001). A 4% response rate was achieved (Powell and Powell, 
2001). This represented 8% of the market steers, 7.5% of the market heifers, and 4.0% 
of the beef cows in Ontario (Powell and Powell, 2001). Of the 587 valid responses, 341 
came from cow-calf herds and 106 were from feedlots (Powell and Powell, 2001). The 
average cow-calf herd size was 40 animals, where half of the farmers reported 20 cows 
or less (Powell and Powell, 2001). The most commonly reported illness was diarrhea 
followed by respiratory disease (Powell and Powell, 2001). Approximately 1/3 of the 
farms reported treating less than 5% of their animals (Powell and Powell, 2001). 
Antimicrobial cost was determined to be an important factor in determining whether an 
antimicrobial was used or not. Most (94.4%) of respondents agreed that it is important 
to reduce AMU (Powell and Powell, 2001). The majority (78.0%) had concerns about 
negative media coverage and felt that his would cause them to re-evaluate their use 
practices (Powell and Powell, 2001). The injectable products used included: 
oxtetracycline (50.0%), penicillin (48.5%) tilmicosin (27.2%), trimethoprim-
sulphadoxine (23.0%), and florfenicol (14.6%) (Powell and Powell, 2001). Off label use 
of enrofloxacin was also reported on some farms (<1.0% of respondents) (Powell and 
Powell, 2001). Over half of the producers in this survey also did not know the 
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difference between an antimicrobial and other injectable products (Powell and Powell, 
2001). Prophylactic use was reported by 65 respondents, and 19 respondents reported 
treating the entire herd when only some animals were sick (Powell and Powell, 2001). 
A strong relationship was seen between treating less than 10% of the animals and 
having a regular veterinarian (Powell and Powell, 2001). 
 
Busani et al., (2004) did a similar survey to Powell and Powell (2001), but targeted 
beef and dairy cattle veterinarians rather than producers. This telephone survey included 
106 veterinarians; 62% treated only diary cattle, 10% treated only beef and 28% treated 
both (Busani et al., 2004). When treating mastitis, enteritis in calves, and when treating 
respiratory disease, laboratory analysis was requested always or frequently by 67.0%, 
37.0% and 17.0% of the veterinarians respectively. Prophylactic AMU for calf enteritis 
was used by 20% of veterinarians often or sometimes. For respiratory disease, 28% of 
veterinarians used prophylactic antimicrobials often or sometimes, and for mastitis, 
62% of the veterinarians reported using antimicrobials prophylactically always or often. 
Veterinarians reported using fluoroquionolones, phenicols, or third generation 
cephalosporins as the drugs of first choice for scours (54%), respiratory disease (12%), 
and mastitis (6%). Most veterinarians were aware of the problem of AMR (94%).  
 
2.10.2. Reason for treatment in cow-calf herds 
 
To date there is also very little information on reason for treatment and AMR in the 
beef industry particularly in cow-calf herds, and there is no information available on 
western Canadian cow-calf herds. The National Animal Health Monitoring System 
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(USDA) is the only available source that provides some insight into the reason for 
treatment in cow-calf herds. USDA (1997) reported a relatively low occurrence of 
disease and treatment in breeding females of cow calf herds. Pinkeye and interdigital 
necrobacillosis were listed as the two primary disease conditions reported among 
breeding females; whereas, diarrhea, followed by pneumonia, were the two most 
commonly reported illness in beef calves (USDA, 1997).  
 
2.10.3. Antimicrobial resistance 
 
The most common resistances detected in fecal E. coli isolates in a variety of species 
has been to tetracycline, sulphamethoxazole, and streptomycin (Kijima-Tanaka et al., 
2003, Khachatryan et al., 2004, Bywater et al., 2004). A similar trend would be 
expected in beef cattle from western Canada. However, the proportion of resistant 
organisms could potentially vary between livestock species and management systems; 
several examples of this are provided.  
 
A study of AMR in E. coli isolated from healthy poultry, pigs, and beef cattle 
demonstrated a diverse range of the proportion of isolates resistant for each species 
investigated and for each antimicrobial (Kijima-Tanaka et al., 2003). In general terms 
broilers had more resistance than pigs which had more resistance than cattle. For 
example, resistance to oxytetracycline ranged from 25 and 69% for cattle and broilers 
respectively (Kijima-Tanaka et al., 2003). This study also reported that fluoroquinolone 
resistance was 10% in broilers, while in cattle and pigs fluoroquinolone resistance was 
detected in <1% of the isolates (Kijima-Tanaka et al., 2003).  
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Schroeder et al., (2002) demonstrated similar trends in their study of E. coli 0157 
isolated from diagnostic samples collected from humans, cattle, swine, and food. Swine 
were found to be the most resistant species investigated in this study. 
Sulphamethoxazole resistance was detected in 74% of the swine isolates, tetracycline 
resistance was detected in 71% of the swine isolates, and cephalothin resistance was 
detected in 54% of the swine isolates (Schroeder et al., 2002). The type or age of the 
cattle was not specified, but 14% of the cattle isolates were positive for 
sulphamethoxazole resistance, 20% were positive for tetracycline resistance, and 3% 
were positive for ampicillin resistance (Schroeder et al., 2002). 
 
Sayah et al. (2005) also reported AMR patterns obtained from domestic and wild 
animal fecal samples, human septage, and surface water. The animal samples were 
collected from beef (7 farms), dairy (7 farms), swine (5 farms), horses (2 farms), sheep 
(6 farms), goats, chickens (2 farms), cats, dogs, deer (2 farms), ducks, and geese. The 
actual number of antimicrobials present in multiple resistant isolates was highest in 
swine, followed by dairy, poultry, and then beef cattle (Sayah et al., 2005). The highest 
levels of AMR varied depending on the antimicrobial of interest and the livestock 
species. Companion animals had the most resistance detected to cephalothin (38%), 
followed by small ruminants (22%), and then cattle (21%). Swine (63%) had the most 
isolates resistant to tetracycline, followed by poultry (35%), and small ruminants (24%) 
(Sayah et al., 2005).  
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A study examining the point prevalence of AMR E. coli O157 in Saskatchewan 
feedlot cattle reported that of 131 isolates, 65% were resistant to at least one 
antimicrobial tested (Vidovic and Korber, 2006). No resistance was observed to 
amikacin, ampicillin, amoxicillin-clavulanic acid, ceftriaxone, ciprofloxacin, cefoxitin, 
gentamicin, kanamycin, nalidixic acid, trimethoprim-sulphamethoxazole, and ceftiofur 
(Vidovic and Korber, 2006). Sulphasoxizole and tetracycline resistance were detected in 
61% and 12% of the isolates respectively (Vidovic and Korber, 2006). Chloramphenicol 
and streptomycin resistance was detected in 2.3% of the isolates (Vidovic and Korber, 
2006).  
 
In a longitudinal feedlot study performed in Alberta, cattle were sampled on arrival, 
at day 70 and again prior to slaughter. Animals were examined for vancomycin-resistant 
Enterococcus faecium (VRE) and Enterococcus faecalis, for Salmonella; quinolone or 
macrolide resistant thermophilic Campylobacter; and quinolone, aminoglycoside, or 
beta-lactam resistant E. coli (Read et al., 2004). No VRE and no Salmonella were 
detected. Low levels of ciprofloxacin, enrofloxacin, azithromycin, gentamicin, and 
meropenem resitance were observed in the Campylobacter isolates (Read et al., 2004). 
No ciprofloxacin resistant E. coli were detected, and only low levels of getamicin 
resistance was detected in E. coli (Read et al., 2004).  Ampicillin resistance was 
detected in 15% of the animals on entry, 60% at the interim sampling, and 63% prior to 
slaughter (Read et al., 2004). Ampicillin resistance was associated with florfenicol use 
and with tetracycline in feed (Read et al., 2004). A subset of the ampicillin resistant 
isolates were also blaCMY-2 positive (Read et al., 2004). The presence of the blaCMY-2 
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gene was associated with therapeutic use of florfenicol, oxytetracycline and tilimicosin 
at entry into the feedlot (Read et al., 2004).  
 
Two dairy cattle prevalence papers were also identified to demonstrate the range of 
AMR in this livestock sector. In one study, of 213 lactating dairy cows on 23 herds in 
Pennsylvania, E. coli isolates were found to be resistant to ampicillin (48%), ceftiofur 
(11%), florfenicol (78%), chloramphenicol (20%), spectinomycin (18%) and 
tetracycline (93%) (Sawant et al., 2007). Multi-drug resistance (≥3 antimicrobials) was 
detected in 40% of the E. coli isolates (Sawant et al., 2007). The most common multiple 
drug resistance pattern contained ampicillin, florfenicol and tetracycline; 36% of the 
multi-resistant isolates contained this pattern (Sawant et al., 2007). The second dairy 
study examined 96, 1 to 9 week old dairy calves from a single herd in Pennsylvania. 
AMR E. coli was found in 100% of the isolates (n=122) (Donaldson et al., 2006). All 
isolates contained both ampicillin and ceftiofur resistance. High levels of resistance 
were also detected for chloramphenicol (94%), florfenicol (93%), gentamicin (89%), 
spectinomycin (72%), tetracycline (98%) and ticarcillin (99%) (Donaldson et al., 2006). 
Cluster analysis indicated that 63% of the isolates belonged to one group (Donaldson et 
al., 2006). The blaCMY2 gene was found in 96% of the ceftiofur resistant isolates 
(Donaldson et al., 2006).  
 
Both beef and dairy calves were included in a study from Scotland. This project 
examined 72 beef suckler calves and 29 dairy calves on 15 cattle farms with cases of 
active enteritis and 9 farms without active cases of enteritis (Gunn et al., 2003). 
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Between 1 and 9 animals were sampled on each farm. Ampicillin resistance was 
founding 84% of the isolates, apramycin resistance in 13% of the isoalates, and 
nalidixic acid resistance in 6% of the isolates (Gunn et al., 2003). AMR was more 
frequently detected in the calves with enteritis than in the controls (Gunn et al., 2003). 
In calves with diarrhea, 95% of the isolates were resistant to ampicillin, 22% to 
apramycin, and 11% to nalidixic acid (Gunn et al., 2003). In control calves, 70% of the 
isolates were resistant to ampicillin, 2% to apramycin, and 0% to nalidixic acid (Gunn 
et al., 2003).  
 
Hoyle et al. (2006) investigated AMR on an organic beef farm in Scotland over a 28 
month period. Multiple resistance was found in >44% of the isolates with ampicillin, 
neomycin, sulphamethoxazole, and tetracycline resistance being the most common 
(Hoyle et al, 2006). In all calf cohorts examined, the peak monthly prevalence for 
ampicillin resistance ranged from 47 to 100% (Hoyle et al, 2006). Apramycin and 
nalidixic acid resistant E. coli were not detected in any fecal samples Hoyle et al, 
(2006).  
 
These papers illustrate a wide range of resistance prevalence depending on the 
species of livestock investigated and the antimicrobial of interest. Even within cattle 
there are numerous AMR patterns and frequencies. Since cattle data are often presented 
together (dairy, feedlot, cow, calf), or as dairy or feedlot specifically, no information 
was found for cow-calf herds.  
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2.10.4. Distribution of AMR in cattle populations 
 
Earlier research has indicated that prevalence of resistance is not equally distributed 
by age (Brophy et al., 1977, Hinton et al., 1984, Hinton, 1985, Matthew et al., 1999, 
Khachatryn et al., 2004). Typically AMR is highest in young animals (Khachatryn et 
al., 2004) and declines linearly with age (Hoyle et al., 2004). This phenomenon is not 
fully understood, but various theories have been investigated.  
 
Hoyle et al. (2004) demonstrated that calves preferentially lost resistant relative to 
susceptible bacteria as they aged. Additionally, other research has indicated that even in 
the absence of antimicrobials, a high prevalence of AMR could be maintained because 
the resistant strains had a fitness advantage in young calves but not in older animals 
(Khachatryan et al., 2004). The presence of these resistant E. coli in the absence of 
treatment/selective pressure could be due to fitness traits that make them better able to 
compete in the calf gut compared to susceptible organisms. These traits may include 
non-scavenging mechanisms (siderophores), increased adhesion and mechanisms that 
enhance colonization, reproduction, and spread (Simmons et al., 1988, Visca et al., 
1991, Allen et al., 1993, Mandal et al., 2001). 
 
2.10.5. Risk factors for AMR in calves 
 
A recent study of commensal E. coli isolated from pre-weaned dairy calves on 
dedicated calf rearing facilities (calf ranches) and on dairy farms described many factors 
associated with AMR (Berge et al, 2003, Berge et al, 2005a). Farm type, animal source, 
58 
calf age, and individual treatments were important predictors of the odds of E. coli 
belonging to resistant clusters (Berge et al., 2005a). Calves 2 weeks of age and older 
were more likely to carry multiple antimicrobial resistant organisms than day old 
calves. Calves on a dedicated calf rearing facility were also more likely to be carrying 
multiple resistant E. coli than calves reared on traditional dairy farms. E. coli isolated 
from calves treated with antimicrobials within 5 days of sampling were also more likely 
to be multiply resistant than E. coli isolated from calves not exposed to antimicrobial 
therapy. The authors concluded that the higher levels of resistance in calves raised on 
calf ranches was a result of selective pressure due to antimicrobials in the milk replacers 
throughout the pre-weaning period. Similarly, it was concluded that systemic 
antimicrobial treatment within 5 days of sampling also applied selective pressure on the 
enteric commensal flora.  
 
Additional work by Berge et al. (2006) investigating prophylactic and therapeutic 
antimicrobial administration on AMR of fecal E. coli in dairy calves indicated that in-
feed antimicrobials were associated with higher levels of multiple AMR; that in calves 
not receiving in-feed antimicrobials, older calves had higher levels of multiple AMR 
than day-old calves; and that individual treatment with antimicrobials transiently 
increased resistance. Based on this and the previously mentioned studies, they 
concluded that the occurrence of AMR in commensal E. coli is dominated by selective 
influence.  
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Further work indicated that in feedlot cattle, treated animals shed a larger proportion 
of resistant organisms in their feces initially after therapy, but that this level declined 
gradually over 4 weeks (Berge et al., 2005b). Despite transient increased shedding of 
resistant organisms in the treated individuals, there was no effect on the shedding of 
resistant organisms in the untreated pen mates (Berge et al., 2005b). The authors 
concluded that this demonstrated that there is limited transfer of AMR bacteria from 
treated to untreated animals (Berge et al., 2005b). 
 
The above feedlot study also demonstrated an interesting dynamic of AMR. The 
calves for the study came from two sources. While individual animal treatment records 
were not available, calves at neither source farm had exposure to antimicrobials in the 
feed prior to arrival at the feedlot, but E. coli isolated from calves from one source 
appeared more susceptible on arrival than E. coli isolated from calves originating from 
the other farm (Berge et al., 2005b). The calves from the source farm that were 
shedding E. coli with lower levels of AMR at arrival eventually did shift to higher 
levels of resistance over time ultimately leading to a more uniform distribution of AMR 
regardless of farm of origin. From this the authors hypothesized that the original source 
of calves may impact fecal E. coli patterns initially, but over time the feedlot 
environment dictates what patterns eventually become established.  
 
2.10.6. How this thesis will fill in the gaps demonstrated in this review 
 
There are very few data on AMU and AMR in beef cattle and no information on 
western Canadian cow-calf herds. For the few studies available, the age and type of 
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animal being sampled are not always defined. In order to appreciate the potential 
diversity of AMR in cow-calf herds, a methodical sampling approach is necessary to 
investigate AMR patterns in the primary age groups found in cow-calf herds. Risk 
factors for AMR development in cow-calf herds also need to be identified including 
information about the reasons for treatment and the types of antimicrobials used. To 
date this information is not available.  
 
2.11. Concluding statements 
 
AMR is a complex issue. While in the last several years great strides have been made 
in gaining a better understanding of the underlying genetic mechanisms for AMR, there 
is still much to be learned. The issue of AMU in livestock and its subsequent impact on 
human health will probably continue to be debated despite the growing knowledge base 
that is being accumulated. While this question may be a long way from being resolved 
any additional work investigating the development of AMR in animals and in people 
will help add an additional piece to the puzzle. Despite a growing body of information 
on AMR scientists are still struggling with grasping all the intricacies of this subject.  
 
When it comes to AMU in livestock the knowledge gap grows exponentially. In 
order to be able to appreciate the true impact of livestock AMU on AMR, a much better 
system of collecting and reporting AMU needs to be developed. For most countries, and 
in the majority of species, unfortunately the reality of collecting good AMU data at this 
time is truly limited.  
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Since AMR is generally a sporadically encountered problem in therapeutic failure in 
veterinary medicine, it may be perceived by some as a non-issue. Unfortunately, it is 
not just therapeutic failure that veterinary medicine and the livestock industry need to 
be concerned with, but it is also the public perception of our role in the spread of AMR 
through “over” use of antimicrobials in the rearing of animals. Public perception and 
intensive scrutiny of AMU in food animal production may ultimately lead to the 
banning of certain antimicrobials and future limitations on the approval of specific 
antimicrobials for use in animals. Our current AMU practices may also lead to potential 
trade barriers from countries that have already banned in feed antimicrobials. 
Unfortunately, in Canada, despite research and surveillance efforts, there are still large 
gaps in our understanding of AMU and AMR. By expanding our current knowledge and 
by conducting research at all levels of the food chain, science can be used to help ensure 
that antimicrobials will remain viable and available for the health and welfare of both 
humans and animals. 
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CHAPTER 3 
ANTIMICROBIAL USE IN 203 WESTERN CANADIAN COW-CALF HERDS 
 
3.1. Introduction 
 
The treatment of infectious disease in food producing animals is an essential 
component of veterinary medicine. Antimicrobial therapy is an important tool available 
to producers and veterinarians and is necessary to ensure that animal health and welfare 
are maintained. In addition to therapeutic use, antimicrobials are also used non-
therapeutically to prevent disease, for growth promotion, and to increase production 
efficiency.  
 
Antimicrobial use (AMU) in food animal production is under increasing scrutiny 
because of reports in both the scientific literature and lay media concerning 
antimicrobial resistance (AMR) and the emergence of multi-resistant pathogens. Most 
authorities believe the association between AMU and AMR to be virtually certain 
(Shales et al., 1997). There is literature supporting the link between the use of 
antimicrobials in both people and animals and the selection for resistant bacterial 
populations (Sandvang et al., 1997, Tollefson et al., 1997, Barton, 1998, Levy, 1998). If 
a link between AMU and AMR is accepted, then the question becomes whether the 
populations of resistant bacteria identified in people and animals are independent or 
whether they comprise a common pool and pose a potential threat to both human and 
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animal health (Salyers and Cuevas, 1997, Barton, 1998). If human and animal bacterial 
populations comprise a common pool, then AMU in animals could impact the AMR in 
both animal and human populations. 
 
Resistance mechanisms have been described and identified for all antimicrobials that 
are currently available for clinical use (McDermott et al., 2002). Research demonstrates 
that both veterinary and human pathogens such as Escherichia coli (Sidjabat et al., 
2006), Salmonella spp. (Lopes et al., 2006), Enterococcus spp. (Manero et al., 2006), 
Staphylococcus spp. (Guardabassi et al., 2004, Sabour et al., 2004), and Campylobacter 
spp. (Randall et al., 2003) have acquired multiple resistant phenotypes. Options for 
antimicrobial therapy against disease caused by these organisms could become limited 
or non-existent in the near future (Levy, 1994, ASM, 1995, Gold and Moellering, 1996, 
Salyers and Cuevas, 1997, Levy, 1998). This concern has resulted in increased 
awareness about AMU and the subsequent development of AMR.  
 
While many countries are developing surveillance systems for AMU and AMR, 
there is little information on which antimicrobials are used, how they are used, and in 
what quantities. While a few studies have provided some insight to more intensive 
livestock production units such as hog farms (Dunlop, 1998, Rajic, 2006), there is no 
information about AMU in western Canadian cow-calf herds.  
 
Based on farm cash receipts the beef industry is the largest livestock commodity in 
Canada (Statistics Canada, Accessed May 18, 2007, 
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http://www.statcan.ca/Daily/English/07022007/d070227a.htm). The provinces of 
Alberta and Saskatchewan contain more than 65% of the beef cow, breeding heifer, and 
calf populations in Canada (Statistics Canada, Accessed July 25, 2006, 
http://www.40.statcan.ca/101/cst01/prim50a.htm). A better understanding of AMU 
patterns in this population is essential to develop a baseline and determine the need for 
future monitoring in the Canadian cow-calf industry.  
 
The objective of this study was to describe the frequency of treatment with 
antimicrobials, common reasons for AMU, and the types of antimicrobials used in 
western Canadian cow-calf herds. It was beyond the scope of this project to attempt to 
quantify the amount of antimicrobials used in these operations.  
 
3.2. Materials and methods 
 
3.2.1. Background and herd selection 
 
The herds examined in this study were part of a multifaceted survey of risk factors 
affecting the productivity and health of cow-calf herds in western Canada 
(https://www.wissa.info). Sixty-one private veterinary clinics across Alberta, 
Saskatchewan, and north-eastern British Columbia were approached and asked to 
participate. Within each practice, herds were identified and enrolled based on the 
selection criteria which considered herd size (>50 cows), animal identification, existing 
calving records, animal handling facilities, routine testing for pregnancy and for bull 
breeding soundness, and relationship with a local veterinary clinic. Only herds using a 
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winter/spring calving season were enrolled in the study. Participating herds were visited 
regularly by one of six veterinarians contracted by the University of Saskatchewan to 
collect samples and data and to monitor the quality and consistency of on-farm records. 
 
The individual animal treatment records from January 1 to June 30, 2002 were 
summarized for 203 study herds. Calf and cow/heifer treatment data were investigated 
separately. In the first step of the analysis only calf treatment data were considered. The 
analysis was restricted to information collected for calves born alive between January 1 
and May 31, 2002. Risk factor data were summarized for calves and their dams meeting 
the inclusion criteria (Table 3.1). The second step of the analysis included treatment 
data reported for all cows, bred heifers and yearling heifers in the herd on January 1, 
2002. Cows and bred heifers with stillborn calves, non-pregnant cows and heifers were 
also incorporated into the total number of animals available for investigation (Table 
3.2). Any cows or heifers purchased after January 1, 2002 were not included.  
 
Available calving records for each cow/heifer included cow/heifer identification, calf 
identification, date of calving, single or twin birth, sex of the calf, the type of assistance 
provided to the cow/heifer, any post calving problems, and calving outcome (born alive, 
stillbirth, died later). If the calf died, the date of death was also reported. Other data 
recorded for each herd included: the ecological region in which the herd was located, 
the veterinary clinic servicing the herd, vaccination status for infectious bovine 
rhinotrachietis (IBR), bovine viral diarrhea virus (BVDV), and also for neonatal 
diarrhea (coronavirus, rotavirus, and E. coli). Cow/heifer body condition (BCS) was 
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scored (9-point scale) at the time of pregnancy diagnosis and again before or during the 
early part of the calving season.  
 
3.2.2. Antimicrobial use data collection 
 
Data on AMU were collected using individual treatment records as well as a herd 
level questionnaire. Producers were provided with a standardized treatment book for 
recording the date of treatment, animal identification, class of animal, reason for 
treatment, type of treatment, outcome, and other notes. A coded list was provided to 
help standardize the responses for class of animal, reason for treatment, type of 
treatment, and outcome. Animal class included: calf, cow, heifer, and bull. Scours 
(diarrhea), navel ill (omphalitis), pneumonia, bloat (ruminal typmpany), arthritis, 
pinkeye (infectious keratoconjunctivitis), coccidiosis, and other were included as 
possible diagnoses. Treatment type was coded as injectable antimicrobial, oral 
antimicrobial, oral and injectable antimicrobial, fluids, and other. Outcome options 
included: survived, died later, slaughtered, and unknown. A notes section allowed 
producers to write in any comments. Where possible the notes section was used to help 
further classify diagnoses or treatments recorded.  
 
Producers could report more than one reason for or type of treatment for each 
treatment episode. The producer was asked to record each treatment occurrence 
however, animals reported as treated more than once for the same diagnosis within a 
seven day period were classified as having one treatment event for the purpose of 
analysis. 
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Treatment data were then summarized in two ways. To attempt to provide an 
estimate of treatment intensity per herd for the period of January 1 to June 30, 2002, a 
count of total treatment events per herd was determined. This was calculated separately 
for both cows/heifers and calves and was reported as the number of treatment events per 
every 100 animals at risk. Animals at risk included the total number of calves or 
cows/heifers in the study for this time period. Treatment occurrence was also 
summarized separately for calves and cows/heifers as risk or cumulative incidence. This 
was calculated as the number of calves (or cows/heifers) that were reported as ever 
having been treated as a percentage of the number of calves (or cows/heifers) in the 
herd at risk of treatment during the study period. 
 
The individual animal records did not consistently include information on the type of 
AMU for treatment, therefore, a questionnaire was developed to identify the types of 
antimicrobial products most commonly used on each cow-calf farm. Herd owners were 
asked about the frequency of use for sulphonamides, tetracylcines/oxytetracyclines, 
trimethoprim/sulphadiazine, and penicillins. Antimicrobials that did not fall into these 
broad categories were classified as “other”. Lists of common trade names were 
provided under each group to simplify the selection of the appropriate drug by the 
producer. Producers were asked to report separately the number of treatments for both 
cows and calves for each drug category listed above. The number of treatments for each 
category was coded as follows: l to 3 animals treated, 4 to 10 animals treated, and 
greater than 10 animals treated.  
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The quality of the treatment records were assessed at the end of the study. The 
veterinarians responsible for data collection and entry were asked for a crude subjective 
and comparative assessment of the quality of the data. They classified the data for each 
herd into one of the following categories: excellent, good or satisfactory, and less than 
satisfactory. Herd owner compliance in completing treatment records was also 
evaluated by considering the relative frequency of calf mortality in the herds that did 
not report any treatments. Complete calf mortality records were available for 
comparison from the baseline productivity study. The plausibility of no reported 
treatments was assessed when compared to the percent calf death loss in each herd.  
 
3.2.3. Statistical analysis 
 
All data were entered into a computerized database (Microsoft® Office Access 2000, 
Microsoft Corporation). Descriptive analyses were completed and variables were 
recoded as necessary for statistical modeling using commercially available software 
programs (SPSS 11.0 for Windows, SPSS Inc., Chicago, Illinois).  
 
3.2.3.1. Mixed models for discrete data 
 
Factors affecting the occurrence of treatment, a class variable with two levels 
(treated or not treated), were examined in both cows/heifers and calves using mixed 
models with a binomial distribution and logit link function. The calculations were 
performed using penalized quasi-likelihood estimates (2nd order PQL) (MLwiN version 
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2.0, Centre for Multilevel Modelling, Institute of Education, London, UK). The strength 
of the association between outcome and exposure was reported as an odds ratio (OR) 
with 95% confidence intervals.  
 
A null model (intercept only) was created for each outcome variable. Random 
intercepts were examined to assess degree of clustering for treatments reported within 
herd, veterinary clinic, and ecological region (ecoregion). Ecoregion is a geographical 
delineation characterized by regional ecological factors such as vegetation, soil, climate, 
water and fauna (Wiken, 1986). Within-herd clustering was accounted for as a random 
intercept in all models. The importance of veterinary clinic and ecoregion as random 
effects were considered for inclusion in the final model if the variance estimate for the 
random effect was larger than its standard error. Models were checked for the presence 
of extra-binomial variation, but extra-binomial parameters in the range of 0.9 to 1.0 
were reset at 1.0 (binomial variation). 
 
Data from the null models were used to estimate the intra-class (i.e., intra-herd) 
correlation coefficient (ρ=σ2h/(σ2h+π2/3)) to measure clustering of each outcome within 
herd. The null models were also used to generate population-average estimates of the 
risk of calf and cow/heifer treatment using the formulas βPA≈βSS/√(1+0.346 σ2h) (Dohoo 
et al., 2003).  
 
The unconditional associations between each of the potential risk factors (Table 3.1 
for calves and Table 3.2 for cows/heifers) and the odds of treatment were examined. All 
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potentially important risk factors (P≤0.25) were identified and a final model was then 
developed using backwards stepwise elimination.  
 
Any potential risk factors where P<0.05 or that were acting as important confounders 
(removal of the potential risk factor from the model changes the effect estimate for the 
exposure by≥20%) were retained in the final model. After establishing the main effects 
model, biologically reasonable first order interaction terms were tested if two or more 
variables (P<0.05) were retained in the final model. The adequacy of all models was 
evaluated using plots of residuals to check that all assumptions had been met as 
appropriate. 
 
Associations between calf treatment and mortality were investigated using 
generalized estimating equations (SAS v.8.2 for Windows (PROC GENMOD); SAS 
Institute, Cary, North Carolina, USA). The number of calves with any treatment 
(numerator) as a proportion of the total number of calves in the herd (denominator) was 
the outcome of interest. The predictor variable, percent calf mortality, was categorized 
into quartiles (<2%, 2-5.9%, 6-14.9% and >15% mortality) with mortality >15% as the 
reference. The model specifications included a binomial distribution, logit link function, 
repeated statement with subject equal to herd, and an exchangeable correlation 
structure.  
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3.3. Results 
 
3.3.1. Farm and animal information 
 
Records from 203 herds across Alberta (146), Saskatchewan (53), and northern 
British Columbia (4) were included. On January 1, 2002, herd size ranged from to 53 to 
481 mature/breeding females, with a median herd size of 154. Of the 203 included in 
the study, 169 herds (83.3%) had between 100 and 400 mature/breeding females.  
 
3.3.1.1. Calf population 
 
Between January 1 and May 31, 2002, 28,573 calves were born alive; the majority of 
calves were born in March and April (64%; 18,285/28,573). Most calves born alive 
were unassisted; 4.4% of live births were twins (Table 3.1). About half of the dams 
were vaccinated for IBR/BVDV prior to breeding in 2001, while about one third of the 
dams received some type of vaccination to prevent neonatal calf bacterial or viral 
diarrhea (Table 3.1). Most cows had a BCS of 5 or higher on a 9-point scale at 
pregnancy testing and again at calving (Table 3.1).  
 
3.3.1.2. Cow and heifer population 
 
There were 36,634 cows and heifers reported in study herds on January 1, 2002. This 
number included all cows/heifers that had calves born alive from January 1 to May 31, 
2002, cows/heifers that had abortions or stillborn calves during this period, and any 
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non-pregnant cows/heifers and replacement heifers. The majority of cows were between 
4 and 10 years of age (Table 3.2). Dystocias were reported in <10% of cows/heifers, 
and <1% of cows/heifers had post partum complications such as retained placentas, 
prolapses, or metritis (Table 3.2).  
 
3.3.2. Individual animal records of treatment and diagnosis 
 
3.3.2.1. Individual calf treatment records 
 
Herd owners reported treating 13.5% (95% CI; 10.7 to 17.0%) of the calves at least 
once between January 1 and June 30, 2002. The median age of calves at the time of 
their first treatment was 11 (range, 0-141) days of age and 58.6% (2171/3702) of the 
treated calves were between birth and 14 days of age. The median percent of calves ever 
treated per farm was 6.5% (range, 0-100%). After accounting for the records where an 
individual calf was treated more than once, the median number of treatment events per 
farm was 6.8 (range 0-104) for every 100 calves at risk.  
 
The most commonly recorded calf treatment was antimicrobial injection (Table 3.3). 
Injectable antimicrobials were used in 56 (27.6%) herds on <1% of the calves, in 70 
(34.5%) herds on 1-5% of the calves, in 56 (27.6%) herds on 5-15% of the calves, and 
in 23 (11.3%) herds on >15% of the calves. Four herd owners treated 50-80% of the 
calves and 3 herd owners treated all of their calves at least once. The maximum number 
of times a calf was treated with injectable antimicrobials was 14 (median, 1; range, 0-
14). 
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The second most commonly reported protocol for calves included treatment with 
both oral and injectable antimicrobials at the same time (Table 3.3). Oral and injectable 
antimicrobials were used on <1% of the calves in 130 (64.0%) herds, on 1-5% of the 
calves in 40 (19.7%) herds, on 5-15% of the calves in 23 (11.3%) herds, and on >15% 
of the calves in 10 (4.9%) herds (maximum, 42.3%).  
 
Oral antimicrobials alone were used in <2% of calves (Table 3.3). One hundred and 
forty-four (70.9%) herd owners treated <1% of their calves with oral antimicrobials, 40 
(19.7%) treated 1-5% of the calves, 13 (6.4%) treated 5-15% of the calves, and 6 (2.9%) 
treated between 15-51% of their calves with oral antimicrobials.  
 
3.3.2.2. Individual calf records of diagnoses 
 
Diarrhea was the most commonly reported reason for treatment in calves and was 
diagnosed in over 5% of the calves and on 60% of the farms (Table 3.4). The percent of 
calves treated per farm ranged from 0 to 89.0% (median, 4.3%). Of the 203 
herds/producers, 145 (71.4%) producers treated 0-5% of their calves for diarrhea, 20 
(9.9%) producers treated 5-10%, 25 (12.3%) producers treated 10-20%, and 13 (6.4%) 
producers treated >20% of their calves for diarrhea.  
 
The next most common reason for treatment was pneumonia (Table 3.4). Just over 
2% of the calves were diagnosed with pneumonia, and calf pneumonia was reported as 
a reason for treatment on 50% of the farms (Table 3.4). Pneumonia treatment rates per 
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farm ranged from 0-52.3% (median, 2.0). One hundred and twenty-six (62.1%) 
producers treated ≤1% of their calves, 51 (25.1%) producers treated 1-5% of their 
calves, 20 (9.9%) producers treated 5-15% of their calves, and 6 (2.9%) producers 
treated >15% of their calves for pneumonia. 
 
Treatment and prevention of omphalitis (navel infection) made up the third most 
common recorded reason for treatment (Table 3.4). Four producers treated between 65 
and 100% of their calves prophylactically for omphalitis.  
 
3.3.2.3. Individual cow treatment records 
 
Between January 1 and June 30, 2002, 2.7% (95% CI; 2.2 to 3.4%) of the cows and 
heifers were treated at least once. The median percent of cows/heifers ever treated per 
farm was 0.9% (range 0-14.7%). Since the majority of cows/heifers were only treated 
once during this time period the number of treatment events per 100 cows/heifers at risk 
was also 0.9 (range 0-14.7). 
 
The most commonly reported treatments in cows and replacement heifers were with 
injectable antimicrobials (Table 3.5). Very few cows or heifers were reported to receive 
either oral antimicrobials or oral and injectable antimicrobials together (Table 3.3). Oral 
treatments were only given in 2 (1.0%) herds and to <3% of the cows in these herds; 
whereas, oral and injectable treatments were given in 5 (2.5%) herds to <1% of cows. 
One hundred and eleven (54.7%) producers treated <1% of their cows with injectable 
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antimicrobials, 69 (34.0%) producers treated 1-5% of their cows, and 23 (11.3%) 
producers treated >5% of their cows with injectable antimicrobials.  
 
Treatments other than antimicrobials were a more commonly reported for cows and 
heifers than for calves (Table 3.3). Treatments categorized as “other” were given on 46 
(22.7%) herds to 0.2-5% of the cows. Other treatments included non-antimicrobial 
treatments such as mineral oil or other products for gastrointestinal disorders. The only 
antimicrobial treatment included in the other category was intra-mammary treatments 
for mastitis. Intramammary products were used on 3.0% of the farms (Table3.6).  
 
3.3.2.4. Individual cow records of diagnoses 
 
Metritis, interdigital necrobacillosis (footrot), and retained placenta were the most 
commonly reported reasons for treatment of cows and heifers (Table 3.5). Metritis was 
diagnosed and treated in <1% of the animals in 182 (89.7%) herds, in 1-2% of the 
animals in 9 (4.4%) herds, and in >2% of the animals in 12 (5.9%) herds. One hundred 
seventy-four (85.7%) herd owners treated <1% of their cows, and 29 (14.3%) of herd 
owners treated 1-5% of their cows for interdigital necrobacillosis. Retained placentas 
were diagnosed and treated in <1% of the animals in 173 (85.2%) herds, in 1-2% of the 
animals in 20 (9.8%) herds, and in 2% of the animals in 10 (4.9%) herds.  
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3.3.3. Antimicrobial use 
 
The most commonly reported antimicrobials used in calves included (Table 3.6): oral 
sulphonamides, florfenicol injectable, and long acting injectable oxytetracycline. Long 
acting oxytetracycline injectable, benzathine/procaine penicillin G, and procaine 
penicillin G injectable were the antimicrobials most commonly reported to have been 
used in the cows and replacement heifers (Table 3.7). When all AMU was summarized 
for each herd, the most commonly reported antimicrobials were oxytetracycline, 
penicillin, and florfenicol (Table 3.8).  
 
Ionophores were used in the feed of cows or heifers in 28.6% (58/203) of the herds. 
Of the herds using ionophores 86.2% (50/58) were including ionophores in both the 
cow and heifer rations, 10.3% (6/58) were including ionophores in heifer ration only 
and 3.4% (2/58) were including ionophores in the cow ration only. Reason for use was 
not clearly specified. 
 
Specific treatment information was investigated for two antimicrobials of interest, 
enrofloxacin and florfenicol. Enrofloxacin was reported as used on 287 calves in 8 
herds. One herd reported treating 172 of 191 (90.1%) calves with a combination of 
enrofloxacin and sulbactum-ampicillin. For all calves treated with enrofloxacin, the 
recorded reason for treatment was scours. Florfenicol was listed specifically in the notes 
section for the treatment records of 92 calves on 17 farms. Of these 92 calves, 41 
(44.6%) were treated for diarrhea, 31 (33.7%) for omphalitis, 5 (5.5%) for pneumonia, 1 
(1.1%) for arthritis, and 14 (15.2%) for other reasons. 
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3.3.4. Effect of herd, veterinary clinic, ecoregion, and other risk factors on 
reported treatment practices for calves and cows  
 
Neither location of the herd by ecoregion or accounting for differences between 
referring veterinary clinics explained a substantial part of the variation in reported 
treatment practices for either calves or cows. However, treatment practices were 
clustered within herd (calf treatment ρ=0.21, cow treatment ρ=0.20).  
 
Calf gender, the need for assistance at parturition, and the percent of cows/heifers 
treated in the herd were unconditionally associated with the odds of a calf having been 
reported as being treated by the herd owner (Table 3.9). After accounting for other 
variables in the model, male calves were at higher risk than female calves to have been 
treated, and calves that had a history of intervention during calving were more likely to 
have been treated than calves that were born unassisted (Table 3.10). Also, for every 
1.0% increase in cow/heifer treatment the odds of calf being treated increased by 1.2 
times (Table 3.10). 
 
Initial analysis of the heifer and cow data demonstrated that yearling heifers were 0.2 
times (95% CI 0.2-0.3, P=0.0001) as likely to be treated than all other breeding females. 
Other risk factors such as breed, precipitation, and body condition score, did not 
significantly contribute to the odds of a cow or heifer being treated.  
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Assessment of pregnant cow or heifer vaccination status and calving related factors 
was completed only for mature females with calving records in 2002 (Table 3.11). After 
accounting for other risk factors, cows or first-calf heifers that had a problem post 
calving such as a prolapse, retained fetal membranes, or metritis were more likely to be 
treated than cows or heifers that did not have a problem post calving (Table 3.12). Also, 
cows or heifers that needed assistance at calving were more likely to be treated than 
cows or heifers that did not.  
 
3.3.5. Assessment of the quality of treatment records 
 
The veterinarians responsible for data collection and entry subjectively rated 39% of 
the herd treatment records as excellent, 41% as good or satisfactory, and 20% as less 
than satisfactory. Herd owner compliance in recording these data was also investigated 
by comparing herd calf mortality and treatment rates in the 28 (13.7%) herds that had 
no reported treatments. Of these herds, 4 had no calf mortality, 10 had <2% calf 
mortality, 8 had 2-5% calf mortality, 4 had 5-10% calf mortality and 2 had >10% calf 
mortality.   The risk of calf mortality was not associated with the proportion of calves 
treated in the study herds (P=0.6). 
 
3.4. Discussion 
 
This study is the first documentation of AMU and rationale for treatment in 
extensively managed cow-calf herds in western Canada. At least 86% of herd owners 
treated one or more calves or cows and heifers during the study period; however, less 
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than 15% of both calves and cows/heifers were reported as treated. The relatively small 
proportion of treated animals is consistent with the finding that the primary reasons for 
antimicrobial use in cow-calf operations were for individual therapeutic uses rather than 
prophylaxis, metaphylaxis, or growth promotion. In contrast, between 75-90% of all 
dairy cattle receive prophylactic antimicrobials to prevent mastitis (Sishco et al., 1993, 
USDA, 2003). Depending upon the size of the feedlot, the type of cattle placed and 
bovine respiratory disease risk designation, anywhere between 16-19% of feedlot cattle 
in the United States (USDA, 1999) and 20-50% of feedlot animals in Canada receive 
prophylactic injectable antimicrobials on arrival for the control of bovine respiratory 
disease (Radostits OM, 2001; personal communication with Calvin Booker, FHMS, 
February 22, 2007). 
 
Although some oral antimicrobials were used, injectable formulations were the most 
commonly reported method of antimicrobial administration on cow-calf farms. Only a 
small number of herds used feed ionophores. This varies from feedlot or swine 
operations where in feed use plays a larger role in antimicrobial delivery (McEwen and 
Fedorka-Cray, 2002, Rajic, 2006). The most commonly used products in cows were 
long acting injectable oxytetracyclines and penicillins. Injectable and oral 
sulphonamides, injectable florfenicol, and injectable oxytetracyclines were the primary 
drugs selected for treatment of calves.  
 
A Michigan study of AMU in cattle reported slightly different results. The AMU 
information in this study was collected by questionnaire and pertained to treatment 
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practices within the previous 60 days (Sayah et al., 2005). No beef cattle (n=89 beef 
cattle on 7 farms) in this study were treated with trimethoprim/sulphamethoxazole, 
tetracycline, or streptomycin (Sayah et al., 2005). The most common treatment was with 
sulphamethazine (55.7%) and chlortetracycline (55.7%), followed by tilmicosin 
(27.9%), oxytetracycline (16.5%), penicillin (2.5%), enrofloxacin (2.5%), and ceftiofur 
(1.3%). There are two major distinctions between the Michigan study and the current 
study. First, the Michigan study reported AMU for all beef cattle without differentiating 
between feedlot and cow-calf herds. Some of the differences in the types of drugs 
reported as used could be a result of this reporting structure. Second, the Michigan 
study only looked at AMU in the 60 days prior to the questionnaire administration in a 
limited number of animals while the current study looked at AMU over a 6 month 
period in a much larger number of animals. 
 
Two unpublished studies from Ontario also provide further insight into AMU in beef 
cattle. The first study looked at 16 feedlots and 13 cow-calf farms (Bair and McEwen, 
2001). Penicillin was used on 45% of the farms, florfenicol on 35%, ceftiofur on 17%, 
oxytetracycline in 22%, tilmicosin on 80%, and sulbactam-ampicillin on 11%. No in 
feed AMU was reported for the cow-calf herds other than the inclusion of an ionophore 
(9/13 farms). In the second Ontario study, 587 (341 cow-calf and 106 feedlot) producers 
were surveyed on their attitudes about AMU (Powell and Powell, 2001). The producers 
surveyed reported using the following injectable antimicrobials: oxytetracycline (50.0% 
of herds), penicillin (48.5%), tilmicosin (78.0%), trimethoprim-sulphadoxine (23.0%) 
and florfenicol (14.5%) (Powell and Powell, 2001). As with the above mentioned 
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Michigan study, the reporting structure of the two Ontario studies does not permit 
differentiation between what was used in cow-calf herds and what was used in feedlots.  
 
Extra-label drug use was reported in some cow-calf herds in the current study. In 
Canada, florfenicol is labeled for bovine respiratory disease and for the treatment of 
interdigital phlegmon (Compendium of Veterinary Products, 2003), but the individual 
animal treatment notes indicate that it was also used in an extra-label manner in calves 
for diarrhea and omphalitis. Extra-label use of fluoroquinolones and cephalosporins was 
also reported. Powell and Powell (2001) also reported off label use of enrofloxacin in 
their survey of Ontario beef producers. At the time of these studies, enrofloxacin was 
not readily obtainable by cattle producers because in 2002 there was only a small 
animal formulation available in Canada. Recently, a cattle formulation has been 
approved for use in Canada for the treatment of bovine respiratory disease 
(Compendium of Veterinary Products, 2003). Follow up studies to see how AMU 
patterns might have changed with a change in product availability are needed. 
 
In addition to describing use patterns, this study identified factors associated with the 
reported frequency of calf treatment. Calves that were assisted during birth were more 
likely to be reported as treated. Sanderson and Dargatz (2000) also reported that 
increasing incidence of dystocia in a herd was associated with increased morbidity. 
Dystocia can lead to decreased vigor, hypoxia and acid-base disturbances (Bellows et 
al., 1987). Another potentially related finding was that male calves were more likely to 
be treated than female calves. This could be because male calves are often larger than 
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females (Bellows et al., 1987). Larger calves are more likely to experience delayed 
parturition and increased fetal stress. This could result in reduced vigor; potentially 
negatively affecting passive transfer and calf health. Calves were also more likely to be 
treated in herds where more cows/heifers were treated. This finding might reflect an 
increased likelihood of exposure to disease on these farms because of management or 
other factors, or it may reflect an increased tendency of these producers to administer 
and report treatment.  
 
Yearling heifers were less likely to be treated than cows. This is probably because 
yearling heifers have not yet entered the breeding herd and, therefore, were not subject 
to the primary risk factors for treatment identified within the breeding herd. Risk factors 
for cow/bred heifer treatment included assistance at calving and post calving problems 
such as a prolapse, retained fetal membranes, and metritis. The odds that a cow or bred 
heifer would be treated if she had any one of the above post calving conditions were 
substantially increased over that of one with no problem at calving. Assistance at 
calving was also a risk factor for treatment. Cows or bred heifers that required any 
manipulation or traction on the fetus at the time of calving or caesarian sections were at 
much higher risk for being treated than those that calved unassisted. 
 
Because cows and bred heifers were more likely to be treated if there was assistance 
at calving, further investigation is needed into whether producers are providing 
treatment prophylactically because of the intervention or it they are treating for an 
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actual condition, either related to parturition or for some other reason. This distinction is 
not entirely clear from the data available.  
 
To minimize the need for treatment, producers should work to decrease the need for 
calving assistance and post partum complications through bull selection, management 
and selection of replacement heifers, and appropriate dystocia intervention (Chenowith 
and Sanderson, 2001). These practices may also help minimize post partum uterine 
prolapses through reduction of dystocias. Increasing the awareness of producers about 
when and why to treat is also essential. Basic manipulations or pulling of calves should 
not generally require antimicrobial treatment of either the dam or the calf. Also, 
providing adequate nutrition will help avoid post partum problems such as retained fetal 
membranes (USDA, 1996) as well as contributing to over all cow/heifer and calf health.  
 
Calves were more likely to be reported as treated than cows/heifers in this study and 
the primary reason reported for calf treatment was diarrhea. Diarrhea was also the most 
commonly reported illness in beef calves in the United States (USDA, 1997) and in a 
survey of beef producers in Ontario (Powell and Powell, 2001). In the current study the 
primary reported reason for treatment of cows/heifers was metritis followed closely by 
interdigital necrobacillosis; whereas in the United States pinkeye and interdigital 
necrobacillosis were listed as the two primary disease conditions reported among 
breeding females (USDA, 1997). The current study only looked at treatment from 
January to June whereas the NAHMS study questions spanned the entire year. 
Infectious bovine keratoconjunctivitis (IKC) is more common in the summer months. 
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Although, there is a difference in the primary reason for cow/heifer treatment between 
western Canada and the United States both studies did report a relatively low 
occurrence of disease and treatment in breeding females.  
 
A higher proportion of animals were reported as treated by owners participating in 
the USDA’s National Animal Health Monitoring System (1997) than in the current 
study. This may in part be due to management, animal genetic and climatic differences 
between western Canada and the United States, but it may also relate to number of 
herds enrolled, and data collection methodology differences in each study. The National 
Animal Health Monitoring System’s (NAHMS) beef ’97 study data were collected from 
2,713 producers via a questionnaire administered on farm from December 30 through 
February 3, 1997 (USDA, 1997). Another factor that could contribute to treatment 
differences is that all of the herds in the current study had more than 100 total cows and 
calves; whereas, less than 60% of the NAHMS herds had a herd size greater than 100. 
Herd size and related management factors could also account for some of the 
differences in treatment rates between the current study and the NAHMS study.  
 
The NAHMS data were limited to the herd as no data were collected at the individual 
animal level. In contrast to the NAHMS study both individual animal records and 
questionnaires were used in the current cow-calf study. Tracking individual animal 
diagnoses and treatments may be less subject to recall bias than using a questionnaire, 
but relying on the completeness of individual animal treatment records may lead to 
underreporting.  
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From the Agriculture census in 2001, Statistics Canada reported that the average beef  
herd size for Canada was 53 cows.  In Saskatchewan and Alberta the average herd sizes 
were 58 and 74 beef cows per herd with 15 and 20 replacement heifers respectively.   
The average study herd size of 180 is larger than that reported by Statistics Canada.  
Because herds were enrolled in the larger productivity study based on their ability to 
provide the required data, these herds probably represent some of the more progressive, 
commercially viable, and intensively managed herds in western Canada. The herds 
providing data for this study therefore represent AMU in this sector of the industry. 
AMU may be different in the few very large cow-calf herds that receive little or no 
treatment interventions or the very small herds present on some mixed or hobby farms. 
 
Future studies need to focus on determining the amount of each antimicrobial used to 
more accurately assess animal AMU exposure. However, AMU data are difficult to 
collect and report for several reasons. Complete and accurate farm based AMU records 
are difficult to obtain. Capture of use information can be demanding for producers 
especially during busy times and with limited resources. Under reporting is potentially a 
problem since producers are busy with day to day operations on the farm and, therefore, 
record keeping is often a relatively low priority and subsequently treatment records may 
be forgotten. Dunlop et al. (1998) reported a 35% under-reporting rate for AMU 
recorded by swine producers when compared to inventory and disappearance data 
collected by the researchers. A preliminary report of AMU in the Ontario beef industry 
estimated average under reporting of AMU on farm was 40% (Bair and McEwen, 
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2001). This estimate was based on treatment diaries and accounting of drug 
disappearance in both feedlots and cow-calf herds. Under reporting for cow-calf herds 
ranged from 1-86% with a mean of 24% (Bair and McEwen, 2001). 
 
It is difficult to fully evaluate the degree of under reporting in this cow-calf project. 
From the crude subjective and comparative assessment of the quality of the data, at least 
20% of the herds had less than satisfactory treatment records. When combined with 
information on the calf mortality and the proportion of herds reporting no treatments 
there is further evidence that there was under reporting by some herds. It would be 
unlikely to have herds with greater than 5% calf death losses with no treatments. A true 
estimate can not be made about the degree of under reporting in these herds. However, 
with 20% of the herds having less than satisfactory treatment records it is likely that 
these herds were under reporting treatment events. Additionally, for the herds with no 
treatments and greater than 5% death losses there are also potentially missing treatment 
records.  
 
The second problem with AMU data collection and reporting is that there is no 
widely accepted method for quantifying AMU (Singer et al., 2006). Use can be reported 
in many ways including, but not limited to, total volume of drug in kilograms, defined 
daily doses (DDD) (Jensen et al. 2006), animal daily doses (ADD) (Jensen et al., 2006), 
or as animal units per treatment days (Dunlop et al, 1998). While each of the above 
methods attempt to capture the true exposure of an animal to a drug limitations still 
exist (Jensen et al., 2006). Although there are problems with data capture and reporting, 
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there is international interest in developing surveillance systems for AMU and AMR 
potentially including farm level or aggregate level of AMU (Rosdahl and Pederson, 
1998, Nicholls et al., 2001 and WHO 2001).  
 
For farm-based AMU data to be valuable in surveillance studies, the following 
pieces of information need to be collected: total amount of antimicrobial used, 
indication for treatment, route of administration, and dose and duration (Singer et al., 
2006). While several of these criteria were met by the individual animal records 
collected as part of the current study, detailed information on which antimicrobials were 
used to treat specific conditions and the dose used were not consistently reported. While 
an attempt was made to collect more information on specific drug use, these data were 
potentially subject to recall bias since the questionnaire was administered at the end of 
the calving season and relied on producer accounts of the number of animals treated 
with each class of antimicrobial.  
  
Despite the limitations, this study does provide the first available documentation of 
the proportion of calves and cows/heifers reported as treated during the calving season 
and the types of conditions most often treated in western Canadian herds. The study 
also provides some initial information about AMU practices in these herds which can be 
used to help address issues such as extra-label drug use, prophylactic treatment of entire 
calf crops, and the importance of minimizing dystocia in reducing the need for 
treatment of either cows/heifers or calves. 
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Table 3.1. Summary of animal and herd-level risk factors for calf treatment and 
mortality during the 2002 calving season (n=28,573; N=203). Data pertains to calves 
born alive January 1 to May 31, 2002 and their dams
Risk factor Proportion of cows 
with attribute 
Proportion of herds with 
at least one cow with 
attribute 
Ecoregion   
1. Aspen Parkland 26.3%(7516) 26.1%(53) 
2. Boreal Transition 10.7%(3047) 10.8%(22) 
3. Fescue Grassland 13.2%(3773) 12.3%(25) 
4. Mixed Grassland 14.7%(4202) 14.3%(29) 
5. Moist Mixed Grassland 12.5%(3566) 12.8%(26) 
6. Northern Continental Divide 4.2%(1193) 3.9%(8) 
7. Peace Lowland 9.5%(2710) 12.3%(25) 
8. Western Alberta Upland 4.7%(1338) 3.9%(8) 
9. Western Boreal 4.3%(1228) 3.5%(7) 
Vaccinated for BVDV/IBR prebreeding 2001   
1. Live vaccine 41.6%(11896) 41.9%(85) 
2. Inactivated vaccine 15.7%(4491) 17.2%(35) 
3. No vaccine 4.1%(1177) 3.5%(7) 
4. Not reported 38.5%(11009) 37.4%(76) 
Heifers vaccinated for diarrhea (E. coli) precalving 2002 38.5%(1828/4748) 35.3%(65/184) 
Cows vaccinated for diarrhea (E. coli) precalving 2002 32.5%(7737/23825) 32.0%(65/203) 
Heifers vaccinated for diarrhea (viral) precalving 2002 37.6%(1785/4748) 34.2%(63/184) 
Cows vaccinated for diarrhea (viral) precalving 2002 31.6%(7518/23825) 31.0%(63/203) 
BCS pre-calving <5 (9-point scale) 5.7%(1636) 70.0%(142) 
BCS at pregnancy testing <5 (9-point scale) 8.3%(2357) 82.8%(168) 
Cow born on farm and not purchased  66.5%(18997) 92.1%(187) 
Twin births 4.4%(1256) 87.7%(178) 
Calf gender   
1. Male 50.8%(14526) 100.0%(203) 
2. Female 47.0%(13416) 100.0%(203) 
3. Not recorded 2.2%(631) 55.7%(113) 
No cow problem other than dystocia 98.8%(28242) 100.0%(203) 
Prolapse 0.2%(50) 21.2%(43) 
Retained fetal membrane (RFM) 1.0%(275) 40.4%(82) 
Metritis 0.02%(6) 2.5%(5) 
Calving assistance reported   
1. No assistance 92.0%(26291) 100.0%(203) 
2. Easy pull 4.9%(1395) 87.2%(177) 
3. Hard pull 1.7%(474) 68.0%(138) 
4. Malpresentation 1.0%(285) 54.7%(111) 
5. Caesarean section surgery 0.5%(128) 34.0%(69) 
Calving Month   
1. January 2002 8.0%(2271) 48.3%(98) 
2. February 2002 21.4%(6115) 74.9%(152) 
3. March 2002 38.9%(11109) 97.0%(197) 
4. April 2002 25.1%(7176) 96.1%(195) 
5. May 2002 6.7%(1902) 81.3%(165) 
Predominant breed type   
1. British 43.2%(12353) 82.8%(168) 
2. Continental 47.9%(13692) 78.8%(160) 
3. Cross 7.9%(2270) 31.5%(64) 
4. No record 0.9%(258) 16.8%(34) 
Age category   
1. Yearling heifer (born 2001) 0.1%(32) 10.3%(21) 
2. 2 year old heifer (born 2000) 16.6%(4748) 90.6%(184) 
3. 3 year old cow (born 1999) 15.7%(4497) 96.6%(196) 
4. Mature cow (born 1993 to 1998) 53.2%(15206) 100.0%(203) 
5. Old cow (born 1991 or earlier) 11.6%(3300) 94.1%(191) 
6. No record of age  2.8%(790) 20.7%(42) 
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Table 3.2. Summary of animal and herd-level risk factors for cow or heifer treatment 
and mortality during the 2002 calving season (n=36,634; N=203)a 
aData pertains to all adult females in the herd as of January 1, 2002, except for attributes that are specific 
to bred cows and heifers. Denominators are provided in instances where data are only applicable to a sub-
set of animals. Calving information includes stillbirths, abortions and live calves. Not all animals had 
BCS available.  
 
Risk factor Proportion of cows 
with attribute 
Proportion of herds 
with at least one cow 
with attribute 
Ecoregion   
1. Aspen Parkland 24.8%(9086) 26.1%(53) 
2. Boreal Transition 10.5%(3838) 10.8%(22) 
3. Fescue Grassland 13.3%(4884) 12.3%(25) 
4. Mixed Grassland 14.4%(5283) 14.3%(29) 
5. Moist Mixed Grassland 13.2%(4822) 12.8%(26) 
6. Northern Continental Divide 4.5%(1648) 3.9%(8) 
7. Peace Lowlad 10.1%(3720) 12.3%(25) 
8. Western Alberta Upland 4.6%(1668) 3.9%(8) 
9. Western Boreal 4.6%(1685) 3.5%(7) 
Vaccinated for BVDV/IBR prebreeding 2001   
1. Live vaccine 15.8%(5772) 17.2%(35) 
2. Inactivated vaccine 41.8%(15317) 41.9%(85) 
3. No vaccine 38.3%(14033) 37.4%(76) 
4. Not reported 4.1%(1512) 3.5%(7) 
Heifers vaccinated for diarrhea (E.coli) precalving 2002 33.6%(1749/5207) 35.1%(65/185) 
Cows vaccinated for diarrhea (E. coli) precalving 2002 34.9%(9092/26040) 34.5%(70/203) 
Heifers vaccinated for diarrhea (viral) precalving 2002 37.8%(1969/5207) 35.1%(65/185) 
Cows vaccinated for diarrhea (viral) precalving 2002 28.9%(7518/26040) 31.0%(63/203) 
BCS pre-calving <5 (9-point scale) 6.0%(1740/29173) 71.9%(146) 
BCS at pregnancy testing <5 (9-point scale) 8.4%(3063/36464) 77.3%(157) 
Cow born on farm and not purchased  51.8%(18997) 92.1%(187) 
No cow problem post partum 99.0%(30901/31247) 100.0%(203) 
Prolapse 0.2%(57/31247) 21.2%(43) 
Retained fetal membrane 0.9%(281/31247) 40.4%(82) 
Metritis 0.03%(8/31247) 2.5%(5) 
Calving assistance reported   
1. No assistance 93.9%(29337/31247) 100.0%(203) 
2. Easy pull 4.4%(1392/31247) 87.2%(177) 
3. Hard pull 1.7%(538/31247) 68.0%(138) 
4. Malpresentation 1.2%(367/31247) 54.7%(111) 
5. Caesarean section surgery 0.5%(151/31247) 34.0%(69) 
Predominant breed type   
1. British 43.0%(15755) 83.7%(170) 
2. Continental 46.6%(17075) 80.3%(163) 
3. Cross 9.4%(3424) 36.0%(73) 
4. No record 1.0%(380) 16.8%(34) 
Age category   
1. Yearling heifer (born 2001) 14.7%(5387) 84.2%(171) 
2. 2 year old  heifer (born 2000) 14.2%(5207) 91.1%(185) 
3. 3 year old cow (born 1999) 13.2%(4837) 96.1%(195) 
4. Mature cow (born 1993 to 1998) 44.7%(16364) 99.5%(202) 
5. Old cow (born 1991 or earlier) 10.0%(3648) 95.6%(194) 
6. No record of age  3.3%(1191) 22.2%(45) 
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Table 3.3. Type of treatment for calves (n=28,573) and cows/heifers (n=36,634) at the 
animal and herd level (N=203) between January 1 and June 30, 2002a 
 
Treatment Number 
(%) of 
calves 
# (%) herds 
reporting calf 
treatment 
Number(%) 
of  
cows/heifers 
# (%) herds 
reporting cow 
treatment 
Fluids 123 (0.4) 54 (26.6) 1 (0.003) 1 (0.5) 
Injectable 
antimicrobials 
2400 (8.4) 162 (79.8) 658 ( 1.8) 123 (60.6) 
Oral antimicrobials 512  (1.8) 80 (39.4) 3 (0.008) 2 (1.0) 
Oral and injectable 
antimicrobials 
852 (3.0) 93 (45.8) 6 (0.02) 5 (2.5) 
Other treatmentb  173 (0.6) 61 (30.0) 91 (0.3) 46 (22.7) 
aAny individual animal may have been treated with more than one type of treatment 
bOther treatment includes; treatment with mineral oil, intramammary infusions, vitamin injections, etc. 
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Table 3.4. Diagnoses recorded from January 1 to June 30, 2002 summarized at the 
individual calf and herd level (n=28,573, N=203).a 
aIndividual calves may have had more than one diagnoses. 
Diagnosis 
Number of 
calves affected 
% of all 
calves 
Number of 
herds % of herds
Diarrhea 1648 5.77 129 63.6 
Pneumonia 625 2.19 103 50.7 
Prophylactic tx for navel infections 529 1.85 4 2.0 
Not recorded 355 1.24 67 33.0 
Omphalitis 300 1.05 87 42.9 
Fever, depression, not doing well 139 0.49 44 21.7 
Coccidiosis 114 0.4 35 17.2 
Prophylactic tx at castration 45 0.16 3 1.5 
White muscle dz suspected 32 0.11 6 3.0 
Ruminal tympany 28 0.1 23 11.3 
Weak 25 0.09 14 6.9 
Interdigital necrobacillosis 27 0.09 20 9.9 
Infectious arthritis 20 0.07 13 6.4 
Lameness 20 0.07 14 6.9 
GI/ torsion/ulcers 21 0.07 15 7.4 
Diptheria 13 0.05 10 4.9 
Ear/eye infections 13 0.05 11 5.4 
Hypothermia 14 0.05 12 5.9 
Abscess 12 0.04 8 3.9 
Dehydrated 8 0.03 8 3.9 
Infectious keratoconjunctivitis 8 0.03 5 2.5 
Surgery 9 0.03 8 3.9 
Meningitis 5 0.02 5 2.5 
Broken bones 7 0.02 7 3.5 
Cuts/wounds 2 0.01 2 1.0 
Prolapsed rectum 2 0.01 2 1.0 
Blind 2 0.01 2 1.0 
Predator Attack 2 0.01 1 0.5 
Dystocia (hard pull) 3 0.01 3 1.5 
Septecemia 3 0.01 3 1.5 
Malnutrion 4 0.01 3 1.5 
Arthritis 1 0.003 1 0.5 
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Table 3.5. Diagnoses made from January 1 to June 30, 2002 summarized at the 
individual cow/heifer and herd level. (n=36,634, N=203) a 
 
Diagnoses 
Number of 
cows/heifers 
affected 
% of  total 
cows and 
heifers 
Number of 
herds % of herds 
Metritis 145 0.4 52 25.62 
Interdigital 
necrobacillosis 
140 
0.38 
51 
25.1 
Retained Placenta 93 0.25 37 18.2 
Not recorded 81 0.22 45 22.2 
Mastitis 41 0.11 28 13.8 
Extraction/C-section 30 0.08 19 9.4 
Gastro-intestinalb 30 0.08 21 10.3 
Fever/depression/not 
doing well 25 0.07 17 8.4 
Prolapse 26 0.07 20 9.9 
Pneumonia 27 0.07 18 8.9 
Abcess/cuts/cellulitis 20 0.05 15 7.4 
Cancer eye 13 0.04 9 4.4 
Lamenss 15 0.04 8 3.9 
Non-antimicrobial 
treatmentsc 10 0.03 4 2.0 
Lump-jaw/woody 
tongue 11 0.03 9 4.4 
Eye or ear infection 9 0.02 8 3.9 
Neurological 9 0.02 8 3.9 
Infectious 
Keratoconjunctivitis 
9 
0.02 
8 
3.9 
Kidney/bladder 
infection 2 0.01 2 1.0 
Diarrhea 2 0.01 2 1.0 
Coccidiosis 3 0.01 2 1.0 
Vaginal tear 4 0.01 4 2.0 
Prophylactic 5 0.01 4 2.0 
Fetotomy 1 0.003 1 0.5 
Dehorned 1 0.003 1 0.5 
Ruminal tympany 1 0 1 0.5 
a Individual animals may have had more than one diagnoses.  
bGastro-intestinal includes hardware and perotinits 
cNo antimicrobial treatments include treatments for lice, milk let down and milk fever 
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Table 3.6. Number (%) of herds recording various antimicrobial treatments used in 
cows/heifers from January 1 to June 30, 2002 (N=203) 
 
Treatment Never used 
Number 
(%) 
Used 1-3 
times 
Number (%) 
Used 4-10 
time 
Number (%) 
Used >10 
times 
Number (%) 
Herds ever 
used 
Cow LA Penicillina 160 (78.8) 26 (12.8) 11 (5.4) 6 (3.0) 43 (21.2) 
Cow SA Penicillinb 180 (88.7) 14 (6.9) 6 (3.0) 3 (1.5) 23 (11.4) 
      
Cow oral sulphonamides 197 (97.0) 5 (2.5) 1 (0.5) 0 (0) 6 (3.0) 
Cow 
trimethoprim/sulphsdiazine 
192 (94.6) 10 (4.9) 0 (0) 1 (0.5) 11 (5.4) 
      
Cow Oxytetrcycline LA 98 (48.3) 46 (22.7) 38 (18.7) 21 (10.3) 105 (51.7) 
Cow Oxytetetrcycline SA 197 (97.0) 4 (2.0) 2 (1.0) 0 (0.0) 6 (3.0) 
Cow tetracycline bolus 199 (98.0) 2 (1.0) 2 (1.0) 0 (0.0) 4 (2.0) 
      
Cow tilmicosin 187 (92.1) 15 (7.4) 1 (0.5) 0 (0.0) 16 (7.9) 
      
Cow florfenicol 194 (95.6) 8 (3.9) 1 (0.5) 0 (0.0) 9 (4.4) 
      
Cow sulbactam-ampicillin 
injectable 
197 (97.0) 1 (0.5) 0 (0.0) 5 (2.5) 6 (3.0) 
      
Cow ceftiofur 200 (98.5) 3 (1.5) 0 (0.0) 0 (0.0) 3 (1.5) 
      
Cow enrofloxacin tablets 
oral 
203 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
      
Cow novobiocin/ 
penicillin G ntramammary 
 
199 (98.0) 2 (1.0) 1 (0.5) 1 (0.5) 4 (2.0) 
Cow cephapirin   
sodium intramammary 
 
200 (98.5) 2 (1.0) 0 (0.0) 1 (0.5) 3 (1.5) 
Cow spectinomycin 
hydrochloride 
 
202 (99.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 
Cow dihydrostreptomycin 
 
202 (99.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 
Cow gentamicin injectable 
 
202 (99.5) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5) 
Cow amprolium 
hydrochloride oral 
 
202 (99.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 
Cow other 
 
199 (98.0) 4 (2.0) 0 (0.0) 0 (0.0) 4 (2.0) 
Cow unknown other 203 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
aLA=Long acting 
b SA=Short acting
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Table 3.7. Number (%) of herds recording various antimicrobial treatments used in 
calves from January 1 to June 30, 2002. (N=203) 
 
Treatment Never used 
Number 
(%) 
Used 1-3 
times 
Number (%) 
Used 4-10 
times 
Number (%) 
Used >10 
times 
Number (%) 
Herds ever 
used 
Calf LA Penicillina 189 (93.1) 7 (3.4) 1 (0.5) 6 (3.0) 14 (6.9) 
Calf SA Penicillinb 177 (87.2) 9 (4.4) 11 (5.4) 6 (3.0) 26 (12.8) 
      
Calf oral sulphonamides 100 (49.3) 24 (11.8) 35 (17.2) 44 (21.7) 103 (50.7) 
Calf injectable 
sulphonamides 
146 (71.9) 18 (8.9) 17 (8.4) 22 (10.8) 57 (28.1) 
      
Calf Oxytetracycline LA 127 (62.6) 22 (10.8) 27 (13.3) 27 (13.3) 76 (37.4) 
Calf Oxytetracyline SA 201 (99.0) 1 (0.5) 1 (0.5) 0 (0.0) 2 (1.0) 
Calf tetracycline bolus 202 (99.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 
      
Calf tilmicosin 161 (79.3) 21 (10.3) 10 (4.9) 11 (5.4) 42 (20.6) 
      
Calf florfenicol 119 (58.6) 20 (9.9) 33 (16.3) 31 (15.3) 84 (41.5) 
      
Calf sulbactam-
ampicillin injectable 
187 (92.1) 8 (3.9) 1 (0.5) 7 (3.4) 16 (7.9) 
      
Calf ceftiofur 187 (92.1) 4 (2.0) 6 (3.0) 6 (3.0) 16 (7.9) 
      
Calf enrofloxacin tablets 
oral 
202 (99.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 
      
Calf gentamicin 
injectable 
201 (99.0) 2 (1.0) 0 (0.0) 0 (0.0) 2 (1.0) 
Calf amprolium 
hydrochloride oral 
199 (98.0) 1 (0.5) 2 (1.0) 1 (0.5) 4 (2.0) 
Calf ampicillin trihydrate 
injectable 
201 (99.0) 2 (1.0) 0 (0.0) 0 (0.0) 2 (1.0) 
Calf erythromycin  
 
202 (99.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Calf cephalexin oral 
 
202 (99.5) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5) 
Calf other 
 
193 (95.1) 10 (4.9) 0 (0.0) 0 (0.0) 10 (4.9) 
Calf unknown other 198 (97.5) 2 (1.0) 1 (0.5) 2 (1.0) 5 (2.5) 
aLA=Long acting  
b SA=Short acting
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Table 3.8. Number (%) of herds that used antimicrobials used at least once on the farm 
in the period from January 1 to June 30, 2002 (N=203) 
 
Treatment No use 
Number (%) 
Used at least once 
Number (%) 
Penicillin 126 (62.1) 77 (37.9) 
Sulphonamide 83 (40.9) 120 (59.1) 
Oxytetracycline/tetracycline 80 (39.4) 123 (60.6) 
Tilmicosin 149 (73.4) 54 (26.6) 
Florfenicol 115 (56.7) 88 (43.3) 
Sulbactam-ampicillin injectable 183 (90.1) 20 (9.9) 
Ceftiofur 185 (91.1) 18 (8.9) 
Enrofloxacin 202 (99.5) 1 (0.5) 
Intramammary products 197 (97.0) 6 (3.0) 
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Table 3.9. The herd-adjusted unconditional associations between non-therapeutic risk 
factors and the odds of calf treatment in 2002 (n=28,573, N=203) 
aP-value based on degrees of freedom determined by the number of levels of the categorical variable 
95% CI Variable Odds 
ratio Lower Upper 
P-value 
Vaccinated for BVDV/IBR prebreeding 2001a     
1. Live vaccine 2.6 0.5 13.1 0.71 
2. Inactivated vaccine 1.6 0.3 8.1 0.95 
3. No vaccine Reference category 
4. No record 2.3 0.4 12.3 0.81 
Heifers vaccinated for diarrhea (scours) precalving 
2002  0.7 0.4 1.3 0.26 
Cows vaccinated for diarrhea (scours) precalving 
2002 0.7 0.4 1.3 0.32 
BCS at pregnancy testing (9-point scale) a     
1. BCS <5 compared to BCS ≥5  0.9 0.8 1.1 0.77 
2. Missing BCS compared to BCS ≥5 1.4 1.2 1.7 0.0001 
Cow purchased  1.2 1.0 1.3 0.03 
Predominant breed typea     
1. British Reference category 
2. Continental 1.0 0.9 1.2 0.99 
3. Cross 0.8 0.6 1.1 0.73 
4. No record 1.1 0.7 1.8 0.96 
Age category a     
1. Yearling heifer  0.8 0.2 2.9 0.99 
2. 2 year old heifer (born 1999) 1.2 1.1 1.4 0.08 
3. 3 year old cow (born 1998) 1.1 1.0 1.3 0.51 
4. Mature cow (born 1992 to 1997) Reference category 
5. Cow age >10 (born in 1991 or earlier)  0.9 0.8 1.1 0.91 
6. No record of age  1.2 0.9 1.8 0.93 
Age re-categorizationa     
Yearling heifer 0.7 0.2 2.7 0.62 
All other breeding females  Reference category  
Problem reported with cow at calvinga     
1. Nothing Reference category 
2. Prolapse 1.5 0.6 3.6 0.84 
3. Retained fetal membranes 1.4 1.0 1.9 0.43 
4. Metritis 2.0 0.2 20.6 0.95 
Calving assistance reporteda     
1. No assistance Reference category 
2. Malpresentation and/or Pull 1.6 1.4 1.8 0.0001 
3. Caesarian section surgery 2.2 1.3 3.7 0.012 
Calf sexa     
1. Male  Reference category  
2. Female 0.8 0.7 0.8 0.0001 
3. Unknown 0.4 0.2 0.6 0.0001 
Precipitation growing season 2001a     
1. 75 to 200 mm 2.2 1.1 4.3 0.09 
2. 200 to 250 mm 2.1 1.1 4.4   0.11 
3. >250 mm  Reference category  
% Cows ever treated in the herd 1.2 1.2 1.3 0.003 
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Table 3.10. The herd-adjusted final multivariable analysis of risk factors for whether a 
calf was ever treated between January and June, 2002 (n=28,573, N=203) 
 
95% CI  
Variable 
 
Odds ratio Lower Upper P-value 
Calf gender     
1. Male Reference category 
2. Female  0.8 0.7 0.9 0.0001
3. Not recorded 0.4 0.3 0.6 0.0006
Calving assistance reported     
1. No assistance  Reference category 
2. Malpresentation and/or pull 1.5 1.3 1.7 0.0001
3. Caesarian section surgery 2.0 1.2 3.3 0.15 
% of cows treated in the herda 1.2 1.1 1.3 0.002 
aThe percentage of cows treated in a herd was calculated from the number of treatments 
administered to any adult female in the herd between January 1 and June 30, 2002 and 
the total number of adult females in that herd as of January 1, 2002. 
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Table 3.11. The herd-adjusted unconditional associations between non-therapeutic risk 
factors and the odds of cow/bred heifer treatment in 2002 (n=31,248, N=203) 
 
95% CI  
Variable 
 
Odds ratio Lower Upper 
 
P-value 
Predominant breed typea     
1. British Reference category 
2. Continental 0.9 0.7 1.3 0.98 
3. Cross 0.4 0.3 0.8 0.03 
4. No record 0.3 0.1 1.2 0.42 
Age categorya     
1. 2 year old heifer (born 2000) 1.3 1.0 1.6 0.25 
2. 3 year old cow (born 1999) 1.0 0.8 1.3 0.99 
3. Mature cow (born 1993 to 1998) Reference category 
4. Cow age >10 (born in 1992 or earlier) 1.2 1.0 1.6 0.57 
5. No record of age  0.6 0.2 1.6 0.96 
Vaccinated for BVD/IBR prebreedinga     
1. Not Vaccinated 1.8 1.1 2.3 0.07 
2. Vaccination status not reported 0.3 0.1 1.6 0.41 
3. Vaccinated  Reference category 
Vaccinated for diarrhea (scours) precalvinga     
      1. No breeding females vaccinated 2.0 1.2 3.2 0.006 
      2. Breeding females vaccinated Reference category 
Calving assistance reporteda     
       1. No assistance Reference category 
       2. Presentation correction or pull  2.8 2.2 3.4 0.00001 
       3. C-section  13.2 8.3 21.0 0.00001 
Problem reported with cow at calvinga     
       1. No problem Reference category 
       2. Prolapse 68.5 35.9 130.9 0.00001 
       3. Retained fetal membranes 114.9 82.3 160.3 0.00001 
       4. Metritis 304.6 47.4 1956.7 0.00001 
aP-value based on degrees of freedom determined by the number of levels of the categorical variable 
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Table 3.12. The herd-adjusted final multivariable analysis of risk factors for whether 
cows and bred heifers were ever treated between January and June, 2002 (n=31,248, 
N=203) 
 
95% CI  
Variable 
 
Odds ratio Lower Upper P-value 
Calving assistance reported     
1. No assistance Reference category 
2. Malpresentation and/or Pull 2.1 1.7 2.7 0.0001 
4. Caesarian section surgery 14.5 8.8 23.8 0.0001 
Problem reported with cow at calving      
1. Nothing Reference category 
2. Prolapse 56.5 29.0 110.0 0.0001 
3. Retained fetal membranes 109.2 77.9 153.0 0.0001 
4. Metritis 311.7 50.1 1940.5 0.0001 
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CHAPTER 4 
PREVALENCE OF ANTIMICROBIAL RESISTANCE IN FECAL GENERIC E. 
COLI ISOLATED IN WESTERN CANADIAN COW-CALF HERDS. PART I: BEEF 
CALVES 
 
4.1. Introduction 
 
The emergence of antimicrobial resistance (AMR) is a serious concern in both 
human and veterinary medicine. Antimicrobial resistant bacteria were first observed 
shortly after the discovery of penicillin (North and Christie, 1946, Barber, 1947), and 
resistance has continued to surface with the introduction of each new antimicrobial 
compound (Levy, 1997). It is generally accepted that antimicrobial use (AMU) is an 
important factor for the selection of AMR bacteria (Aarestrup, 1999, van den Bogaard 
and Stobberingh, 2000, McEwen and Fedorka-Cray, 2002). Selective pressure for AMR 
can be affected by treatment formulation, dose, interval, and duration (Catry et al., 
2003). Because AMU varies widely within the livestock industry, describing AMR in 
one livestock class, species, or management system will not be representative of other 
systems. 
 
Most AMU and AMR research in the food animal sector has been conducted in 
swine, poultry or feedlot operations (Dargatz et al., 2003, Fitzgerald et al., 2003,  Lanz 
et al., 2003, Bywater et al., 2004, Khachatryan  et al., 2004, Rajic et al., 2004, 
Hershberger et al., 2005). Animals in intensively managed facilities can be exposed to 
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antimicrobials in feed, in water, or via metaphylaxis protocols involving injectable 
formulations (McEwen and Fedorka-Cray, 2002). Feed antimicrobials are uncommon in 
cow-calf herds, and injectable AMU is infrequent especially in adult animals (Gow and 
Waldner, 2007). The selective pressures experienced in cow-calf herds may differ and, 
therefore, lead to fewer AMR bacteria compared to other food animal populations that 
are exposed to more intensive selective pressure associated with routine AMU practices.  
 
Although there is a growing amount of literature on AMR, to the best of our 
knowledge, there is no information currently available regarding AMR in cow-calf 
herds in western Canada. The cow-calf industry is a vital and important part of the 
agricultural economy in all parts of Canada, but particularly in Saskatchewan and 
Alberta. These two provinces are home to more than 65% of the beef cow, breeding 
heifer, and calf populations in Canada (Statistics Canada, Accessed July 25, 2006; 
http://www.40.statcan.ca/101/cst01/prim50a.htm). A better understanding of AMR in 
this industry is essential to develop baseline data and determine the need for future 
monitoring. The objective of this study was to describe AMR patterns in calves from 
western Canadian cow-calf herds in the spring and fall of 2002 using E. coli as an 
indicator organism. 
 
4.2. Materials and methods 
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4.2.1. Study overview 
 
This project was one step in a larger initiative to examine the prevalence of and risk 
factors associated with AMR in cow-calf herds (Figure 4.1). Targeted sampling was 
initiated in 2002 to investigate the prevalence of AMR at different stages of production. 
Fecal samples were collected in the spring from cows and calves. These samples were 
not from cow-calf pairs, and not all of the same herds had both cow and calf samples 
collected. Calves were also sampled in the fall near the time of weaning. Due to 
logistical constraints, not all of the same herds and none of the same calves were 
sampled in both time periods. This analysis focuses on the calves sampled in the spring 
and fall of 2002. In part II of this study, the prevalence of AMR is described for the 
cows sampled in the spring of 2002 and for cow-calf pairs sampled in the spring of 
2003 (Gow et al., 2007). 
 
4.2.2. Background and herd selection 
 
Fecal samples were collected from a convenience subset of herds participating in a 
survey of risk factors affecting cattle productivity and health (https://www.wissa.info). 
Private veterinary clinics across Alberta, Saskatchewan, and north-eastern British 
Columbia were approached and asked to participate. Within each practice, herds were 
identified and enrolled based on the selection criteria which considered factors such as 
herd size (>50 cows), animal identification, existing calving records, animal handling 
facilities sufficient for pregnancy testing and bull evaluation, and a relationship with a 
local veterinary clinic. Participating herds were visited at least quarterly by one of six 
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veterinarians hired to collect data and samples. Fecal samples for this AMR study were 
collected between January and May 2002 for the calves sampled in the spring, and 
between September and December 2002 for the calves sampled in the fall. 
 
4.2.3. Sample collection 
 
Fecal samples were collected in the spring from 480 individually identified calves 
that were accessible in the calving and nursery area on 91 privately owned cow-calf 
farms in Alberta and Saskatchewan. Fecal samples were also collected from 394 calves 
on 45 farms while calves were being handled for fall processing procedures such as 
vaccination, castration, and sorting for sale. All fecal samples were obtained either 
directly from the rectum or from the ground immediately after defecation. A separate 
disposable glove and container were used for each animal sampled. 
 
4.2.4. Laboratory methods 
 
4.2.4.1. Escherichia coli culture 
 
Fecal samples were sent on ice to a diagnostic laboratory (Prairie Diagnostic 
Services, Saskatoon, Saskatchewan) for culture. The samples were cultured onto 
MacConkey agar plates at 37◦C for 18 hours for isolation of E. coli. At least three 
individual lactose fermenting colonies identified as E. coli using standard biochemical 
tests, including indole, triple sugar iron (TSI) slant, citrate, and urea, were saved from 
each sample. If both dry and mucoid colonies were detected within a sample, then three 
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isolates from each colony type were tested. Individual E. coli isolates were stored in 
50% glycerol and Luria-Bertani (LB) broth at -80ºC.  
 
4.2.4.2. Susceptibility testing methodology 
 
E. coli isolates were tested for susceptibility (Alberta Agriculture and Food) using 
microbroth dilution (Sensititre®, TREK Diagnostic Systems Inc., Cleveland, Ohio) and 
the standard 2002 National Antimicrobial Resistance Monitoring System (NARMS) 
CMV7CNCD gram negative public health panel (CIPARS, 2006). 
 
Minimum inhibitory concentrations (MICs) were assessed for sixteen antimicrobial 
agents (Table 4.1). Breakpoints for susceptibility were used as defined by the National 
Committee of Clinical Laboratory Standards (NCCLS) (NCCLS, 2000). All isolates in 
the intermediate susceptibility range were classified as susceptible. Amikacin results > 
4µg/mL were labeled not interpretable because the breakpoint is 4 dilutions beyond the 
range of the panel. The breakpoint used for streptomycin was 64µg/ml (CIPARS, 2006). 
 
For the antimicrobials tested the minimum inhibitory concentration were presented 
classified according to the Veterinary Drug Directorate (VDD), Health Canada 
Guidelines (Figure 2) (CIPARS, 2006). Category I antimicrobials are considered to 
have very high importance in human medicine and from the gram negative NARMS 
2002 public health panel include ceftiofur, ceftriaxone, and ciprofloxacin. Category II 
includes drugs considered highly important in human medicine such as: amikacin, 
amoxicillin/clavulanic acid, gentamicin, kanamycin, nalidixic acid, streptomycin, and 
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trimethoprim/sulphamethoxazole. Category III antimicrobials are of medium 
importance and include: ampicillin, cefoxitin, cephalothin, chloramphenicol, 
sulphamethoxazole, and tetracycline. To facilitate consistent comparisons with the 
Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) 
(http://www.phac-aspc.gc.ca/cipars-picra), the same nomenclature for patterns of 
resistance were used (CIPARS, 2006). Multiple resistance was defined as resistance to 
≥2 antimicrobials. 
 
4.2.5. Statistical analysis 
 
Descriptive analyses were completed using a commercially available software 
program (SPSS 11.0 for Windows, SPSS Inc., Chicago, Illinois). If any one isolate from 
a calf was resistant to a particular antimicrobial, then that calf was identified as being 
positive for resistance to that antimicrobial. Additionally, if any calf from a herd was 
classified as positive, then the herd was also reported as positive for resistance to that 
antimicrobial. 
 
Population-average prevalence estimates and 95% confidence intervals (CI) for 
AMR were determined using the intercept from null models. Models were developed 
using generalized estimating equations (GEE) to account for clustering within herd 
(SAS v.8.2 for Windows (PROC GENMOD); SAS Institute, Cary, North Carolina, 
USA). Model specifications included a binomial distribution, logit link function, 
repeated statement with subject equal to herd, and an exchangeable correlation 
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structure. Where the proportion of isolates with resistance was equal to zero, Fleiss 
quadratic 95% CI formulas for a single proportion were calculated (Fleiss et al., 2003). 
 
Using the same model specifications described above, unconditional associations 
between resistance to any antimicrobial and calf age (categorized by quartiles), calf 
gender, calf breed, whether the calf was ever treated prior to sampling, and the number 
of days since the last treatment were investigated separately for the spring and fall 
samples (treated calves only). In addition to the above predictors, dam age (2 years, 3 
years, 4 to 10 years, and >10 years) was also considered when modeling calf AMR 
status in the spring.  
 
For the twenty herds sampled in both the spring and the fall of 2002, we investigated 
whether the proportion of isolates or calves with resistance in the spring was a predictor 
of the proportion (count of AMR positive isolates (or calves) / number of isolates (or 
calves) collected) with resistance in the fall using GEE and the above model 
specifications.  
 
The frequency of AMR was also compared between the spring and fall where both 
sets of samples were available for the same herd using GEE with the model 
specifications outlined above. The total number of calves with any type of AMR 
(numerator) as a proportion of the total number of calves sampled (denominator) was 
compared between when the herds were tested in the spring and fall.  
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The extent of clustering of isolate resistance within individual calves and herds was 
described for the samples collected in the spring. The variance components for a three-
level model were estimated using penalized quasi-likelihood estimates (2nd order PQL) 
(MLwiN version 2.0, Centre for Multilevel Modeling, Institute of Education, London, 
UK), a binomial distribution, and logit link function. Data from this null model were 
used to estimate the variation at the isolate level (n=1677) (ρi=π2/3/ (σ2h+ σ2c +π2/3)), 
calf level (ρc= σ2c/(σ2h+ σ2c +π2/3)), and herd level  (ρh= σ2h/(σ2h+ σ2c +π2/3)) (Dohoo et 
al., 2003). The low prevalence of AMR in the samples collected in the fall and the lack 
of variation only allowed for variation estimates to be calculated for a two-level model; 
if a third level for calf was included the model would not converge. The proportion of 
variation was reported for isolates (n=1187) within herds (ρ=π2/3(σ2h +π2/3)) and 
between herds (ρ=σ2h/(σ2h +π2/3)) (Dohoo et al., 2003). 
  
4.3. Results 
 
4.3.1. Study conducted in the spring of 2002  
 
From the 480 calves sampled (212 female and 268 male), 1677 isolates were 
recovered for further testing. Healthy calves made up 92.5% (444/480) of the sample 
population. Calf age ranged from 0 to 151 days (median, 6; inter-quartile range (IQR), 4 
to 10). Median herd size (N=91) was 177 (range, 89 to 411) breeding females. The 
median number of samples collected per herd was 5 (range, 1 to11; IQR, 4 to 6). Before 
sample collection, 8.3% (40/480) of calves had been reported as treated with either oral 
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or injectable antimicrobials or both. Calf age at last treatment prior to sample collection 
ranged from 0 to 56 days of age (median, 2; IQR, 0 to 7). For treated calves, the number 
of days between last treatment and sample collection ranged from 0 to117 days 
(median, 5; IQR, 1 to 10).  
 
4.3.2. Observed AMR in the calves sampled in the spring of 2002 
 
Resistance to at least one antimicrobial was identified in 48.8% of isolates, 62.2% of 
calves, and in 91% of herds (Tables 4.1 to 4.3). The two antimicrobials to which 
resistance was most commonly identified were tetracycline and sulphamethoxazole. No 
resistance was identified to ceftriaxone and ciprofloxacin, and low levels of resistance 
were identified for ceftiofur and gentamicin. 
 
The maximum number of antimicrobials to which an isolate demonstrated resistance 
was 10. Resistance to at least 6 antimicrobials was observed in 9.4% (157/1677) of the 
isolates; these highly resistant isolates were identified in 10.2% (49/480) of calves and 
14% (13/91) of herds. The most common pattern found in the multiresistant isolates was 
ampicillin, kanamycin, streptomycin, sulphamethoxazole, tetracycline, and 
trimethoprim/sulphamethoxazole. Of the isolates with resistance to at least six 
antimicrobials, 75.8% (119/157) had a pattern including streptomycin, 
sulphamethoxazole, tetracycline, and trimethoprim/sulphamethoxazole resistance. 
 
No resistance was detected to the Category I antimicrobials except for one isolate 
that had resistance to ceftiofur (Figure 4.2). The median MIC ranges for Category I, II, 
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and III antimicrobials were several dilutions away from the break point, except for 
streptomycin and tetracycline respectively.  
 
Calf AMR status was not significantly associated with calf gender (P=0.54), breed 
(P=0.40), dam age (P=0.72), or if the calf was ever treated (P=0.65) prior to sample 
collection. Calves 0 to 3 days of age were 0.55 (95% CI, 0.30 to 1.0; P=0.04) times as 
likely to be positive for any AMR as calves >10 days of age. The AMR status of calves 
4 to 5 and 6 to 9 days of age were not significantly different from calves ≥10 days of 
age (P>0.49). For the calves that had been treated, the number of days from last 
treatment was not associated with the presence of AMR (P=0.92).  
 
In the null model the proportion of variance in AMR accounted for at the isolate, 
calf, and herd levels was 65.1%, 14.6%, and 20.3%.  
 
4.3.3. Study conducted in the fall of 2002 
 
Samples were collected from 394 healthy calves (242 female, 152 male) on 45 farms. 
Calf age ranged from 118 to 323 days (median, 219); 79% of the samples were 
collected from calves less than 250 days of age. The median number of samples 
collected per herd was 10 (range, 1 to10; IQR, 10 to 10), and the median herd size was 
125 (range, 52 to 265) breeding females. Before sample collection, 10.6% (39/367) of 
the calves had been treated with either an oral or injectable antimicrobial or an oral and 
injectable antimicrobial together. Calf age at last treatment ranged from 0 to 46 days of 
age (median, 14 days; IQR, 10 to 20). For treated calves the median number of days 
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between sample collection and the calf’s last treatment was 186 days (range, 140 to 
284; IQR, 178 to 208). 
 
4.3.4. Observed AMR in the calves sampled in the fall of 2002 
 
AMR was relatively less common in the 1186 isolates recovered from the fall 
samples; 7.0% were resistant to at least one antimicrobial (Table 4.1). At least one 
resistant isolate was identified in 12.7% of calves and 56% of herds (Table 4.2 to 4.3). 
The majority of the resistance detected was to tetracycline and sulphamethoxazole. No 
resistance was identified for several antimicrobials including: ceftiofur, ceftriaxone, 
cefoxitin, ciprofloxacin, and gentamicin. 
 
The maximum number of antimicrobials to which an isolate demonstrated resistance 
was 5; 0.4% of isolates and 0.8% of calves demonstrated resistance to 5 antimicrobials. 
The most common pattern found in multiresistant isolates was streptomycin, 
sulphamethoxazole, and tetracycline. 
 
No resistance was detected to the Category I antimicrobials, and the median MIC 
ranges for these antimicrobials were several dilutions away from the break point (Figure 
4.3).All of the median MICs for the Category II and III antimicrobials were also several 
dilutions below the breakpoint. The exceptions were streptomycin, which was 
immediately below the breakpoint (Figure 4.3), and tetracycline and cephalothin, which 
were only two dilutions below the breakpoint (Figure 4.3).  
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Calf AMR status in the fall was not associated with calf age (P=0.75), gender 
(P=0.85), breed (P=0.38), and whether the calf had ever been treated (P=0.13) prior to 
sample collection. For the calves that had been previously treated, the number of days 
since last treatment (P=0.74) was not associated with any AMR. Based on a two-level 
model of these data, 84.9% of the total variation in AMR was accounted for between 
isolates within herds and 15.1% was accounted for by variation between herds.  
 
4.3.5. Association between the prevalence of resistance in calf samples collected in 
the spring and the occurrence of resistance in calves in the fall 
  
In the 20 herds sampled at both time points, the proportion of isolates and calves that 
were positive for resistance in the spring were not statistically significant predictors of 
the proportion of isolates (P=0.82) or calves positive (P=0.37) for resistance in the fall. 
Beef calves sampled in the spring were 9.6 (95% CI, 4.5 to 20.7) times more likely to 
have at least one resistant isolate than those sampled in the fall from the same herds. 
 
4.4. Discussion 
 
Information is needed to determine the extent and severity of AMR in the cow-calf 
industry given that these are the most common livestock operations in western Canada 
and that veterinary supervised herd health programs in these herds are still relatively 
uncommon compared to other commodities. This study, which provides some of the 
first available on-farm data describing AMR in cow-calf herds, found that resistance to 
antimicrobials identified as very important in human medicine was rare. E. coli isolates 
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from both the spring and fall samples were most commonly resistant to tetracycline, 
sulphamethoxazole, and streptomycin. This finding is consistent with other reports of 
AMR in E. coli isolates collected from a variety of different animal species (Kijima-
Tanaka et al., 2003, Bywater et al., 2004, Khachatryan et al., 2004). The other key 
finding of this study was that young calves sampled in the spring had a higher 
prevalence of AMR than older calves sampled in the fall. 
 
While it is difficult to directly compare AMR across food animal studies due to 
methodological differences, general trends have been noted. Even though the most 
common resistances detected are relatively similar between livestock species and 
management systems, the proportion of resistant organisms vary. For example, broilers 
tended to have more resistant E. coli isolates than healthy swine or beef cattle (Kijima-
Tanaka et al., 2003). Tetracycline resistance was detected in 69% of the broiler isolates 
and in 25 % of the cattle isolates (Kijima-Tanaka et al., 2003). Schroeder et al. (2002) 
demonstrated that swine carried the highest number of resistant isolates when compared 
to human, cattle, and food diagnostic samples. Resistance to sulphamethoxazole and 
tetracycline was detected in 74% and 71% of the swine isolates but in only 14% and 
20% of cattle isolates (Schroeder et al., 2002). Because the prevalence of AMR varies 
across species, studying resistance in one livestock species is not necessarily 
representative. In order to appreciate the range of AMR and the effect of AMU 
practices in agriculture, industry specific investigations, as reported here, are required.  
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Resistance to antimicrobials that were classified as very important in human 
medicine was detected in less than 1% of the isolates in this study. Additionally, for the 
majority of antimicrobials of interest to human medicine, the median MICs were well 
below the breakpoint for resistance. Median MICs several dilutions below the 
breakpoint indicate that the E. coli populations in these calves were highly sensitive to 
those antimicrobials. Based on these findings, it appears that on-farm exposure to beef 
calves presents a low risk to human health. Hoyle et al. (2004) reported much higher 
levels of ampicillin (64%) and nalidixic acid (24%) resistance in calves on a Scottish 
beef farm. The discrepancy in prevalence may be the result of a variation in selection 
pressure due to different management systems.  
 
Chloramphenicol resistance was detected despite the ban of chloramphenicol use in 
Canadian food producing animals since 1985 (Gilmore, 1986). This may indicate that 
co-selection was maintaining chloramphenicol resistance genes in the population. The 
persistence of chloramphenicol resistance despite the elimination of chloramphenicol 
use has also been reported by national surveillance programs in Japan and in Canada 
(Kijima-Tanaka et al., 2003, CIPARS, 2006). Molecular studies are needed to further 
examine this question in cow-calf herds.   
 
Individual calf attributes such as dam age, calf gender, breed, and whether the calf 
had ever been treated prior to sampling were not associated with the occurrence of 
resistance in the beef calves in this study. However, resistance was less common in 
calves less than 3 days of age than in calves that were at least 10 days of age. This 
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finding may be due to a greater opportunity for colonization with resistant organisms, 
gained either from the environment or other animals in the herd, with increasing calf 
age. A similar result was previously reported by Berge et al. (2005a) who described a 
higher level of AMR in 2 week old dairy calves as compared to day old calves.  
 
In the current study, there was no association between the number of days from last 
treatment and the presence of AMR in treated calves. Berge et al. (2005a) indicated that 
the effect of individual animal treatment was transitory and was associated with AMR if 
the sample was collected less than 7 days post treatment. This discrepancy could be the 
result of differences in selection pressures between the two groups or the result of host 
specific differences between beef and dairy calves. It may also be due to different 
approaches in methodology and in statistical analyses between the two projects. Berge 
et al. (2005a) examined dairy calves longitudinally, they allocated isolates to AMR 
clusters based on mean zone size diameters, and Monte Carlo simulation of the non-
parametric Jonckeheere-Terpstra test was used to examine days from last treatment and 
cluster membership. The current project used a single sample collection for each 
animal, AMR was considered present or absent, and GEE logistic regression was used 
to examine the relationship between time from treatment and AMR. 
 
In this study, herds with a high prevalence of AMR in the spring were not more 
likely to have a high prevalence in the fall. These findings suggest that AMR profiles 
are not static and may be affected by a number of factors potentially including calf 
physiology and environment. The transitory nature of AMR has also been demonstrated 
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in the feedlot. In the feedlot AMR levels shifted towards a uniform population dictated 
by the feedlot environment regardless of AMR prevalence at arrival (Berge et al., 
2005b).  
 
Beef calves sampled in the spring were almost ten times more likely to shed resistant 
organisms than those sampled in the fall. The reason for this difference is unknown. 
There was no association in these data between individual calf treatment history and the 
occurrence of resistance. Other factors that might explain  this finding include an 
increased intensity of herd AMU in the spring calving season compared to the summer 
pasture season, an increased degree of crowding and opportunity for AMR transmission 
in the spring calving season compared to the summer pasture season, and the status of 
the dam at calving were not addressed directly in this part of the study.  
 
The age-related differences in calf physiology between the first few weeks of life and 
weaning might also explain the difference in AMR prevalence. Young calves are pre-
ruminants, are on a milk based diet, and are primarily housed in close confinement. 
Older calves in the fall are ruminants, on a forage based diet, and are usually managed 
extensively on pasture before weaning. This study was not specifically designed to 
examine the associations between calf age and the difference in AMR between the 
spring and fall samples. To assess this association, individual calves could be followed 
longitudinally from birth through to weaning. Any changes in AMR prevalence with 
age could then be detected and potentially differentiated from the influence of herd 
level AMU and other management practices. 
 139 
 
Previous research has demonstrated that calves rapidly acquire AMR bacteria within 
days of birth (Hoyle et al., 2004). The presence of AMR in these animals is not 
necessarily related to AMU (Khachatryn et al., 2004, Berge et al.; 2005a), but rather 
animal age (Hinton et al., 1984, Hinton, 1985, Brophy et al., 1977, Mathew et al., 1999, 
Khachatryn et al., 2004). Typically AMR is highest in young animals (Khachatryn et 
al., 2004) and declines linearly with age (Hoyle et al., 2004). This phenomenon has not 
previously been described in beef calves and is not fully understood in other species and 
production environments 
 
One possibility is that the decline in AMR could be an artifact reflecting no change 
in the proportion of resistant organisms, but rather the overall decline in total E. coli 
with the absolute number of resistant bacteria falling below the detection limits of the 
test in older animals (Hoyle et al., 2004). Although a natural gradual reduction of E. coli 
with increasing age has been previously been reported (Smith and Crabb, 1961), the 
decline in E. coli as an animal matures does not appear to explain the decrease in the 
AMR organisms detected.  
 
Hoyle et al. (2004) demonstrated that beef calves preferentially lost resistant relative 
to susceptible bacteria as they aged. Additionally, other research has indicated that, in 
the absence of antimicrobials, AMR could be maintained because SSuT strains had a 
fitness advantage in young calves but not in older animals (Khachatryan et al., 2004). 
The presence of these resistant E. coli in the absence of treatment and selective pressure 
 140 
could be due to fitness traits that make them better able to compete in the calf gut 
compared to susceptible organisms. These traits may include non-scavenging 
mechanisms (siderophores), increased adhesion, and mechanisms that enhance 
colonization, reproduction, and spread (Visca et al., 1991, Allen et al., 1993, Simmons 
et al., 1988, Mandal et al., 2001). 
 
Because there are still many unknowns regarding the determinants of resistance in 
these herds, a multi-level analysis was used to attempt to determine where most of the 
unexplained variation exists in the occurrence of AMR and potentially where 
interventions could be most successfully targeted. The majority of variation detected 
was at the isolate level. Since interventions cannot be applied to the isolate, potential 
AMR risk factors and AMR reducing interventions should be investigated at the calf 
and then herd level. However, in this study no specific individual animal risk factors 
were identified suggesting the need to look further at the calf’s environment within the 
herd. 
 
This is the first available information describing the prevalence of AMR in calves 
from western Canadian beef herds during the calving season and at weaning. Baseline 
information is necessary to measure variation resulting from changing production 
practices and to develop strategies to control AMR emergence. Knowledge of stage of 
production and timing of sample collection is critical to interpreting surveillance data 
from these herds. Additional research is needed to understand why AMR varies 
between the groups targeted in this study. Future studies should consider animal age, 
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season, AMU, and herd management. Continued monitoring of AMR patterns in cow-
calf herds will illustrate any emerging issues potentially important to public health. 
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Figure 4.1. Sampling structure for study of AMR in western Canadian cow-calf herds 
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Figure 4.2. Minimum inhibitory concentrations for fecal E. coli isolates collected from calves in the spring of 2002 arranged by the 
Veterinary Drug Directorate, Health Canada, classification of drugs and presented as a percentage of the total number of isolates 
(N=1677) 
MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 1677 0.25 0.25 3.2 72.5 20.1 1.8 0.1 0.8 0.9 0.6
Ceftriaxone 1677 <=0.25 0.25 95.8 1.8 0.2 0.2 0.8 0.8 0.5 0.1
Ciprofloxacin 1677 <=0.015 <=0.015 99.4 0.4 0.1 0.2
Amikacin 1677 2 2 0.5 29.6 65.1 4.4 0.4
Amoxicillin-Clavulanic Acid 1677 4 8 2.7 22.0 47.6 16.9 6.1 2.1 2.6
Gentamicin 1677 1 1 10.0 24.9 63.7 0.6 0.3 0.4 0.2
Kanamycin 1677 <=8 <=8 77.1 0.1 22.8
Nalidixic Acid 1677 4 4 0.8 30.6 65.9 2.5 0.1 0.2
Streptomycin 1677 <=32 64 62.6 20.9 16.5
Trimethoprim-Sulphamethoxazole 1677 <=0.12 0.5 52.6 14.7 12.0 0.9 19.8
Ampicillin 1677 4 >=64 2.8 34.9 33.3 2.8 0.9 0.2 25.1
Cefoxitin 1677 4 4 0.2 20.6 56.0 17.4 1.6 4.2
Cephalothin 1677 8 16 1.0 13.4 57.5 21.0 1.6 5.5
Chloramphenicol 1677 8 8 2.1 39.6 39.1 1.4 0.2 17.5
Sulphamethoxazole 1677 <=16 >512 52.9 0.1 0.1 0.4 46.6
Tetracycline 1677 8 >=64 49.1 1.1 0.2 1.6 48.0
IV
Distribution (%) of MICs
I
II
III
Antimicrobial n*
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Figure 4.3. Minimum inhibitory concentrations for fecal E. coli isolates collected from calves in the fall of 2002 arranged by the 
Veterinary Drug Directorate, Health Canada, classification of drugs and presented as a percentage of the total number of isolates 
(N=1186) 
MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 1186 0.25 0.25 5.2 76.1 18.6
Ceftriaxone 1186 <=0.25 0.25 99.9 0.1
Ciprofloxacin 1186 <=0.015 <=0.015 99.7 0.3
Amikacin 1186 2 2 3.4 42.3 52.9 1.3 0.2
Amoxicillin-Clavulanic Acid 1186 4 4 1.4 24.5 63.5 10.2 0.4
Gentamicin 1186 1 1 21.1 26.5 52.3 0.2
Kanamycin 1186 <=8 <=8 98.9 1.1
Nalidixic Acid 1186 4 4 0.1 1.3 43.7 53.7 1.3
Streptomycin 1186 <=32 <=32 97.2 2.1 0.7
Trimethoprim-Sulphamethoxazole 1186 <=0.12 <=0.12 94.2 4.9 0.7 0.3
Ampicillin 1186 4 4 5.0 39.0 50.8 3.3 0.3 0.3 1.3
Cefoxitin 1186 4 4 0.1 0.1 25.3 62.3 11.7 0.5
Cephalothin 1186 8 8 0.9 15.7 66.4 16.4 0.5 0.1
Chloramphenicol 1186 4 8 7.9 59.0 31.6 0.8 0.6
Sulphamethoxazole 1186 <=16 <=16 96.0 4.0
Tetracycline 1186 <=4 <=4 92.6 2.4 0.4 0.1 4.6
Distribution of Isolates (%) Across Minimum Inhibitory Concentrations (MIC) Ranges
I
II
III
Antimicrobial n*
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Table 4.1. Prevalence (%) of AMR for E. coli isolates cultured from calves in the spring 
(n=1677) and in the fall (n=1186) of 2002 adjusted for clustering by herd 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline 
 
  
Isolate prevalence for calves  
in the spring  
Isolate prevalence for calves 
in the fall 
Antimicrobial 
 
Prevalence (%) 
 
Lower CI Upper CI Prevalence (%) Lower CI Upper CI 
Amikacin 0.0 0.0 0.3 0.0 0.0 0.4 
Amoxicillin-Clavulanic 
Acid 4.5 2.6 7.8 0.0 0.0 0.4 
Ampicillin 22.7 18.0 28.2 1.6 0.7 3.3 
Cefoxtin 4.1 2.3 7.2 0.0 0.0 0.4 
Ceftiofur 1.7 0.7 3.8 0.0 0.0 0.4 
Ceftriaxone 0.0 0.0 0.3 0.0 0.0 0.4 
Cephalothin 6.7 4.3 10.1 0.6 0.3 1.4 
Chloramphenicol 14.8 10.8 19.9 0.6 0.2 1.8 
Ciprofloxacin 0.0 0.0 0.3 0.0 0.0 0.4 
Gentamicin 0.5 0.2 1.3 0.0 0.0 0.4 
Kanamycin 20.7 16.1 26.2 1.1 0.4 2.8 
Nalidixic Acid 0.2 0.02 1.2 0.0 0.0 0.4 
Streptomycin 34.8 29.4 40.7 2.8 1.6 4.9 
Sulphamethoxazole 42.8 36.9 48.9 4.0 2.7 6.1 
Tetracycline  46.4 40.2 52.7 5.0 3.4 7.5 
Trimethoprim-
Sulphamethoxazole 16.3 12.2 21.4 0.3 0.1 1.0 
AMR (≥1 antimicrobial)  48.8 42.6 55.1 7.0 4.8 9.9 
Multi AMR (≥2 
antimicrobials)  46.2 40.1 52.5 5.5 3.7 8.2 
A3Ca 1.6 0.7 3.8 0.0 0.0 0.4 
ACSSuTb 2.6 1.3 5.0 0.0 0.0 0.4 
AKSSuTc 6.2 4.0 9.5 0.4 0.1 2.0 
ACKSSuTd 5.0 2.9 8.5 0.0 0.0 0.4 
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Table 4.2. Prevalence (%) of AMR in calves sampled in the spring (n=480) and in the 
fall (n=395) of 2002 accounting for clustering of AMR within herd 
 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline. 
 
 Individual animal prevalence for calves in 
the spring 
Individual animal prevalence for calves 
 in the fall 
Antimicrobial 
Prevalence 
(%) 
Lower CI Upper CI Prevalence 
(%) 
Lower CI Upper CI 
Amikacin 0.0 0.0 1.0 0.0 0.0 1.2 
Amoxicillin-
Clavulanic Acid 7.1 4.4 11.2 0.0 0.0 0.0 
Ampicillin 31.1 25.2 37.7 3.0 1.4 6.4 
Cefoxtin 6.4 4.1 10.0 0.0 0.0 1.2 
Ceftiofur 2.9 1.2 6.6 0.0 0.0 1.2 
Ceftriaxone 0.0 0.0 1.0 0.0 0.0 1.2 
Cephalothin 11.5 7.8 16.6 1.5 0.7 3.2 
Chloramphenicol 22.3 16.6 29.2 0.8 0.3 2.3 
Ciprofloxacin 0.0 0.0 1.0 0.0 0.0 1.2 
Gentamicin 1.0 0.4 2.4 0.0 0.0 1.2 
Kanamycin 28.9 22.9 35.8 2.2 0.9 5.4 
Nalidixic Acid 0.2 0.03 1.5 0.0 0.0 1.2 
Streptomycin 49.1 42.3 56.0 5.3 3.0 9.1 
Sulphamethoxazole 56.3 49.6 62.7 7.3 4.8 11.0 
Tetracylcine  60.0 53.3 66.4 9.9 6.2 15.5 
Trimethoprim-
Sulphamethoxazole 24.3 18.7 31.0 0.5 0.1 1.9 
AMR (≥1 
antimicrobial)  62.2 55.4 68.5 12.7 8.5 18.4 
Multi AMR (≥2 
antimicrobials)  59.3 52.6 65.6 9.9 6.4 15.2 
A3Ca 2.7 1.1 6.6 0.0 0.0 1.2 
ACSSuTb 4.9 2.6 9.1 0.0 0.0 1.2 
AKSSuTc 8.7 5.2 14.1 0.8 0.2 3.1 
ACKSSuTd 10.0 6.7 14.6 0.0 0.0 1.2 
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Table 4.3. Prevalence (%) of AMR at the herd level as determined by calves sampled in 
the spring (n=91) and in the fall (n=45) of 2002 
 
  
Herd Prevalence for calves in 
 the spring   
Herd prevalence for calves 
 in the fall 
Antimicrobial  
Prevalence  
(%) 
Lower 
CI 
Upper 
CI 
Prevalence  
(%) 
Lower 
CI 
Upper 
CI 
Amikacin 0.0 0.0 5.0 0.0 0.0 9.8 
Amoxicillin-Clavulanic 
Acid 22.0 14.6 31.6 0.0 0.0 9.8 
Ampicillin 62.6 52.3 71.9 17.8 9.2 31.7 
Cefoxtin 1.1 0.2 7.4 0.0 0.0 9.8 
Ceftiofur 8.8 4.5 16.6 0.0 0.0 9.8 
Ceftriaxone 0.0 0.0 5.0 0.0 0.0 9.8 
Cephalothin 31.9 23.1 42.1 13.3 6.1 26.7 
Chloramphenicol 41.8 32.1 52.1 6.7 2.2 18.7 
Ciprofloxacin 0.0 0.0 5.0 0.0 0.0 9.8 
Gentamicin 5.5 2.3 12.5 0.0 0.0 9.8 
Kanamycin 57.1 46.8 66.9 11.1 4.7 24.1 
Nalidixic Acid 1.1 0.2 7.4 0.0 0.0 9.8 
Streptomycin 80.2 70.8 87.2 26.7 15.8 41.3 
Sulphamethoxazole 87.9 79.5 93.2 40.0 26.9 54.8 
Tetracylcine  90.1 82.1 94.8 44.5 30.8 59.0 
Trimethoprim-
Sulphamethoxazole 48.4 38.3 58.6 4.4 1.1 16.1 
AMR (≥1 antimicrobial)  91.2 83.4 95.5 55.6 41.0 69.2 
Multi AMR (≥2 
antimicrobials)  90.1 82.1 94.8 46.7 32.8 61.1 
A3Ca 7.7 3.7 15.3 0.0 0.0 9.8 
ACSSuTb 13.2 7.6 21.8 0.0 0.0 9.8 
AKSSuTc 26.4 18.4 36.4 4.4 1.1 16.1 
ACKSSuTd 20.9 13.7 30.4 0.0 0.0 9.8 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline
 152 
 
CHAPTER 5 
PREVALENCE OF ANTIMICROBIAL RESISTANCE IN FECAL GENERIC E. 
COLI ISOLATED IN WESTERN CANADIAN BEEF HERDS. PART II: COWS AND 
COW-CALF PAIRS 
5.1. Introduction 
 
Antimicrobial resistance (AMR) in veterinary medicine is a complex issue. As in 
human medicine, there is concern about the loss of efficacious treatment options as a 
result of AMR. However, the bigger issue facing veterinarians and the livestock 
industry is the public health aspect of the issue because of evidence that agricultural use 
of antimicrobials contributes to increasing AMR in the human population. Several 
studies have investigated the potential link between antimicrobial use (AMU) and AMR 
in animals and the development of resistance in humans (Hummel et al., 1986, Endtz et 
al; 1991, Johnson et al., 1995, Bager et al., 1997, Aarestrup, 1999, Winokur et al., 2001, 
Swartz, 2002). Other studies of commensal and pathogenic resistant bacteria have been 
conducted in swine, poultry, feedlot, and dairy operations in order to more fully 
understand the type and level of resistance that is present in livestock (Dargatz et al., 
2003, Fiztgerald et al., 2003, Lanz et al., 2003, Bywater et al., 2004, Rajic et al., 2004, 
Khachatryan et al., 2004, Hershberger et al., 2005).  
 
Cow-calf herds in western Canada are subjected to less intensive management 
practices and different antimicrobial exposures than livestock species that are raised 
more intensively such as poultry, swine, or cattle in dairies or feedlots (Gow and 
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Waldner, 2007). The potential difference in selective pressure within cow-calf herds 
could, therefore, result in a different profile of AMR organisms when compared to other 
types of livestock. To the best of our knowledge there is currently no information on 
AMR in the cow-calf industry in western Canada. The objective of this study was to 
describe AMR patterns in cows and cow-calf pairs from western Canadian beef herds 
using E. coli as an indicator organism. 
 
5.2. Materials and methods 
 
As a part of a strategic research initiative to study AMR and AMU in cow-calf herds 
(Gow and Waldner, 2007, Gow et al., 2007a, Gow et al., 2007b), this project was 
undertaken to compliment an investigation of AMR in beef calves (Gow et al., 2007b). 
This paper describes AMR in generic fecal E. coli isolated from cows and cow-calf 
pairs. In the spring of 2002, feces were collected from a convenience sample of 533 
individually identified cows that were accessible in the calving and nursery areas on 69 
privately owned cow-calf farms in Alberta and Saskatchewan. In 2003, fecal samples 
were also collected from 105 cow-calf pairs on 10 farms. This analysis focuses on the 
above described population, but comparisons are made to other available data (Gow et 
al., 2007b) where calves had been sampled in the same herds.  
 
The materials and methods utilized in this study have been described in detail 
elsewhere (Gow et al., 2007b). Briefly, fecal samples were obtained either directly from 
the rectum or from the ground immediately after defecation. A separate disposable 
glove and container were used for each animal. Fecal samples were cultured for generic 
 154 
E. coli (Prairie Diagnostic Services, Saskatoon, Saskatchewan). A minimum of three 
isolates per sample identified as E. coli were selected and stored at -80°C. Isolates were 
tested for susceptibility using microbroth dilution (Sensititre®, TREK Diagnostic 
Systems Inc., Cleveland, Ohio) and the standard 2002 National Antimicrobial 
Resistance Monitoring System (NARMS) public health panel (CIPARS, 2006) (Agri-
Food Laboratories Branch, Alberta Agriculture and Food, Edmonton, Alberta, Canada). 
All testing was done in accordance with NCCLS guidelines (NCCLS, 2000). 
 
5.2.1. Statistical analysis 
 
The approach utilized for data manipulation, and population averaged prevalence 
estimates have been described in detail elsewhere (Gow et al., 2007b). Models were 
developed using generalized estimating equations (GEE) to account for clustering 
within herd (SAS v.8.2 for Windows (PROC GENMOD); SAS Institute, Cary, North 
Carolina, USA). Model specifications included a binomial distribution, logit link 
function, repeated statement with subject equal to herd, and an exchangeable correlation 
structure. For the examination of unconditional associations between AMR and animal 
level risk factors of interest, the predictors included: cow breed, cow age (2 year old 
heifers, 3 year old cows, 4 to 10 year old cows, and cows >10 years of age), and 
whether the cow was ever treated in 2002 prior to sample collection. The AMR 
outcomes (yes/no) examined included resistance to sulphamethoxazole, to tetracycline, 
to any antimicrobial, or to multiple antimicrobials. The association between dam 
resistance status (yes/no) and calf resistance status (yes/no) was also examined using the 
model specifications outlined above.  
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The frequency of AMR was compared between calves and cows in the same herd. 
Generalized estimating equations using the above model specifications were used to 
compare the total number of samples with any type of AMR (numerator) as a proportion 
of the total number of animals sampled (denominator), first between cows and calves in 
the spring of 2002 and again in 2003, and then between cows in the spring of 2002 and 
calves in the fall of 2002. Only herds where both cows and calves were sampled were 
included in these analyses. There were 37 herds where both calf (Gow et al., 2007b) and 
cow samples were collected in the spring of 2002, and 10 herds from the present study 
where both calves and cows were sampled in the spring of 2003. There were nine herds 
where samples were collected from cows in the spring of 2002 and also from the calves 
in the fall of 2002 (Gow et al., 2007b).  
 
In addition to examining the role of the cow-calf pair relationship in determining calf 
resistance status, we also investigated whether the most common resistance types found 
in the cow herd were a potential determinant of the types and frequency of resistance 
found in the calves. For the herds with both cow and calf samples in spring, we 
examined whether the proportion of cows with resistance to either sulphamethoxazole 
or tetracycline in the herd was a predictor of the proportion of calves in the herd (count 
of AMR positive calves / number of calves collected) with resistance to each of these 
antimicrobials respectively (Gow et al., 2007b), using GEE and the above model 
specifications.  
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5.3. Results 
 
5.3.1. Study conducted in the spring of 2002  
 
Cow age ranged from 2 to 14 years (median, 5 years; interquartile range (IQR), 3 to 
8). Median herd size was 154 (range, 71 to 437) breeding females. The median number 
of samples collected per herd was 8 (range, 2 to10; IQR, 6 to 10). Before sample 
collection, producers reported that 4.1% (22/533) of cows had been treated with 
antimicrobials. The number of days between last treatment and sample collection 
ranged from 6 to 147 (median, 37).  
 
5.3.2. Observed AMR in cows sampled in 2002 
 
Resistance to at least one antimicrobial was identified in 9.8% of the 1555 isolates 
examined in 2002. At least one resistant isolate was identified in 15.1% of cows and 
61% of herds (Tables 5.1 to 5.3). The antimicrobials to which resistance was most 
commonly identified were tetracycline and sulphamethoxazole (Tables 5.1 to 5.3). For 
all other drugs tested, the frequency of resistance was less than 2% (Tables 5.1 and 5.2). 
No resistance was identified to ceftriaxone, ciprofloxacin, and nalidixic acid. 
 
The maximum number of antimicrobials to which an isolate demonstrated resistance 
was 11; 0.5% (7/1555) of isolates were resistant to at least five antimicrobials. The most 
common multi-resistance pattern found in this group of isolates included: ampicillin, 
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chloramphenicol, streptomycin, sulphamethoxazole, and tetracycline. Three of the 
seven isolates with resistance to five or more antimicrobials exhibited this pattern.  
 
No resistance was detected to the Category I antimicrobials except for one isolate 
that had resistance to ceftiofur (Figure 5.1). The median MIC ranges for Category I 
antimicrobials were several dilutions away from the break point. With the exception of 
streptomycin, the median MICs for all Category II and III antimicrobials were also 
several dilutions below the breakpoint.  
 
The detection of any AMR or multiple AMR was not associated with cow breed 
(P=0.16; P=0.11), cow age (P=0.14, P=0.42), or previous cow treatment (P=0.56, 
P=0.32). Tetracycline and sulphamethoxazole resistance were also not associated with 
cow breed (P=0.09, P=0.45), cow age (P=0.20, P=0.22), or previous cow treatment (P= 
0.44, P=0.28).  
 
5.3.3. Study of cow-calf pairs conducted in 2003 
 
The median number of samples collected per herd was 10 (range, 9 to 16; IQR, 10 to 
10), and median herd size was 130 (range, 86 to 382) breeding females. Cow age ranged 
from 2 to 19 years of age (median, 5 years; IQR, 3 to 8). Ninety-two percent of the 
cows were classified as healthy at the time of sample collection. Fifty-eight percent 
(61/105) of the calves sampled were male, and 91.4% (96/105) of the calves were 
classified as healthy at sample collection. Median calf age was 47 days (range, 1 to 129; 
IQR; 28 to 60).  
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5.3.4. Observed AMR in the cows from the cow-calf pairs sampled in 2003 
 
Of the 312 isolates recovered from the cow samples in 2003, 6.1 % were resistant to 
at least one antimicrobial (Table 5.1); 8.6% of cows had at least one resistant isolate as 
did 60% of the herds (Table 5.2 to 5.3). Most of the resistance detected was to 
tetracycline and sulphamethoxazole. 
 
The maximum number of antimicrobials that an isolate was resistant to was 7; 1.9% 
(6/312) of isolates demonstrated resistance to at least 5 antimicrobials. The most 
common pattern found in this group of isolates included: ampicillin, kanamycin, 
streptomycin, sulphamethoxazole, and tetracycline.  
 
No resistance was identified to the Category I antimicrobials, and the median MIC 
ranges for these antimicrobials were several dilutions below the breakpoint (Figure 5.2). 
All of the median MICs for the Category II and Category III antimicrobials were several 
dilutions below the breakpoint (Figure 5.2), except for streptomycin which had a 
median MIC in the dilution immediately below the breakpoint.  
 
5.3.5. Observed AMR in the calves from the cow-calf pairs sampled in 2003 
 
Of the 318 calf isolates, 25.8 % were resistant to at least one antimicrobial (Table 
5.1). The proportion of calves and herds with at least one resistant isolate were 37.9% 
and 100% respectively (Table 5.2 to 5.3). The majority of the resistance detected was to 
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tetracycline and sulphamethoxazole and no resistance was identified to ceftriaxone, 
nalidixic acid, and ciprofloxacin. 
 
The maximum number of antimicrobials that an isolate was resistant to was 12; 9.1% 
(29/318) of isolates and 12.3% (13/105) of calves demonstrated resistance to at least 
five antimicrobials. The most common patterns found in this group of isolates included 
resistance to: ampicillin, choramphenicol, kanamycin, streptomycin, 
sulphamethoxazole, and tetracycline.  
 
Ceftiofur was the only Category I antimicrobial to which isolates demonstrated 
resistance (Figure 5.3). The median MIC ranges for these Category I, Category II 
(except for streptomycin), and Category III antimicrobials were several dilutions below 
the breakpoint (Figure 5.3). 
 
5.3.6. Observed AMR in the cow-calf pairs 
 
Resistant E. coli were identified in both the cow and the calf for only 4.8% (5/105) 
of the pairs examined and 3 of 10 farms. Three of five resistant pairs had isolates 
resistant to two or more antimicrobials. Tetracycline was the most common drug 
resistance detected and was identified in four of five pairs. Calf resistance was not 
predicted by dam resistance (P=0.36).  
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5.3.7. Comparison of AMR prevalence between cows and calves  
 
The prevalence of AMR was lower in generic fecal E. coli isolates collected from 
beef cows in the spring than in young calves from the same herds. In the 10 herds 
described above with cow-calf pair data for the spring of 2003, the calves were 7.1 
(95% CI, 2.8 to 18.3; P<0.0001) times more likely to shed resistant isolates than the 
cows. A similar trend was detected for 37 herds that had samples collected in the spring 
of 2002 from both calves (Gow et al., 2007b) and cows. Calves were 10.0 (95% CI, 5.8 
to 17.0; P<0.0001) times more likely to be positive for AMR than cows from the same 
herds. The median number of samples collected from the 37 herds (212 calves and 299 
cows) was 13 (IQR, 12 to 17; range, 7 to 20). 
 
There was no difference in the prevalence of AMR when comparing cows sampled 
in the spring of 2002 to calves sampled in the fall of 2002 (Gow et al., 2007b) from the 
same herds sampled (OR, 1.1; 95%CI, 0.3 to 3.7; P=0.91). The median number of 
samples from these 9 herds (81 calves and 74 cows) was 19 (IQR, 15 to 20; range, 9 to 
20).  
 
5.3.8. Association between the frequency of resistance in cow and calf samples  
 
For the 37 herds that had both cow and calf samples collected in the spring of 2002, 
the odds that calves would be resistant to sulphamethoxazole increased with the 
proportion of cows that were resistant to sulphamethoxazole (OR, 7.5; 95% CI, 1.3  to 
41.7; P=0.02). A similar increase in the odds of tetracycline resistance was seen with an 
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increasing proportion of cows positive for tetracycline resistance (OR, 6.1; 95% CI, 1.5 
to 25.3; P=0.01).  
 
5.4. Discussion 
 
This study increases the knowledge of AMR in beef cattle by providing 
complementary data to a study of calves from cow-calf herds (Gow et al., 2007b). The 
prevalence of AMR is relatively low in cow populations particularly to drugs classified 
as important to human medicine by Health Canada. Beef cows in this study were much 
less likely to shed resistant organisms than very young calves; however, cows and 
calves have similar AMR prevalence by weaning. Other key findings of this study were 
that the individual cow is not the primary determinant of the AMR status of her calf, but 
that the frequency of common types of resistance in the calves is associated with 
exposure from the cow herd. 
 
E. coli isolates collected from both the cows and calves were most commonly 
resistant to tetracycline and sulphamethoxazole. This pattern was explored by 
considering whether the proportion of cows in the herd with either tetracycline or 
sulphamethoxazole resistance was predictive of these same resistances in calves in the 
spring of 2002. The association between resistance in the cow herd and the occurrence 
of the same types of resistance in the calves indicates that young calves might be 
acquiring resistance by contact with the cow herd or fecal contamination of the 
environment by the cow herd. The data from the cow-calf pair study suggests that the 
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status of the calf’s dam is less important than the herd environment in determining the 
calf’s status. 
 
The most common resistances detected in this study are consistent with what others 
have reported for E. coli isolates from a variety of different animal species (Kijima-
Tanaka et al., 2003, Khachatryan et al., 2004, Bywater et al., 2004, Gow et al., 2007b). 
The difference in AMR prevalence between species (Schroeder et al., 2002, Kijima-
Tanaka et al., 2003, Sayah et al., 2005) may be the result of variation in AMU selection 
pressure between industries. The perception is that in-feed antimicrobials are 
infrequently used in cow-calf herds and that there is often minimal routine injectable 
AMU. Currently there are limited data to supports this assumption; further work is 
necessary to understand the impact of selective pressures experienced in cow-calf herds. 
 
The frequency of resistance was low in generic fecal E. coli isolates harvested from 
beef cows, especially to antimicrobials classified as important to human health. No 
ciprofloxacin or ceftriaxone resistance was present, and only one ceftiofur resistant 
isolate was identified from the cow samples. For the majority of the antimicrobials 
tested, the median MICs were also well below the breakpoint for resistance, indicating 
that most of the E. coli population in these animals was highly sensitive to those 
particular drugs. These findings indicate that on-farm exposure to beef cows probably 
poses a relatively low risk as a source of AMR for human health. However, additional 
molecular studies would provide more insight into what AMR genes are being carried 
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in these populations. Follow up monitoring is needed to detect emerging resistance 
issues in this population that could be of greater concern to public health. 
 
To appreciate the impact on animal health research is needed to assess animal health 
pathogens in cow-calf herds and their AMR patterns. In an Alberta feedlot project some 
initial work has been performed on AMR in bovine respiratory pathogens (Read et al., 
2004), but nothing is currently available from cow-calf herds. Access to clinical 
laboratory databases could provide some insight into AMR in animal pathogens, but 
often this information is incomplete and difficult to obtain. To assess the impact of 
AMR on animal health pathogens a prospective study to collect and test samples of 
interest from diseased animals prior to and after treatment, along with detailed treatment 
and outcome data would be needed. 
  
There were slight differences in the AMR prevalence estimates between the 2002 
and 2003 cow samples, but the antimicrobials to which resistance was detected were 
very similar. The confidence intervals for the two prevalence estimates overlap 
suggesting the difference was not significant. In the cow-calf pair study, only 105 
animals on 10 herds were enrolled, while there were over 500 animals on 69 herds for 
the cow study. There were also differences in the prevalence estimates between the 
calves from the cow-calf pair study in 2003 (25.8%) and a larger sample of beef calves 
from a related study in the spring of 2002 (48.8%) (Gow et al., 2007b). But again, the 
antimicrobials to which resistance was detected was very similar in the two populations. 
The 2002 studies involved larger populations of cows and calves and were probably 
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more representative of western Canadian cow-calf herds. Additionally, the area covered 
by the 2002 studies was more geographically diverse and included more farms with 
varying management practices. The calves sampled in 2003 (median, 47 days) were also 
older on average than the calves sampled in 2002 (median, 6 days). 
 
While the prevalence of AMR in the cows was significantly lower than that observed 
in young calves in the spring of the year, the prevalence estimates from cows were 
similar to those of older calves sampled in the fall. While these studies were not 
specifically designed to study the effect of age on the prevalence of AMR organisms in 
beef cattle, it does appear that there may be an age-related difference between the pre-
ruminant calves and older animals in each study. The observation of relatively high 
levels of AMR in young animals has also been described by other researchers (Brophy 
et al., 1977, Hinton et al., 1984, Hinton, 1985, Mathew et al., 1999, Khachatryn et al., 
2004, Gow et al., 2007b). Further work is necessary to describe the determinants of 
AMR in young calves. With the exception of a lower risk of AMR in calves less than 3 
days of age, there were no individual animal risk factors identified for AMR in either 
calves or cows in either this or the previous study (Gow et al., 2007b). The results of the 
present study suggest that the calf’s dam is the not the primary determinant of whether 
or not it sheds resistant organisms, but the association of AMR in the cow herd and in 
the calves may indicate that calves are acquiring AMR from either the cow herd itself or 
from contamination of the environment by the cow herd.  
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Seasonal variation of AMR in cow-calf herds could be examined by following cattle 
over time. The intention of the current study was to assess cattle in cow-calf herds at a 
time when animals are potentially under the highest stress. The calving season is also 
often the period when antimicrobial treatment may be most common because animals 
are most susceptible to disease as a result of crowding, confinement, stress associated 
with calving, and potentially adverse weather conditions. 
 
The main limitation of this and the related calf study (Gow et al., 2007b) was the use 
of convenience samples rather than having a formal random sampling strategy for 
selecting herds and animals within herds. Access to the herds and the necessary calving 
and treatment records were provided through a larger study looking at factors affecting 
productivity in beef herds (https:/www.wissa.info). Substantial additional funding 
would have been required to run this as an independent study. Secondly, recruiting cow-
calf herds for research during calving season is very difficult. Calving is an extremely 
busy time in commercial cow-calf operations and herd owners are reluctant to allow 
visitors for any purpose because of biosecurity concerns. Given the limitations of the 
available budget for laboratory analysis, we collected samples from as many herds as 
agreed to participate during this stressful period.  
 
Random sampling of animals within the herd was also not practical. Herd owners 
could not be asked to provide access to all cows or calves to permit formal random 
sampling because of liability concerns associated with disease transmission due to 
crowding and handling and the potential for trauma related injuries in pregnant cows or 
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very young calves. Samples were collected from accessible animals on the day of a 
routine herd visit while trying to minimize any incursion on the herd owner’s time. Any 
other approach to sample collection would have been met with immediate rejection by 
the majority of herd owners. However, this said, the potential for selection bias was 
low. Herd management as well as the risk of treatment and death loss in these herds was 
representative of what would be expected in moderate to large, commercial beef herds 
in western Canada (https:/www.wissa.info). Neither the herds nor animals sampled 
were chosen with any knowledge of the owners’ AMU practices or AMR status. 
 
These are the first available on-farm data describing the prevalence of AMR in beef 
cows in western Canada. The prevalence of resistance to drugs classified of high 
importance to human medicine by Health Canada was very low. These results suggest 
that AMR is relatively uncommon in beef cows at calving, but that cows shed a lower 
proportion of resistant bacteria as compared to their calves in the spring of the year. 
While it is unclear why the prevalence of AMR changes as the animal ages and after the 
summer pasture season, documenting this finding in cow-calf herds is important as 
baseline information is required as a first step in the development of any long-term 
monitoring and control programs. 
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Figure 5.1.  Minimum inhibitory concentrations for fecal generic E. coli isolates recovered from cows in the spring of 2002 arranged 
by Health Canada’s classification of drugs (n=1555) 
MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 1555 0.25 0.25 5.9 73.7 20.1 0.2 0.1 0.1
Ceftriaxone 1555 <=0.25 0.25 99.9 0.1
Ciprofloxacin 1554 <=0.015 <=0.015 99.7 0.3
Amikacin 1555 1 2 2.0 49.8 45.9 1.9 0.4
Amoxicillin-Clavulanic Acid 1555 4 4 3.3 23.1 69.2 4.0 0.2 0.1 0.1
Gentamicin 1554 0.5 1 19.3 44.5 35.5 0.6 0.1
Kanamycin 1555 <=8 <=8 99.3 0.1 0.6
Nalidixic Acid 1555 2 4 0.1 3.2 51.4 44.5 0.7
Streptomycin 1555 <=32 <=32 96.5 2.3 1.2
Trimethoprim-Sulphamethoxazole 1555 <=0.12 <=0.12 92.7 4.9 1.9 0.5
Ampicillin 1555 4 4 5.0 38.5 51.7 4.1 0.1 0.1 0.6
Cefoxitin 1555 4 4 0.7 28.5 59.5 10.5 0.6 0.2
Cephalothin 1555 8 8 0.7 18.3 60.7 20.1 0.1 0.2
Chloramphenicol 1555 4 8 5.5 59.5 33.6 0.7 0.7
Sulphamethoxazole 1555 <=16 <=16 92.8 0.1 0.1 0.1 6.9
Tetracycline 1555 <=4 <=4 90.7 0.8 0.6 0.3 7.6
IV
Distribution (%) of MICs
I
II
III
Antimicrobial n*
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Figure 5.2. Minimum inhibitory concentrations for generic fecal E. coli isolates recovered from the cows of the cow-calf pair samples 
in the spring of 2003, arranged by Health Canada’s classification of drugs (n=312) 
 MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 312 0.25 0.25 2.6 79.2 18.3
Ceftriaxone 312 <=0.25 0.25 100.0
Ciprofloxacin 312 <=0.015 <=0.015 99.4 0.6
Amikacin 312 1 2 1.3 50.3 46.8 1.6
Amoxicillin-Clavulanic Acid 312 4 4 3.5 25.6 65.4 3.8 1.6
Gentamicin 312 1 1 16.7 27.2 55.4 0.6
Kanamycin 312 <=8 <=8 97.1 2.9
Nalidixic Acid 312 2 4 2.2 64.7 32.1 1.0
Streptomycin 312 <=32 <=32 96.5 1.6 1.9
Trimethoprim-Sulphamethoxazole 312 <=0.12 <=0.12 92.3 5.4 0.3 0.3 1.6
Ampicillin 312 4 4 4.5 35.6 50.6 7.4 1.9
Cefoxitin 312 4 4 0.3 35.9 48.7 15.1
Cephalothin 312 8 8 1.6 13.5 67.0 17.3 0.6
Chloramphenicol 312 4 8 3.8 61.2 32.7 2.2
Sulphamethoxazole 312 <=16 <=16 95.5 4.5
Tetracycline 312 <=4 <=4 90.4 4.5 5.1
IV
Distribution of Isolates (%) Across Minimum Inhibitory Concentrations (MIC) Ranges
I
II
III
Antimicrobial n*
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Figure 5.3. Minimum inhibitory concentrations for generic fecal E. coli isolates collected from the calves of the cow-calf pair samples 
in the spring of 2003, Health Canada’s classification of drugs (n=318) 
 
 MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 318 0.25 0.25 2.2 73.3 19.5 0.9 0.6 3.5
Ceftriaxone 318 <=0.25 0.25 95.0 0.6 0.3 1.3 1.9 0.9
Ciprofloxacin 318 <=0.015 <=0.015 100.0
Amikacin 318 1 2 4.7 48.1 44.0 2.2 0.9
Amoxicillin-Clavulanic Acid 318 4 4 0.3 11.9 72.6 9.1 0.9 1.6 3.5
Gentamicin 318 1 1 23.0 6.0 70.4 0.3 0.3
Kanamycin 318 <=8 <=8 92.5 0.3 7.2
Nalidixic Acid 318 2 4 0.3 50.0 48.1 1.6
Streptomycin 318 <=32 <=32 85.5 6.3 8.2
Trimethoprim-Sulphamethoxazole 318 <=0.12 <=0.12 75.2 11.0 4.4 0.6 8.8
Ampicillin 318 4 4 0.9 37.1 49.7 2.5 9.7
Cefoxitin 318 4 4 0.3 24.2 58.2 11.9 0.9 4.4
Cephalothin 318 8 16 0.6 6.0 56.3 30.2 1.9 5.0
Chloramphenicol 318 4 8 3.8 57.2 29.9 9.1
Sulphamethoxazole 318 <=16 >512 73.6 26.4
Tetracycline 318 <=4 <=4 76.1 1.3 0.3 22.3
IV
Distribution of Isolates (%) Across Minimum Inhibitory Concentrations (MIC) Ranges
I
II
III
Antimicrobial n*
 
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
 174 
Table 5.1. Prevalence (%) of AMR in E coli isolates recovered from cows (n=1555) in 
the spring of 2002 and for cows (n=312) and calves (n=318) in the spring of 2003 
adjusted for clustering at the herd level. 
 
 Cows 2002 Pair Cows 2003 Pair Calves 2003 
Antimicrobial   
95% Confidence  
Interval  
95% Confidence  
Interval  
95%  Confidence 
 Interval 
 
Prevalence 
(%) 
Lower  Upper Prevalence 
(%) 
Lower Upper Prevalence 
(%) 
Lower Upper 
Amikacin 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 1.5 
Amoxicillin-
Clavulanic Acid 0.3 0.1 0.8 0.0 0.0 1.5 3.9 1.1 13.0 
Ampicillin 0.7 0.2 2.3 2.0 0.3 12.0 8.7 4.1 17.7 
Cefoxtin 0.2 0.0 0.8 0.0 0.0 1.5 3.2 0.7 13.1 
Ceftiofur 0.1 0.0 0.4 0.0 0.0 1.5 2.9 0.6 13.8 
Ceftriaxone 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 1.5 
Cephalothin 0.3 0.1 0.8 0.7 0.1 4.1 6.0 2.7 12.7 
Chloramphenicol 0.8 0.2 3.0 0.0 0.0 1.5 7.9 3.4 17.1 
Ciprofloxacin 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 1.5 
Gentamicin 0.2 0.1 0.6 0.0 0.0 1.5 0.3 0.0 2.0 
Kanamycin 0.7 0.2 2.9 2.7 0.6 10.4 5.9 1.8 17.3 
Nalidixic Acid 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 1.5 
Streptomycin 3.4 1.2 9.3 3.4 1.1 9.7 13.0 7.2 22.3 
Sulphamethoxazole 7.1 3.4 14.2 4.4 1.8 10.2 24.3 15.2 36.5 
Tetracylcine  8.7 4.4 16.5 5.1 2.2 11.2 20.6 12.5 32.1 
Trimethoprim-
Sulphamethoxazole 0.5 0.2 1.7 1.7 0.3 10.1 7.3 2.7 18.2 
AMR (≥1 
antimicrobial)  9.8 5.1 18.2 6.1 3.1 11.7 25.8 16.6 37.8 
Multi AMR (≥2 
antimicrobials)  7.1 3.2 15.0 3.4 1.1 9.7 23.2 14.3 35.3 
A3Ca 0.1 0.0 0.4 0.0 0.0 1.5 2.9 0.6 13.8 
ACSSuTb 0.1 0.0 0.4 0.0 0.0 1.5 0.9 0.3 3.5 
AKSSuTc 0.1 0.0 0.4 2.0 0.3 12.0 1.2 0.3 5.0 
ACKSSuTd 0.2 0.0 1.3 0.0 0.0 1.5 2.9 0.6 13.8 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline 
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Table 5.2. Prevalence (%) of AMR in cows (n=533) sampled in the spring of 2002 and 
for cows (n=105) and calves (n=105) of the cow-calf pairs sampled in the spring of 
2003 adjusted for clustering at the herd level. 
 
 Cows 2002 Pair Cows 2003 Pair Calves 2003 
Antimicrobial  
95%  
Confidence  
Interval  
95%  
Confidence Interval  
95%  
Confidence 
Interval 
 
Prevalence 
(%) 
Lower Upper Prevalence 
(%) 
Lower Upper Prevalence 
(%) 
Lower Upper 
Amikacin 0.0 0.0 0.9 0.0 0.0 4.4 0.0 0.0 4.4 
Amoxicillin-
Clavulanic Acid 0.8 0.3 1.9 0.0 0.0 0.0 4.9 1.6 14.2 
Ampicillin 1.5 0.8 2.9 2.0 0.3 11.8 11.7 5.7 22.3 
Cefoxtin 0.6 0.2 1.7 0.0 0.0 4.4 4.9 1.6 14.2 
Ceftiofur 0.2 0.0 1.3 0.0 0.0 4.4 3.8 0.9 14.3 
Ceftriaxone 0.0 0.0 0.9 0.0 0.0 4.4 0.0 0.0 4.4 
Cephalothin 0.8 0.3 1.9 0.9 0.1 6.0 10.5 5.9 17.9 
Chloramphenicol 1.7 0.8 3.6 0.0 0.0 4.4 10.2 4.3 22.1 
Ciprofloxacin 0.0 0.0 0.9 0.0 0.0 4.4 0.0 0.0 4.4 
Gentamicin 0.4 0.1 1.5 0.0 0.0 4.4 0.9 0.1 6.0 
Kanamycin 1.3 0.7 2.6 2.8 0.7 10.1 7.7 2.5 21.4 
Nalidixic Acid 0.0 0.0 0.9 0.0 0.0 4.4 0.0 0.0 4.4 
Streptomycin 6.7 4.5 9.9 4.8 2.1 10.5 20.7 12.4 32.6 
Sulphamethoxazole 11.1 8.0 15.1 5.7 2.9 10.8 33.8 21.3 49.0 
Tetracylcine  13.4 10.2 17.5 7.7 3.5 16.2 31.6 20.6 45.2 
Trimethoprim-
Sulphamethoxazole 1.7 0.7 4.3 2.0 0.3 11.8 9.2 3.6 21.2 
AMR (≥1 
antimicrobial)  15.1 11.7 19.3 8.6 4.3 16.3 37.9 25.3 52.4 
Multi AMR (≥2 
antimicrobials)  11.6 8.6 15.6 4.8 2.1 10.5 32.7 21.5 46.2 
A3Ca 0.2 0.0 1.3 0.0 0.0 4.4 3.8 0.9 14.3 
ACSSuTb 0.2 0.0 1.3 0.0 0.0 4.4 1.9 0.5 6.5 
AKSSuTc 0.2 0.0 1.3 2.0 0.3 11.8 2.1 0.7 6.3 
ACKSSuTd 0.4 0.1 1.4 0.0 0.0 4.4 3.8 0.9 14.3 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline 
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Table 5.3. Herd prevalence (%) of AMR for cows (N=69 herds) sampled in the spring 
of 2002 and for cows (N=10 herds) and calves (N=10 herds) of the cow-calf pairs 
sampled in the spring of 2003 adjusted for clustering at the herd level. 
 
 Cows 2002 Pair Cows 2003 Pair Calves  2003 
Antimicrobial  
95% 
 Confidence 
Interval  
95%  
Confidence 
Interval  
95% 
 Confidence 
Interval 
 
Prevalence 
(%) 
Lower  Upper Prevalence 
(%) 
Lower Upper Prevalence 
(%) 
Lower Upper 
Amikacin 0.0 0.0 6.5 0.0 0.0 34.5 0.0 0.0 34.5 
Amoxicillin-
Clavulanic Acid 5.8 2.2 14.5 0.0 0.0 34.5 30.0 10.0 62.4 
Ampicillin 11.6 5.9 21.5 10.0 1.4 46.7 50.0 22.5 77.5 
Cefoxtin 4.4 1.4 12.6 0.0 0.0 
34.5 
30.0 10.0 62.4 
Ceftiofur 1.5 0.2 9.6 0.0 0.0 
34.5 
20.0 5.0 54.1 
Ceftriaxone 0.0 0.0 6.5 0.0 0.0 
34.5 
0.0 0.0 34.5 
Cephalothin 5.8 2.2 14.5 10.0 1.4 46.7 70.0 37.6 90.0 
Chloramphenicol 10.2 4.9 19.8 0.0 0.0 
34.5 
50.0 22.5 77.5 
Ciprofloxacin 0.0 0.0 6.5 0.0 0.0 
34.5 
0.0 0.0 34.5 
Gentamicin 2.9 0.7 10.9 0.0 0.0 34.5 10.0 1.4 46.7 
Kanamycin 10.2 4.9 19.8 20.0 5.0 54.1 40.0 15.8 70.3 
Nalidixic Acid 0.0 0.0 6.5 0.0 0.0 34.5 0.0 0.0 34.5 
Streptomycin 34.8 24.5 46.7 40.0 15.8 70.3 80.0 45.9 95.0 
Sulphamethoxazole 49.3 37.7 60.9 50.0 22.5 77.5 100.0 50.0 50.0 
Tetracylcine  53.6 41.9 65.0 50.0 22.5 77.5 100.0 50.0 50.0 
Trimethoprim-
Sulphamethoxazole 8.7 4.0 18.0 10.0 1.4 46.7 40.0 15.8 70.3 
AMR (≥1 
antimicrobial)  60.9 49.0 71.6 60.0 29.7 84.2 100.0 N/A N/A 
Multi AMR (≥2 
antimicrobials)  53.0 41.9 65.0 40.0 15.8 70.3 100.0 N/A N/A 
A3Ca 1.5 0.2 9.6 0.0 0.0 
34.5 
20.0 5.0 54.1 
ACSSuTb 1.5 0.2 9.6 0.0 0.0 
34.5 
20.0 5.0 54.1 
AKSSuTc 1.5 0.2 9.6 10.0 1.4 46.7 20.0 5.0 54.1 
ACKSSuTd 2.9 0.7 10.9 0.0 0.0 34.5 20.0 5.0 54.1 
aA3C-ampicillin, cefoxitin, ceftiofur, cephalothin  
bACSSuT-ampicillin, chloramphenicol, streptomycin, sulphamethoxazole and tetracycline 
cAKSSuT-ampicillin, kanamycin, streptomycin, sulphamethoxazole and tetracycline  
dACKSSuT-ampicillin, chloramphenicol, kanamycin, streptomycin, sulphamethoxazole and tetracycline 
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CHAPTER 6 
FACTORS ASSOCIATED WITH ANTIMICROBIAL RESISTANCE IN CALVES 
BORN IN 89 WESTERN CANADIAN BEEF HERDS 
 
6.1. Introduction 
 
Antimicrobial use (AMU) in agriculture is a concern because of the potential for the 
spread of antimicrobial resistance (AMR) between animals and humans (Prescott and 
Dowling, 2000; McEwen and Fedorka-Cray, 2002, Anderson et al., 2003). Because 
AMU can lead to selection of resistant organisms, investigating the relationship 
between AMR and AMU is critical to understanding the risk factors associated with the 
development of resistance. The most commonly used antimicrobials in food animals are 
usually from one of five major classes: beta-lactams, tetracyclines, aminoglycosides, 
macrolides, and sulphonamides (White and McDermott, 2001). While all of these 
antimicrobials may not be “critical” antimicrobials in human medicine, the capacity of 
bacteria to carry multiple linked resistance genes may result in the transfer of unrelated 
resistance genes. 
 
Since bacteria can carry multiple resistance genes on plasmids, transposons, and 
integrons it is necessary to investigate not only specific AMU/AMR combinations, but 
also to consider the effect of unrelated antimicrobials on the persistence of resistance in 
a population. For example, Read et al. (2002) demonstrated that the use of tetracycline, 
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florfenicol, and tilimicosin in feedlot cattle was associated with of the presence of the 
beta-lactamase enzyme blacmy2 gene. This finding suggests that AMU can select not 
only for resistance to that specific antimicrobial, but that it may also result in co-
selection of other resistance genes.  
 
In examining the risk factors for resistance development in a population, it is 
necessary to consider AMU in all members of the population and not just the animals 
from which samples have been collected. Antimicrobial use in some individuals can 
increase the risk of colonization or infection with resistant organisms in others who 
have not been treated. Members of a population can experience indirect effects of AMU 
including an increased risk for acquiring a resistant organism because of AMU in others 
in the population (Lipsitch and Samore; 2002). In environments with long-term AMU 
there will be a change in the ecology and resistant organisms will gain dominance 
within the population (White and McDermott, 2001).  
 
The study objective was to investigate herd-level treatment and vaccination practices 
potentially associated with AMR in fecal generic E. coli collected from calves in beef 
herds from western Canada. Risk factors of potential interest included AMU in the herd, 
proportion of calves ever being treated, herd vaccination status for infectious bovine 
rhinotracheitis (IBR) and bovine virial diarrhea virus (BVDV), and vaccination status 
for calf-associated diarrhea cause by E. coli, rotavirus or coronavirus.  
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6.2. Materials and methods 
 
6.2.1. Background and herd selection 
 
In the spring of 2002, fecal samples were collected from calves born on western 
Canadian cow-calf herds. Participating herds were a subset of herds recruited for a 
multifaceted survey of risk factors affecting cattle productivity and health 
(https://www.wissa.info). Private veterinary clinics across northern British Columbia, 
Alberta, and Saskatchewan were approached and asked to participate in the larger study. 
Within each practice, herds were identified and enrolled based on the selection criteria 
which considered herd size (>50 cows), animal identification, existing calving records, 
animal handling facilities sufficient for  pregnancy testing and bull evaluation, and 
relationship with a local veterinary clinic. Participating herds were visited at least 
quarterly by one of six study veterinarians to collect samples and data, and to monitor 
the quality and consistency of on-farm records.  In a subset of herds, fecal samples and 
farm records for the current risk factor study were collected between January and June, 
2002.  
 
Calving records for each cow included cow identification, calf identification, date of 
calving, single or twin birth, sex of the calf, the degree of assistance provided to the 
cow, any post calving problems, and calving outcome (born alive, stillbirth, died later). 
If the calf died, the date of death was also included. Other data recorded for each herd 
included the herd vaccination status for infectious bovine rhinotrachietis (IBR), bovine 
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viral diarrhea virus (BVDV), and neonatal diarrhea (coronavirus or rotavirus, and E. 
coli). Herd inventory was monitored and tracked closely by study participants. 
 
6.2.2 Antimicrobial use data collection 
 
Antimicrobial use data were collected using individual treatment records as well as a 
questionnaire examining herd AMU (Gow and Waldner, 2007). Because the individual 
animal records did not consistently include information on the type of antimicrobial 
used for treatment, a questionnaire was developed to identify the types of antimicrobial 
products most commonly used on each cow-calf farm for the period of January 1 to 
June 30, 2002. Herd owners were asked about the frequency of use for sulphonamides, 
tetracylcines / oxytetracyclines, trimethoprim / sulphadioxine, and penicillins. 
Antimicrobials that did not fall into these broad categories were classified as “other”. 
Lists of common trade names were provided under each group to simplify the selection 
of the appropriate antimicrobial by the producer. Producers were asked to report 
separately the number of treatments for both cows and calves for each antimicrobial 
category listed above. The numbers of treatments for each category were coded as 
follows: l to 3 animals treated, 4 to 10 animals treated, and >10 animals treated. Only 
herd data were considered in investigating associations between AMU and AMR. 
 
For each herd individual animal treatment data were summarized in order to assess 
the impact of the proportion of calves ever treated (yes/no) with antimicrobials and/or 
fluids on AMR. Treatment occurrence was reported for calves as cumulative incidence. 
The number of calves reported as ever having been treated as a percentage of the 
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number of calves in the herd at risk of treatment during the study period was used for 
this calculation. 
 
6.2.3. Sample collection 
 
Fecal samples were collected from 466 individually identified animals on 89 
privately owned farms in Alberta and Saskatchewan. The calf samples were collected 
from accessible animals in the calving and nursery areas. Fecal samples were obtained 
either directly from the rectum or from the ground immediately after defecation. A 
separate disposable glove and container were used for each animal.  
 
6.2.4. Laboratory methods 
 
6.2.4.1 Escherichia coli culture 
 
Fecal samples were sent on ice to a private diagnostic laboratory (Prairie Diagnostic 
Services, Saskatoon, Saskatchewan) for culture. The samples were cultured onto 
MacConkey agar plates at 37◦C for 18 hours for isolation of E. coli. At least three 
individual lactose fermenting colonies identified as E. coli using standard biochemical 
tests, including indol, triple sugar iron (TSI) slant, citrate, and urea, were saved from 
each sample. If both dry and mucoid colonies were detected within a sample, then three 
isolates from each colony type were tested. Individual E. coli isolates were stored in 
50% glycerol and Luria-Bertani (LB) broth at -80ºC until susceptibility testing was 
performed.  
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6.2.4.2. Susceptibility testing methodology 
 
Susceptibility testing was performed by Alberta Agriculture, Food and Rural 
Development. All E. coli isolates were tested for susceptibility using a microbroth 
dilution technique (Sensititre®, TREK Diagnostic Systems Inc., Cleveland, Ohio) and 
the standard 2002 National Antimicrobial Resistance Monitoring System (NARMS) 
CMV7CNCD gram negative public health panel.  
 
Minimum inhibitory concentrations (MICs) for a total of 16 antimicrobial agents 
were assessed (Figure 1). Breakpoints for susceptibility were used, as defined by the 
NCCLS (NCCLS, 2000) (Figure 2). All isolates that fell into the intermediate 
susceptibility range were classified as susceptible. Amikacin results > 4µg/mL were 
labeled not interpretable because the breakpoint is 4 dilutions beyond the range of the 
panel. The breakpoint used for streptomycin was 64µg/ml (CIPARS, 2006). 
 
6.2.5. Statistical analysis 
 
All data were entered into a computerized database (Microsoft® Office Access 2000, 
Microsoft Corporation). Descriptive analyses were completed and variables were 
recoded as necessary for statistical modeling using commercially available software 
programs (SPSS 11.0 for Windows, SPSS Inc., Chicago, Illinois).  
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Herd risk factors for AMR were investigated using generalized estimating equations 
(GEE) to account for clustering within herd (SAS v.8.2 for Windows (PROC 
GENMOD); SAS Institute, Cary, North Carolina, USA). Model specifications included 
a binomial distribution, logit link function, and an exchangeable correlation structure. 
Statistically significant associations were reported as an odds ratio with the lower and 
upper 95% confidence interval.  
 
Separate models were run for each outcome of interest including the proportion of 
calves with resistance to: tetracycline, ampicillin, streptomycin, sulphamethoxazole, 
trimethoprim/sulphamethoxazole, kanamycin, chloramphenicol, ≥1 antimicrobial, and 
resistance to ≥2 antimicrobials. The numerator for each outcome was the number of 
positive calves for the herd and the denominator was the number of calves sampled 
from that herd.  
 
In the first step of the analyses, the unconditional association between each of the 
outcomes of interest and the individual antimicrobials listed in tables 2 and 3 were 
investigated.  Antimicrobial use was first modeled as a yes/no variable indicating 
whether the antimicrobial was used in the herd or not.  If a statistically significant 
association was detected at a P≤0.05 level for the outcome and the use of that 
antimicrobial, then AMU was considered separately for cows and calves.  
 
If a statistically significant association at ever used in the cows or calves on the farm 
was detected, then the analysis was repeated to consider the number of times the 
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antimicrobial was used in either cows or calves. The relationship between resistance 
and the increasing use of a particular antimicrobial was explored to determine if the 
odds of resistance increased with the number of times an antimicrobial was reported as 
used on the farm i.e. used 1-3 times, 4-10 times or >10 times. If a reasonable dose-
response relationship was evident, then this categorization of the AMU was considered 
for use in building a multivariable herd-adjusted model. If the multivariable herd-
adjusted model would not converge with the AMU categorized by use 1-3 times, 4-10 
time or >10 times, then a second model was developed to evaluate a yes/no variable 
indicating any use of that antimicrobial for either cows and/or calves in the herd as 
appropriate. Again if this new model did not converge, then a summary yes/no variable 
indicating any use of the antimicrobial in the herd was evaluated in the model. 
 
The final multivariable model was developed using backwards stepwise elimination. 
Any potential risk factors where P≤0.05 or that were acting as important confounders 
(removal of the potential risk factor from the model changes the effect estimate for the 
exposure by ≥20%) were retained in the final model. After establishing the main effects 
model, biologically reasonable first order interaction terms were tested if two or more 
variables (P≤0.05) were retained in the final model.  
 
6.2.6. Post hoc power calculations 
 
Post hoc power calculations were performed to evaluate whether limited study power 
was a factor in not detecting associations between specific AMU and AMR to that 
antimicrobial or class of antimicrobials. The most commonly reported antimicrobial 
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used and resistance detected was for tetracycline, therefore sample size estimates were 
based on this antimicrobial. The calculations were based on being able to detect a 
minimum expected increase of 1.5 times in the proportion of tetracycline resistance in 
calves from herds that used tetracycline compared with calves from herds that did not 
use tetracycline. Computations were performed using sample size calculations for 
comparing two proportions (Dohoo et al., 2003) to develop crude estimates of the 
required sample size per group.  Data from a null model were used to estimate variance 
for AMR in calves across herds using penalized quasi-likelihood estimates (2nd order 
PQL) (MLwiN version 2.0, Centre for Multilevel Modeling, Institute of Education, 
London, UK), a binomial distribution, and logit link function. These results were 
utilized in adjusting the sample size estimates for clustering at the herd level (Dohoo et 
al., 2003). 
 
6.3. Results 
 
6.3.1. Study population 
 
Between 1 and 12 calf fecal samples (median, 5; interquartile range (IQR), 4 to 6) 
were collected from each of 89 herds. Enrolled herds ranged in size from 74 to 393 
breeding females (median, 137). Of the 466 calves sampled, 56% (259/466) were male 
and ranged in age from new born to 151 days (median, 6). Dam age ranged from 2 to 17 
years with a median of 6 years of age. The percentage of calves treated on each farm 
varied from 0 to 100% (median, 8.1%, IQR, 4.1 to 20.9%); 94% (440/466) of calves 
were classified as healthy at the time of sample collection.  
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Modified-live BVDV and IBR vaccines were used in 45% (40/89) of herds, 37% 
(33/89) of herd owners used an inactivated vaccination, 3% (3/89) vaccinated but the 
type was not reported, and 15% (33/89) did not vaccinate. Vaccination of the 
cow/heifers for prevention of neonatal calf diarrhea was reported in 32% (28/89) of 
herds.  
 
6.3.2. Summary of AMR and AMU in study herds 
 
The MICs for 16 antimicrobials were summarized for each of the 1677 isolates 
recovered in this study (Figure 6.1). For the 7 antimicrobials that resistance was most 
commonly detected, the crude calf prevalence ranged from 22.5 to 60.5% (Table 6.1).   
For the same 7 antimicrobials the median proportion of calves with AMR per herd was 
21.0% to 59% (Table 6.1). 
 
Ninety-one percent of herds had at least one calf positive for resistance to ≥1 
antimicrobial. Similarly, resistance to ≥2 antimicrobials was detected in 89% of the 
herds. The most common resistances identified on farms were to tetracycline (90% of 
herds), sulphamethoxazole (88%), and streptomycin (80%).   
 
More than 70% of the farms used tetracyclines/oxytetracylcines; the majority of this 
use was in the cow herd (Table 6.2). Slightly fewer than 70% of the herds used 
sulphonamides, but the majority of this use was in the calf herd (Table 6.2). Penicillin, 
tilmicosin and florfenicol were used on about half of the farms (Table 6.2 and 6.3). 
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Gentamicin, ceftiofur, and sulbactam:ampicillin were used by less than 12% of the 
herds. One percent of the herds reported off label use of either cephalexin or 
enrofloxacin (Table 6.3). Ionophores were incorporated into the rations of cows and 
heifers in 25.8% (23/89) herds. 
 
6.3.3. Observed risk factors associated with AMR 
 
Vaccination status for BVDV was not associated with resistance to streptomycin 
(P=0.58), sulphamethoxazole (P=0.37), trimethoprim/sulphamethoxazole (P=0.20), 
kanamycin (P=0.96), chloramphenicol (P=0.82), ampicillin (P=0.29), ≥1 antimicrobial 
(P=0.53), or ≥2 antimicrobials (P=0.55). Vaccination status of either heifers or cows, 
respectively, for calf associated diarrhea was also not associated with resistance to 
streptomycin (P=0.61, P=0.61), sulphamethoxazole (P=0.32, P=0.32), 
trimethoprim/sulphamethoxazole (P=0.16, P=0.14), kanamycin (P=0.57, P=0.61), 
chloramphenicol (P=0.09, P=0.09), ampicillin (P=0.84, P= 0.79), ≥1 antimicrobial 
(P=0.17, P=0.16), or ≥2 antimicrobials (P=0.31, P=0.30) .  Ionophore use in the herd 
was not associated with resistance to streptomycin (P=0.77), sulphamethoxazole 
(P=0.40), tetracycline (P=0.56),trimethoprim/sulphamethoxazole (P=0.84), kanamycin 
(P=0.66), chloramphenicol (P=0.48), ampicillin (P=0.65), ≥1 antimicrobial (P=0.42), or 
≥2 antimicrobials (P=0.61). 
 
 There were, however, several statistically significant unconditional associations 
between AMU and resistance to tetracycline (Table 6.4), streptomycin (Table 6.5), 
sulphamethoxazole (Table 6.6), trimethoprim/sulphamethoxazole (Table 6.7), 
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kanamycin (Table 6.8), chloramphenicol (Table 6.9), ampicillin (Table 6.10), ≥1  
antimicrobial (Table 6.11), or ≥2 antimicrobials (Table 6.12). 
 
In the final multivariable model for tetracycline resistance, any sulbactam:ampicillin 
use in the herd increased the odds of resistance 2.8 (95% CI, 1.0 to 7.4; P=0.04) times 
and the use of gentamicin in calves increased the odds of resistance 3.5 times (95% CI, 
2.4 to 4.8; P<0.0001). 
 
Sulbactam:ampicillin (OR, 3.2; 95% CI, 1.3 to 7.8; P=0.01) and gentamicin (OR, 
5.5; 95% CI, 4.0 to 7.7; P<0.0001) use in calves were associated with an increased odds  
of streptomycin resistance in the final multivariable model. 
 
The use of sulbactam:ampicillin in cows (OR, 6.1; 95% CI, 1.1 to 35; P=0.04) and 
gentamicin use in calves (OR, 3.4; 95% CI, 1.6 to 2.2; P<0.0001) was associated with 
the occurrence of sulphamethoxazole resistance in the final multivariable model . 
 
The odds of trimethoprim/sulphamethoxazole resistance were 2.3 (95% CI, 1.1 to 
5.0; P=0.03) times higher in herds that used any sulbactam:ampicillin than herds that 
did not.  For every incremental increase in the proportion of calves treated in a herd, 
trimethoprim/sulphamethoxazole resistance also increased by 6.1 (95% CI, 1.5 to 25; 
P=0.01) times. 
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The final model of kanamycin resistance contained several risk factors. Kanamycin 
resistance was 3.9 (95% CI, 1.6 to 9.3; P=0.002) times more frequent in herds that used 
sulbactam:ampicillin in calves and 28.2 (95% CI, 4.8 to 166; P=0.0002) times more 
common in herds that used sulbactum:ampicillin in cows than herds that did not use 
sulbactum: ampicillin in calves or cows respectively. Kanamycin resistance was 6.2 
(95% CI, 4.1 to 9.3; P<0.0001) times more likely in herds that used genatmicin in 
calves than in herds that did not use gentamicin in calves. 
 
Only one risk factor was associated with chloramphenicol resistance.  Resistance to 
chloramphenicol was 2.7 (95% CI, 1.2 to 6.0; P=0.02) times more frequent on farms 
that used florfenicol in calves. 
 
Ampicillin resistance was 3.0 (95% CI, 1.5 to 6.1; P=0.002) times more likely in 
herds that used sulbactam:ampicillin in their calves and 5.3 (95% CI, 2.1 to13; 
P=0.0003) times more frequent in herds that used ceftiofur in calves than in herds that 
did not use either of these antimicrobials. The occurrence of ampicillin resistance was 
also 3.2 (95% CI, 2.3 to 4.5; P<0.0001) times more likely in herds that used 
enrofloxacin in calves than herds that did not use enrofloxacin in calves.  
 
Resistance to ≥1 antimicrobial was associated with sulbactam:ampicillin use and 
gentamicin use in calves.  Resistance to ≥1 antimicrobial was 3.1 (95% CI, 1.1 to 8.8; 
P=0.03) times more likely in herds that used any subactam:ampicillin and 3.2 (95% CI, 
2.2 to 4.5; P<0.0001) times more likely in herds that used any gentamicin in calves.   
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Resistance to ≥2 antimicrobials in herds with any sulbactam:ampicillin use was 3.2 
(95% CI, 1.2 to 8.6; P=0.02) times greater than herds that did not use 
sulbactam:ampicillin and 3.6 (95% CI, 2.5 to 5.0; P<0.0001) times greater in herds that 
used gentamicin in calves then herds that did not use gentamicin in calves. 
 
6.3.4. Post hoc power calculations 
 
The use of a specific antimicrobial was not commonly associated with resistance to 
that same antimicrobial or class of antimicrobials for some of the most prevalent 
resistances detected. For example, tetracycline resistance was not related to 
tetracycline/oxytetracycline use, sulphonamide use was not a risk factor for 
sulphamethoxazole or trimethoprim/ sulphamethoxazole resistance, and ampicillin 
resistance was not associated with penicillin use. The reason for this apparent 
discrepancy may be due to limited power in the analysis associated with restricted 
variation between herds in the frequency of both resistance and AMU for most of the 
above antimicrobials.   
 
Tetracyline was used for the sample size calculations. In this population there were 
57.5% (73/127) animals that were positive for tetracycline resistant isolates on farms 
with no tetracycline use. For farms with tetracycline use there were 61.7% (209/339) 
animals with tetracycline resistance. The difference in the percentage of animals with 
tetracycline resistance on farms with or without tetracycline use was only 1.1 
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(61.7/57.5) times.    To adjust the sample size for clustering rho (0.87) was calculated 
for calves across herds. 
 
Post hoc adjusted sample size calculations based on tetracycline and collecting 5 
samples per herd, indicated that at least 190 animals would be needed per group to 
detect an odds ratio of 1.5. The current study had only 127 animals in herds that did not 
use any tetracycline, therefore the study lacked sufficient power to detect a minumum 
risk of 1.5 times between the study groups. 
 
6.4. Discussion 
 
This is one of the first studies to investigate factors associated with the frequency of 
AMR in fecal generic E. coli isolated from beef calves in cow-calf herds. The use of 
two antimicrobials, sulbactam:ampicillin and gentamicin, were identified as risk factors 
for the occurrence of  resistance to several unrelated antimicrobials. These findings can 
potentially be explained by considering known mechanisms of AMR and the potential 
for co-selection of resistance genes. 
 
Bacteria have a variety of methods to facilitate the promotion and transfer of 
resistance genes. Resistance genes can encode resistance not just to a particular 
antimicrobial, but to an entire class of antimicrobials (McDermott et al., 2003; Catry et 
al., 2003). They can also encode resistance to compounds that are structurally diverse 
through cross-resistance (Catry et al., 2003), therefore resulting in resistance to a variety 
of antimicrobials. Additionally, mobile genetic elements can also often carry several 
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resistance genes which can confer resistance to multiple antimicrobials through the 
acquisition of a single mobile element (McDermott et al., 2003). As a result, the 
treatment with any one antimicrobial, where resistance to that antimicrobial is encoded 
on a bacteria carrying multiple resistance genes, could promote the selection of 
resistance to the other antimicrobials through gene linkage (Enne et al.; 2001, Catry et 
al.; 2003).  
 
Plasmids are one mechanism used by bacteria to carry and spread multiple resistance 
genes. The associations between the use of certain classes of antimicrobials and 
resistance to a different class could be explained by isolates carrying multi-resistant 
plasmids. These plasmids could then be selected for by any number of different 
antimicrobials and perpetuate resistance to a variety of unrelated antimicrobials.    
 
From the data available it is impossible to tell what type of plasmid or other genetic 
mechanism is being selected in this population of beef calves, but one possibility that 
could explain the associations between sulbactam:ampicillin use and resistance to 
unrelated antimicrobials is the presence of a blacmy2 plasmid. Winokur et al. (2001) 
demonstrated that Salmonella carrying blacmy2 plasmids also carry resistance genes for 
tetracycline, aminoglycosides, and sulphonamides. Winokur et al. (2001) went on to 
illustrate that the blacmy2 plasmid can transfer between Salmonella and E. coli, and that 
these E. coli also had high rates of co-resistance to the following antimicrobials: 
gentamicin, tobramycin, streptomycin, tetracycline, trimethoprim/sulphamethoxazole, 
and chloramphenicol.  
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Allen and Poppe (2002) also demonstrated that a non-conjugative blacmy2 plasmid 
with resistance for ampicillin, cefoxitin, ceftiofur, cephalothin, streptomycin, 
sulfisoxizole and tetracycline originally detected in Salmonella could be transferred to 
E. coli. In this same study chloramphenicol, florfenicol, kanamycin, and neomycin 
resistance were also transferred to E. coli from S. Ohio and S. typhimurium (Allen and 
Poppe; 2002).  
 
Considering these earlier findings, in the current study the presence of a AmpC-like 
Beta-lactamase blacmy2 plasmid carrying resistance to multiple antimicrobials could 
explain why the use of sulbactam:ampicillin is associated with resistance to tetracycline, 
sulphamethoxazole, streptomycin, trimethoprim/ sulphamethoxazole, ampicillin, and 
resistance to ≥2 antimicrobials in this population of beef calves.  
 
In addition to the use of sulbactam:ampicillin, resistance to kanamycin, 
streptomycin,  tetracycline, sulphamethoxazole, and to ≥2 antimicrobials was also 
associated with gentamicin use in calves. As described above, the blacmy2 plasmid can 
carry kanamycin and neomycin resistance which may confer cross resistance to 
gentamicin.  
 
The association between kanamycin and streptomycin resistance and gentamicin use 
are also likely the result of cross resistance between aminoglycosides. Selection of 
sulphamethoxazole and tetracycline resistance with gentamicin use could be the result 
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of a multiple resistant plasmid containing aminoglycoside resistance genes and 
resistance genes for each of these antimicrobials respectively.  
 
While the presence of a blacmy2 plasmid appears to correspond with the combination 
of antimicrobial uses found to be significant risk factors for a variety of resistances, it is 
not the only possible explanation for these findings.  Any multiple resistant plasmid or 
other multiple resistant genetic element could be carrying non blacmy2 beta-lactam 
resistance genes or aminoglycoside resistance genes along with other AMR genes. This 
means that the use of sulbactam:ampicillin or gentamicin could select for resistance to 
any number of different antimicrobials. Molecular analysis would be necessary to 
determine what mechanisms of resistance are involved for these particular isolates. 
Since the extended spectrum cephalosporins are important in the treatment of human 
disease if the presence of a blacmy2 plasmid was detected in this population it could have 
an impact on the spread of blacmy2 associated resistances in both people and animals.  
Continued monitoring would be needed to detect any potential rise in the AMR 
phenotypes associated with blacmy2.   
 
In addition to the associations mentioned above, the study also detected an 
association between florfenicol use and chloramphenicol resistance. The relationship 
between florfenicol use and chloramphenicol resistance has also been described in 
feedlot cattle. Berge et al. (2005) demonstrated that immediately after treatment with 
florfenicol, all treated cattle shed isolates positive not only for chloramphenicol 
resistance, but for other antimicrobials as well. 
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In another feedlot study, Read et al. (2002) reported an association between 
ampicillin resistance and florfenicol use. This association was not detected in the calves 
of the current study. The current study did note an association between ampicillin 
resistance and both ceftiofur and sulabactum:ampicillin use, but these associations were 
not detected in the Read et al. (2002) study. The discrepancies between these two 
projects may be explained by a variety of factors including: methodological differences 
between these studies (fecal pat vs. swab fecal), animal age (young beef calves vs. 
feedlot beef calves post weaning), sampling differences (point in time vs. repeated 
sampling), methodological differences in sensitivity testing (microbroth dilution vs. 
agar dilution), and the level at which the analysis was performed (herd vs. individual). 
Finally and potentially most importantly, differences in AMU between cow-calf herds 
and feedlots may also have affected the outcomes.  
 
While this investigation provides some of the first available data examining risk 
factors for beef calves, a recent study of commensal E. coli isolated from pre-weaned 
dairy calves on calf ranches and dairies described many factors associated with AMR 
(Berge et al, 2003; Berge et al, 2005). Farm type, animal source, calf age and individual 
treatments were important predictors of the odds of E. coli belonging to resistant 
clusters (Berge et al., 2006). Individual treatment with an injectable (yes/no) and/or oral 
(yes/no) AMU and calf age were investigated as risk factors, but were not associated 
with the occurrence of AMR in this group of beef calves (Gow et al., 2007).  
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One limitation of the current study was that detailed data on the type and dose of 
specific antimicrobials used were not gathered for individual animals, and therefore the 
relationship between specific antimicrobials and resistances could not be investigated at 
the individual animal level. A second limitation was that information on the frequency 
of herd AMU by producers was gathered retrospectively at the end of the calving 
season. Recall bias associated with retrospective data collection could result in potential 
over or under estimation of the number of times a particular antimicrobial was used in 
the herd or if it was used at all. Finally, because proportion of calves treated and AMU 
data were summarized for the entire period and not relative to the time of sample 
collection on that farm there is also misclassification bias.  The herd might have been 
considered exposed to a certain antimicrobial or antimicrobials, but that exposure may 
have been subsequent to the sample collection. This same problem with time sequence 
would apply when considering the proportion of calves ever treated since many of the 
treatments could have taken place after sample collection, thereby having no relevance 
to the AMR patterns detected.  Future studies could require individual treatment records 
that included the type of antimicrobial used, the date of use, and dose administered to 
more accurately determine individual animal exposure. However, historically detailed 
individual calf treatment records have been very difficult to obtain from most 
commercial cow-calf herds (Waldner, 2001)  
 
Study power to investigate AMU/AMR associations was also limited. In these 
instances the lack of variability between farms made it impossible to investigate the 
association between resistance and AMU. Most of the herds enrolled in the study 
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routinely used tetracyclines, sulphonamides and penicillins. Many of these herds also 
had calves with AMR to the same antimicrobial. The lack of variability between farms 
in AMU and AMR detection meant that in order to study these associations that the 
numbers of animals in herds without tetracycline use would need to be increased to see 
a significant association if one was present.    
 
This study does provide insight into whether treatment and vaccination practices 
influence AMR found in young calves in beef operations. This initial investigation 
suggests that because of the potential for linkage of unrelated resistance genes, we not 
only need to be aware of the risk of selecting for resistance to the antimicrobial being 
used, but we also need to consider that other resistance genes might be inadvertently 
selected and the potential impact that gene selection may have on both human and 
animals health.  
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Figure 6.1.  Minimum inhibitory concentration distribution for 1677 isolates from 466 calves tested for antimicrobial sensitivity using 
Sensititre 2002 NARMS CMV7CNCD plate configuration. Numbers are presented as a percentage of the total isolates (n=1677). 
MIC Percentiles
Median 75th <=0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
Ceftiofur 1677 0.25 0.25 3.2 72.5 20.1 1.8 0.1 0.8 0.9 0.6
Ceftriaxone 1677 <=0.25 0.25 95.8 1.8 0.2 0.2 0.8 0.8 0.5 0.1
Ciprofloxacin 1677 <=0.015 <=0.015 99.4 0.4 0.1 0.2
Amikacin 1677 2 2 0.5 29.6 65.1 4.4 0.4
Amoxicillin-Clavulanic Acid 1677 4 8 2.7 22.0 47.6 16.9 6.1 2.1 2.6
Gentamicin 1677 1 1 10.0 24.9 63.7 0.6 0.3 0.4 0.2
Kanamycin 1677 <=8 <=8 77.1 0.1 22.8
Nalidixic Acid 1677 4 4 0.8 30.6 65.9 2.5 0.1 0.2
Streptomycin 1677 <=32 64 62.6 20.9 16.5
Trimethoprim-Sulphamethoxazole 1677 <=0.12 0.5 52.6 14.7 12.0 0.9 19.8
Ampicillin 1677 4 >=64 2.8 34.9 33.3 2.8 0.9 0.2 25.1
Cefoxitin 1677 4 4 0.2 20.6 56.0 17.4 1.6 4.2
Cephalothin 1677 8 16 1.0 13.4 57.5 21.0 1.6 5.5
Chloramphenicol 1677 8 8 2.1 39.6 39.1 1.4 0.2 17.5
Sulphamethoxazole 1677 <=16 >512 52.9 0.1 0.1 0.4 46.6
Tetracycline 1677 8 >=64 49.1 1.1 0.2 1.6 48.0
IV
Distribution (%) of MICs
I
II
III
Antimicrobial n*
 
Note: Roman numerals I-III indicate the ranking of human importance, established by the Veterinary Drug Directorate, Health Canada. The unshaded fields 
indicate the range tested for each antimicrobial in the plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median.  
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Table 6.1. Antimicrobial resistance to any of the 7 antimicrobials to which resistance 
was most commonly detected, to any antimicrobial, or to ≥2 antimicrobials,were 
summarized as crude prevalence of AMR for calves (n=466) tested in all herds and as 
the median proportion of calves tested in each herd (IQR) (N=89) 
 
   
 Crude calf 
prevalence 
Herd prevalence 
Antimicrobial  Median % (IQR) 
Ampicillin 30.5% (142/466) 20.0% (0.0-50.0%) 
Chloramphenicol 22.5% (105/466) 0.0% (0.0-38.0%) 
Kanamycin 28.3% (132/466) 20.0% (0.0-50.0%) 
Sulphamethoxazole 57.9% (270/466) 57.0% (33.0-80.0%) 
Streptomycin 49.4% (230/466) 50.0% (20.0-80.0%) 
Tetracycline 60.5% (282/466) 60.0% (33.0-80.0%) 
Trimethoprim/sulphamethoxazole 24.5% (144/466) 0.0% (0.0-50.0%) 
Any AMR 62.7% (292/466) 67.0% (40.0-90.0%) 
AMR≥2 antimicrobial 60.1% (280/466) 60.0% (40.0-83.0%) 
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Table 6.2. The number (%) of herds using penicillins, sulphonamides, and 
tetracyclines/oxytetracycline (N=89) 
 
Antimicrobial and cow or 
calf usage 
# (%) of 
herds 
# (%) of 
herds 
 
Number of times used on the farm 
 with no use 
with use 
(Y/N) 1-3 times 4-10 times >10 times 
Cow penicillin long acting 65 (73.0) 24 (27.0) 14 (15.7) 6 (6.7) 4 (4.5) 
Cow penicillin short acting 79 (88.8) 10 (11.2) 4 (4.5) 3 (3.4) 3 (3.4) 
Cow penicillin any 59 (66.3) 30 (33.7) — — — 
       
Calf penicillin long acting 82 (92.1) 7 (7.9) 4 (4.5) — 3 (3.4) 
Calf penicillin short acting 78 (87.6) 11 (12.4) 4 (4.5) 5 (5.6) 2 (2.2) 
Calf penicillin any 74 (83.1) 15 (16.9) — — — 
      
Herd penicillin any 50 (56.2) 39 (43.8) — — — 
      
Cow oral sulphonamide 86 (96.6) 3 (3.4) 2 (2.2) 1 (1.1) — 
Cow injectable 
sulphonamide 81 (91.0) 8 (9.0) 7 (7.9) — 1     (1.1) 
Cow any sulphonamide 78 (87.6) 11 (12.4) — — — 
      
Calf oral sulphonamide 37 (41.6) 52 (58.4) 8 (9.0) 16 (18.0) 28 (31.5) 
Calf injectable 
sulphonamide 59 (66.3) 11 (12.4) 6 (6.7) 13 (14.6) 30 (33.7) 
Calf any sulphonamide 31 (34.8) 58 (65.2) — — — 
      
Herd any sulphonamide 29 (32.6) 60 (67.4) — — — 
      
Cow oxytetracycline LA 35 (39.3) 54 (60.7) 21 (23.6) 21 (23.6) 12 (13.5) 
Cow oxytetracycline LP 86 (96.6) 3 (3.4) 2 (2.2) 1 (1.1) — 
Cow tetracycline bolus 87 (97.8) 2 (2.2)  1 (1.1) 1 (1.1) — 
Cow any 
oxytetracycline/tetracycline 33 (37.1) 56 (62.9) — — — 
      
Calf oxytetracycline LA 54 (60.7) 35 (39.3) 9 (10.1) 15 (16.9) 11 (12.4) 
Calf oxytetracycline LP 88 (98.9) 1 (1.1) — 1 (1.1) — 
Calf tetracycline bolus 88 (98.9) — — 1 (1.1) 1 (1.1) 
Calf any 
oxytetracycline/tetracycline 53 (59.6) 36 (40.4) — — — 
      
Herd any 
oxytetracycline/tetracycline 26 (29.2) 63 (70.8) — — — 
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Table 6.3. The number (%) of herds using tilmicosin, florfenicol, sulbactam:ampicillin, 
ceftiofur, enrofloxacin, gentamycin, amprolium and cephalexin (N=89) 
 
Antimicrobial and cow or calf usage No Use Used (Y/N)
 
Number of times used on the 
farm 
   
1-3 
times 
4-10 
times 
>10 
times 
Cow tilmicosin 79 (88.8) 10 (11.2) 9 (10.1) 1 (1.1) — 
Cow  any tilmicosin 79 (88.8) 10 (11.2) — — — 
      
Calf tilmicosin 65 (73.0) 24 (27.0) 
12 
(13.5) 5 (5.6) 7 (7.9) 
Calf any tilmicosin 65 (73.00 24 (27.0) — — — 
      
Herd any tilmicosin 57 (64.0) 32 (36.0) — — — 
      
Cow florfenicol 83 (93.3) 6 (6.7) — — — 
Calf florfenicol 47 (52.8) 42 (47.2) — — — 
Herd any florfenicol 45 (50.6) 44 (49.4) — — — 
      
Cow any sulbactam:ampicillin 87 (97.8) 2 (2.2) — — — 
Calf sulbactam:ampicillin 81 (91.0) 8 (9.0) 4 (4.5) — 4 (4.5) 
Calf any sulbactam:ampicillin 81 (91.0) 8 (9.0) — — — 
Herd any sulbactam:ampicillin 79 (88.8) 10 (11.2) — — — 
      
Cow any ceftiofur 88 (98.9) 1 (1.1) — — — 
Calf ceftiofur 82 (92.1) 7 (7.9) 1 (1.1) 2 (2.2) 4 (4.5) 
Calf any ceftiofur 82 (92.1) 7 (7.9) — — — 
Herd any ceftiofur 82 (92.1) 7 (7.9) — — — 
       
Calf enrofloxacin calf 88 (98.9) 1 (1.1) — — 1 (1.1) 
Herd enrofloxacin 88 (98.9) 1 (1.1) — — — 
       
Cow any mastitis 87 (97.8) 2 (2.2) — — — 
      
Cow any gentamicin 88 (98.9) 1 (1.1) — — — 
Calf any gentamicin 87 (97.8) 2 (2.2) — — — 
Herd any gentamicin 86 (96.6) 3 (3.4) — — — 
      
Calf amprolium 87 (97.8) 2 (2.2)  1 (1.1) 1 (1.1) — 
Calf any amprolium 87 (97.8) 2 (2.2) — — — 
      
Calf any cephalexin 88 (98.9) 1 (1.1) — — — 
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Table 6.4. The statistically significant herd-adjusted unconditional association between 
AMU in the herd and the occurrence of resistance to tetracycline in E.coli isolates from 
beef calves (n=466, N=89) 
 
Risk factor Odds Ratio 95% Confidence Interval P-value 
   Lower Upper   
Sulbactam:ampicillin     
Sulbactam:ampicillin used 2.7 1.0 7.2 0.04 
No sulbactam:ampicillin used Reference category 
     
Ceftiofur     
Any ceftiofur used in calves 3.0 2.1 4.2 <0.0001 
No ceftiofur used in calves Reference category 
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Table 6.5. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to streptomcyin 
(n=466, N=89) 
 
Risk factor Odds Ratio 95% Confidence 
Interval 
P-value 
  Lower Upper  
Sulbactam:ampicillin     
Sulbactam:ampicillin used 3.0 1.3 7.0 0.01 
No sulbactam:ampicillin used Reference Category 
 
Sulbactam:ampicillin used in calves 3.0 1.3 7.4 0.01 
No sulbactam:ampicillin in calves Reference category 
     
     
Gentamicin     
Any gentomcyin used in calves 4.8 3.4 6.6 <.0001 
No gentamicin used in calves Reference category 
     
Cephalexin     
Any cephalexin used in calves 4.2 3.1 5.6 <.0001 
No cephalexin used in calves  Reference category 
  
Other  
Other antimicrobials used in calves 4.1 2.4 6.8 <.0001 
No other antimicrobials used in calves Reference category 
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Table 6.6. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to 
sulphamethoxazole (n=466, N=89) 
 
Risk factors Odds Ratio 
95% Confidence 
Interval P-value
  Lower Upper  
Sulbactam:ampicillin     
Sulbactam:ampicillin used 2.6 1.0 6.6 0.05 
No Sulbactam:ampicillin used Reference category 
     
Sulbactam:ampicillin used in cows 6.0 1.0 34.5 0.05 
No sulbactam:ampicillin in cows Reference category 
     
Gentamicin     
Any gentamicin used in calves 3.3 2.4 4.7 <.0001 
No gentamicin used in calves Reference category 
     
Other     
Any other antimicrobials used in calves 2.1 1.1 4.0 0.03 
No other antimicrobials used on calves Reference category 
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Table 6.7. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to 
trimethoprim/sulphamethoxazole (n=466, N=89) 
 
Risk Factors Odds Ratio 95% Confidence Interval P-value 
  Lower Upper   
Sulbactam:ampicillin     
Any sulbactam:ampicillin used 2.6 1.1 6.3 0.04
No sulbactam:ampicillin used Reference category 
         
Ceftiofur         
Any ceftiofur used on farm 3.5 1.1 11.6 0.04
No ceftiofur used on farm Reference category 
         
Any ceftiofur used in calves 3.5 1.1 11.6 0.04
No ceftiofur used in calves Reference category 
         
Proportion of calves treated         
Total proportion of calves treated 7.2 1.4 36.2 0.02
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Table 6.8. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to kanamycin 
(n=466, N=89) 
 
Risk Factor Odds 
Ratio 
95% Confidence 
Interval 
P-value 
  Lower Upper  
Sulbactam:ampicillin     
Any sulbactam:ampicillin used on the farm 4.4 1.9 10.0 <.001 
No sulbactam:ampicillin used on the farm Reference category 
     
Any sulbactam:ampicillin used in the cows 21.5 3.7 125.6 <.001 
No sulbactam:ampicillin used in the cows Reference category 
     
Any sulbactam:ampicillin used in the calves 3.4 1.4 8.0 0.01 
No sulbactam:ampicillin used in the calves Reference category 
     
Gentamicin     
Any gentamicin used on the farm 3.0 1.3 6.9 <.0001 
No gentamicin used on the farm Reference category 
     
Any gentamicin used in the calves 4.6 3.1 6.9 <.0001 
No gentamicin used in the calves Reference category 
     
Other     
Any other antimicrobials used in the calves 3.0 1.2 7.1 0.01 
No other antimicrobials used in the calves Reference category 
     
Proportion of calves treated     
Proportion of calves treated 7.1 1.6 32.5 0.01 
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Table 6.9. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to chloramphenicol 
(n=466, N=89) 
 
Risk factor Odds Ratio 95% Confidence Interval P-value 
  Lower Upper  
Florfenicol      
Any florphenical used on farm 2.7 1.2 6.2 0.02 
No florphenical used on farm Reference category 
       
Any florfenicol used in calves 2.7 1.2 6.0 0.02 
No florphenical used in calves Reference category 
      
Ceftiofur      
Any ceftiofur used on the farm 4.0 1.0 16.4 0.05 
No ceftiofur used on the farm Reference category 
      
Any ceftiofur used in calves 4.0 1.2 16.4 0.05 
No ceftiofur used in calves Reference category 
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Table 6.10. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to ampicillin (n=466, 
N=89) 
 
Risk Factor Odds Ratio 95% Confidence 
Interval 
P-value 
  Lower Upper  
Penicillin     
Any penicillin used on farm 2.0 1.1 3.7 0.04 
No penicillin used on farm Reference category 
     
Florfenicol     
Any florfenicol used on farm 1.9 1.0 3.6 0.04 
No florfenicol used on farm Reference category 
     
Any florfenicol used in calves 1.9 1.0 3.5 0.05 
No florfenicol used in calves Reference category 
     
Sulbactam:ampicillin     
Any sulbactam:ampicillin used on farm 2.5 1.1 6.0 0.04 
No sulbactam:ampicillin used on farm Reference category 
     
Any sulbactam:ampicillin used in calves 3.2 1.3 7.7 0.009 
No sulbactam:ampicillin used in calves Reference category 
     
     
Ceftiofur     
Any ceftiofur used on farm 5.6 1.9 16.5 0.002 
No ceftiofur used on farm Reference category 
     
Any ceftiofur used in cows 7.0 5.0 9.7 <.0001 
No ceftiofur used in cows Reference category 
     
Any ceftiofur used  in calves 5.6 1.9 16.5 0.002 
No ceftiofur used in calves Reference category 
     
Enrofloxacin      
Any enrofloxacin used in calves 2.3 1.7 3.2 <.0001 
No enrofloxacin used in calves Reference category 
     
Cephalexin     
Any cephalexin used in calves 1.5 1.1 2.1 0.01 
No cephalexin used in calves Reference category 
     
Gentamicin     
Any gentamicin used in calves 2.3 1.7 3.2 <.0001 
No gentamicin used in calves Reference category 
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Table 6.11. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to any antimicrobial 
(n=466, N=89) 
 
Risk factor Odds 
Ratio 
95% Confidence 
Interval 
P-value 
  Lower Upper  
Sulbactam:ampicillin      
Any sulbactam:ampicillin used on farm 3.0 1.1 8.5 0.04 
No sulbactam:ampicillin used on farm Reference category 
       
Gentamicin      
Any gentamicin used in calves 2.7 1.9 3.9 <0.0001 
No gentamicin used in calves Reference category 
      
Cephalexin      
Any cephalexin used in calves 2.4 1.8 3.3 <0.0001 
No cephalexin used in calves Reference category 
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Table 6.12. The statistically significant herd-adjusted unconditional association between 
AMU risk factors in the herd and the occurrence of calf resistance to two or more 
antimicrobials (n=466, N=89) 
 
Risk factor Odds 
Ratio 
95% Confidence 
Interval 
P-value 
  Lower Upper  
Sulbactam:ampicillin    
Any sulbactam:ampicillin used in cows 3.1 1.1 8.3 0.03 
No sulbactam:ampicillin used in cows Reference category 
     
Gentamicin     
Any gentamicin used in calves 3.1 2.2 4.3 <.0001 
No gentamicin used in calves Reference category 
     
Other     
Any other antimicrobials use in calves 2.6 1.5 4.3 0.0004 
No other antimicrobials antimicrobials 
in calves 
Reference category 
     
Cephalexin     
Any cephalexin used in calves 2.7 2.0 3.6 <.0001 
No cephalexin used in calves Reference category 
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CHAPTER 7 
MOLECULAR CHARACTERIZATION OF AMR IN FECAL GENERIC 
ESCHERICHIA COLI ISOLATES IN WESTERN CANADIAN COW-CALF HERDS: 
PART I ASSOCIATIONS BETWEEN PHENOTYPE AND GENOTYPE 
 
7.1. Introduction 
 
 There are many different genetic determinants of antimicrobial resistance (AMR) 
and each determinant may present a different distribution among bacterial populations 
(Lanz et al., 2003). Typically, AMR is reported based only on the expressed phenotype 
derived from susceptibility testing of the organism. However, resistance phenotypes 
alone do not always represent all of the underlying resistance genes. Alternatively, the 
presence or absence of a resistance gene does not imply that the particular strain is 
resistant or susceptible to an antimicrobial (Aarts et al., 2006). Evaluating both 
phenotype and genotype together provides a more complete understanding of the 
epidemiology of AMR. 
 
Bacteria are proficient at sharing genetic information necessary to survive in the 
presence of antimicrobials (McDermott et al. 2002). The ability to readily exchange 
genes increases the potential of the spread of AMR determinants from commensal 
organisms present in animals and people to veterinary or human pathogens (Salyers and 
Cuevas, 1997). Rapid transfer of resistance can happen within and between genera of 
bacteria (McDermott et al., 2002). Even the passage of an ingested resistant organism 
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through the intestinal tract can result in the transfer of resistant genes to resident 
microflora, which may subsequently be transmitted to pathogenic bacteria (McDermott 
et al. 2002).  
 
The speed of resistance development is affected by the bacteria involved, the 
selective pressure from AMU, and the availability and transferability of resistance genes 
(Schwartz et al., 2006). Loss of acquired resistance is influenced mainly by selective 
pressure, but also by the co-location of the resistance genes in multi-resistance gene 
clusters or integron structures (Schwartz et al., 2006). When resistance genes are 
organized in gene clusters or integrons, the loss of acquired resistance genes may not 
occur even in the absence of direct selective pressure (Schwartz et al., 2006).  
 
Molecular methods have helped determine the genetic basis for AMR and provide 
the means for understanding how resistance genes are acquired and transmitted among 
bacteria. These methods could also lead to novel approaches to limit AMR 
dissemination. The localization of AMR genes on plasmids or chromosomes suggest 
that genes conferring multiresistance can exist as complex configurations of physically 
linked elements (Carattoli, 2001). Many aspects of the development of AMR remain 
uncertain. It is known, however, that AMR is the result of numerous and complex 
interactions among antimicrobials, micro-organisms, and the surrounding environment 
(White and McDermott, 2001). These factors may vary between livestock species; 
therefore the investigation of resistance patterns within different livestock production 
 216 
systems is necessary to continue developing a clearer understanding of AMR 
epidemiology.  
 
While there is some information about AMR in swine (Dunlop et al., 1998, Rajic et 
al., 2006), dairy (Mackie et al., 1988) and feedlot cattle (Read et al., 2005) there are 
very little data for cow-calf herds. As a part of a larger study designed to look at calf 
health and productivity, AMR was examined for various age groups within cow-calf 
herds in western Canada. A subset of the E. coli isolates collected for susceptibility 
testing were selected for more intensive investigation including resistance gene testing. 
The objective of this study was to measure the associations between AMR phenotypes 
and resistance genes in 207 generic Escherichia coli isolates obtained from a study of 
77 cow-calf herds. 
 
7.2. Materials and methods 
 
7.2.1. General aspects of the study and sample collection 
 
Fecal samples were collected from 1407 individually identified animals on 148 
privately owned beef farms in Alberta and Saskatchewan (Figure 7.1) (Gow et al., 
2007a, Gow et al., 2007b). The farms were part of a larger survey for risk factors 
affecting calf health. Samples were collected from three study groups: (1) 480 calves 
and (2) 533 cows in the spring of 2002 and (3) 394 calves sampled in the fall of 2002. 
Where possible samples collected in the fall came from the same farms as samples 
collected in the spring. The spring samples were collected from accessible cows or 
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calves in the calving and nursery area. The fall samples were collected from calves prior 
to weaning and during fall processing. Fecal samples were obtained either directly from 
the rectum or from the ground immediately after defecation. A separate disposable 
glove and container were used for each animal sampled. Spring samples were collected 
from March to July and fall samples were collected between August and December. 
 
7.2.2. Laboratory methods 
 
7.2.2.1 Escherichia coli culture 
 
Fecal samples were sent on ice to a diagnostic laboratory (Prairie Diagnostic 
Services, Saskatoon, Saskatchewan) for culture. The samples were cultured onto 
MacConkey agar plates at 37◦C for 18 hours for isolation of E. coli. At least three 
individual lactose fermenting colonies from each sample were identified as E. coli using 
standard biochemical tests including indole, Triple Sugar Iron (TSI) slant, citrate and 
urea. If both dry and mucoid colonies were detected within a sample, then three isolates 
from each colony type were tested. Individual E. coli isolates were stored in 50% 
glycerol and Luria-Bertani (LB) broth at -80ºC until sensitivity testing was completed.  
 
7.2.2.2. Susceptibility testing methodology 
 
E. coli isolates were tested for susceptibility (Alberta Agriculture and Rural 
Development) using a microbroth dilution technique (Sensititre®, TREK Diagnostic 
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Systems Inc., Cleveland, Ohio) and the standard 2002 National Antimicrobial 
Resistance Monitoring System (NARMS) panel (CIPARS, 2006). 
 
Minimum inhibitory concentrations (MICs) were assessed for 16 antimicrobial 
agents (Figure 7.1). Breakpoints for susceptibility were used, as defined by the National 
Committee on Clinical Laboratory Standards (NCCLS) (NCCLS, 2000) (Figure 7.2). 
All isolates that fell into the intermediate susceptibility range were classified as 
susceptible. Amikacin results > 4µg/ml were labeled not interpretable because the 
breakpoint is 4 dilutions beyond the range of the panel. The breakpoint used for 
streptomycin was 64µg/ml (CIPARS, 2006). 
 
7.2.2.3. Methodology for detecting resistance genes 
 
7.2.2.3.1. Selection of samples for genotype testing 
 
Genetic testing was completed on 12.2% (134/1099) of all resistant isolates collected 
and 2.2% (73/3319) of all susceptible isolates (Figure 7.1). The isolates were divided 
into susceptible or resistant.  Since genetic determinants of AMR were of interest the 
majority of isolates (65%, 134/207) selected for this project were classified as resistant 
phenotypically.  From either the susceptible or resistant list, isolates were randomly 
selected ensuring that not ≥1isolate from the same animal was included; therefore, this 
subset of isolates represents 207 animals from 77 farms.  
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DNA hybridization and PCR were used to test for 24 resistance genes from 6 
antimicrobial families (Département de Pathologie et Microbiologie, Faculté de 
Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec). The 
antimicrobial family, the genetic marker along with the PCR primer sequence, and 
source of DNA are summarized in Table 7.1. 
 
7.2.2.3.2. Bacterial strains and growth conditions 
 
 The 28 strains used as positive controls and templates for DNA amplification were 
obtained from different laboratories (Maynard et al., 2003, Maynard et al., 2004). These 
strains were stored at -80°C in tryptic soy broth medium containing 10% glycerol 
(vol/vol) and were propagated on Luria-Bertani broth or agar containing one of the 
following antimicrobial agents at the appropriate concentrations: ampicillin (50 µg/ml), 
gentamicin (30 µg/ml), kanamycin (50 µg/ml), tetracycline (10 µg/ml), chloramphenicol 
(10 µg/ml), trimethoprim (10 µg/ml), and sulfamethazine (200 µg/ml).  
 
7.2.2.3.3. Detection of antimicrobial resistance genes 
 
Oligonucleotide primers for PCR amplification of AMR gene sequences are 
described in Maynard et al. (2003, 2004). Template DNA was prepared from bacterial 
cultures by the boiling method of Daigle et al. (1994). PCR reactions (total volume, 50 
µl) contained 1x PCR buffer (10 mM Tris-HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl2 
(Amersham Pharmacia Biotech Inc., Piscataway, N.J.), 200 µM each of the four 
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deoxynucleoside triphosphates, 1 U of Taq DNA polymerase (Amersham Pharmacia 
Biotech Inc.), 25 pmol of each primer and 5 µL of template. DNA amplification was 
carried out in a GeneAmp PCR system 9700 (Perkin-Elmer, Foster City, Calif.) with the 
following conditions: 5 min at 94°C, followed by 30 cycles of 94°C for 30 s, 50°C for 
30 s, and 72°C for 1.5 min. An aliquot (3 µL) of each PCR reaction was resolved in a 
1.2% agarose gel to confirm product size and purity. PCR products were labeled with [
-32P] dCTP by using Ready-To-Go DNA Labeling Beads (Amersham Pharmacia 
Biotech Inc.). Colony hybridizations were performed as described previously (Harel et 
al., 1991).  
 
7.2.3. Statistical analysis 
 
Descriptive analyses were completed using commercially available software (SPSS 
11.0 for Windows, SPSS Inc., Chicago, Illinois). Initially all isolates were coded as to 
the presence or absence of each phenotype and resistance gene considered in the 
analysis (Table 7.2). Multiple AMR was defined as phenotypic resistance to ≥2 
antimicrobials. Isolates were further categorized for the presence or absence of at least 
one gene for each of the six families of antimicrobials considered. For example, if an 
isolate contained any individual tet resistance gene or any combination of tet resistance 
genes it would have been classified as being positive for the individual genes 
respectively, but it also would have been classified as being tetracycline gene positive.  
 
Antimicrobial resistance patterns consistent with the Canadian Integrated Program 
for Antimicrobial Resistance Surveillance (CIPARS, 2006) program were investigated 
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for associations with resistance genes. The specific patterns included; A3C (ampicillin, 
cefoxitin, ceftiofur and cephalothin), ACSSuT (ampicillin, chloramphenicol, 
streptomycin, sulphonamides, tetracycline), AKSSuT (ampicillin, kanmycin, 
streptomycin, sulphonamides, tetracycline), and ACKSSuT (ampicillin, 
chloramphenicol, kanamycin, streptomycin, sulphonamides, tetracycline). These 
patterns are often used in reference to Salmonella spp. (Ihnot et al., 1998; Bolton et al., 
1999; Casin et al., 1999; Schmieger and Schicklmaier, 1999) and though the mechanism 
of resistance carriage for these patterns may not be the same in E. coli, they do permit 
the reporting of common resistance patterns detected in E. coli using a standard 
nomenclature.  
 
All four of the above patterns as well as individual antimicrobial phenotypes that 
contribute to the A3C, ACSSuT, AKSSuT, or ACKSSuT patterns were explored for any 
association with the resistance genes investigated (Table 7.2). If the proportion of 
isolates carrying a particular resistance gene was less than 1.5%, the gene was excluded 
from the analysis. Unconditional associations were analyzed using generalized 
estimating equations (GEE) to account for clustering within herd (SAS v.8.2 for 
Windows (PROC GENMOD); SAS Institute, Cary, North Carolina, USA). Model 
specifications included a binomial distribution, logit link function, repeated statement 
with subject equal to herd, and an exchangeable correlation structure.  
 
Statistically significant associations were reported as odds ratios (OR) with 95% 
confidence limits. Odds ratios >1 indicate an increasing occurrence of the genotype 
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being studied with the phenotype being measured (a positive association) while those 
<1 indicate a decreasing occurrence of the genotype being studied with increases in the 
measured phenotype (a negative association). Multiple comparisons were accounted for 
using a Bonferroni correction to provide a conservative estimate for the level of 
statistical significance (Dohoo et al., 2003) An association was significant if P<0.004 
after correction for 14 comparisons (P < 0.05/k, k = number of comparisons) (Dohoo et 
al., 2003).  
 
The relationship between the number of antimicrobials to which an isolate was 
resistant and the number of resistance genes detected was analyzed using GEE to 
account for clustering within herd. Model specifications included a Poisson distribution, 
log link function, repeated statement with subject equal to herd, and an exchangeable 
correlation structure. Variables in the unconditional analysis were considered 
statistically significant at P<0.05.  
 
7.3. Results 
 
7.3.1. Description of the samples examined in the phenotype and genotype 
comparison study 
 
The subset of 207 fecal generic E. coli isolates represented 6.4% (107/1677) of all 
isolates recovered from the calves tested in the spring of 2002, 3.2% (50/1555) of 
isolates from the cows tested in the spring of 2002, and 4.2% (50/1186) of isolates from 
the calves tested in the fall of 2002.  
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The median age of the calves (n=107 from 58 herds) at the time of collection in the 
spring of 2002 was 6 days (range, 1 to 120 days). The age of the dams for these calves 
ranged from 2 to13 years (median, 5 years). Fifty-seven percent of the calves were 
male, and healthy calves accounted for 91.2% (98/107) of the population sampled.  
 
Samples were also examined in the spring of 2002 from healthy cows (n=50) in 18 
herds that ranged in age from 2 to 10 years (median, 5 years).  
 
The remaining isolates were from calves (n=50 from 23 herds) sampled in the fall of 
2002 for which the median age was 204 days (range, 118 to 301 days). Median dam age 
for these calves was 6 years (range, 2 to 14 years). Fifty-six percent of these calves were 
male and all calves were classified as healthy.  
 
7.3.2. Phenotypic antimicrobial susceptibility in the selected isolates 
 
Resistance to at least one antimicrobial was detected in 64.7% of the 207 selected 
isolates (Figure 7.2). The most common antimicrobials to which resistance was detected 
were tetracycline, sulphamethoxazole, and streptomycin (Table 7.3). No isolates were 
resistant to amikacin, ceftriaxone, ciprofloxacin, or nalidixic acid.  
 
Twenty-nine different multiple resistance patterns were detected including the A3C, 
ACSSuT, AKSSuT, and ACKSSuT resistance patterns (Table 7.3). The most common 
pattern (17.9%, 37/207) contained a grouping of streptomycin, sulphamethoxazole, and 
 224 
tetracycline. The next most common AMR pattern was sulphamethoxazole and 
tetracycline (10.6%, 22/207). The median number of antimicrobials observed per 
pattern was 3 and the maximum was 11.  
 
7.3.3. Resistance genes detected in the selected isolates 
 
Resistance genes were detected in 64.3% of all isolates tested, in 93.3 % (125/134) 
of resistant isolates, and in11.0 % (8/73) of susceptible isolates. Those most commonly 
detected included a gene for sulphonamide resistance, sulII, a gene for tetracycline 
resistance, tetB, and a gene for streptomycin resistance, ant(3”)-Ia (aadA1) (Table 7.3). 
The resistance genes blaSHV , ant(2”)-Ia, aac(3)-IIa, aph(3”)-IIa, and dhfrXV were not 
detected in any isolates.  
 
Sixteen different multiple resistance gene patterns (≥2 resistance genes) were 
identified. The median number of resistance genes in the observed patterns was 2 with a 
maximum of 7. The most common pattern detected was sulII and tetB together (n=40, 
19.3%). The next most common pattern (6 isolates) contained a grouping of blaTEM, 
aph(3’)-Ia, tetB, and sulII (2.9%).  
 
Several different combinations of resistance genes comprising the ACSSuT, 
AKSSuT, or ACKSSuT patterns were identified. For example, 3 different resistance 
gene patterns in 6 isolates were identified for ACSSuT. AKSSuT isolates had 2 distinct 
patterns in 6 isolates. ACKSSuT isolates had 4 patterns in 7 isolates. Three of 5 isolates 
with the ACSSuT gene pattern had blaTEM, catI, ant(3")-Ia (aadA1), tetA, dhfrI, and 
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sulI. Five of 6 isolates with the AKSSuT pattern had the blaTEM, aph(3')-Ia, ant(3")-Ia 
(aadA1), sulI, tetB, and dhfrI. The resistance genes detected in 4 of 7 isolates with the 
ACKSSuT pattern were blaTEM, catI,  aph(3')-Ia, ant(3")-Ia (aadA1), tetB, dhfrI, and 
sulI. 
 
7.3.4. Phenotypic antimicrobial susceptibility and associated resistance genes 
 
Genotypes did not always correspond with the phenotypic expression within 
individual isolates. Eight isolates carried resistance genes, but had no evidence of 
phenotypic resistance (Table 7.4). Alternatively there were also 8 isolates that were 
classified as resistant based on MICs with no resistance genes identified (Table 7.4). 
Genotypes did not correspond for 25.0% (2/8) of the ACSSuT, for 58.3% (7/12) of the 
AKSSuT, and for 33.3% (3/9) of the ACKSSuT phenotypes (Table7.5).  
 
There were 122 isolates classified as resistant to tetracycline based on the MICs, of 
these isolates 15 (12%) were tetA, 83 (68%) were tetB, 4 (3.3%) were tetC, 3 (2.5%) 
were tetA and tetB together, 7 (5.7%) were tetA and tetC together, and 1 (0.8%) isolate 
was tetA, B, and C positive. There were also 9 (7.4%) isolates that were classified as 
resistant to tetracycline that did not have a corresponding tetracycline resistance gene.  
 
Of the 114 sulphamethoxazole resistant isolates, 9 (7.9%) were sulI, 76 (67%) were 
sulII, 20 (18%) were sulI and sulII together, and 9 (7.9%) were positive for 
sulphamethoxazole phenotypically but not genotypically. For trimethoprim-
sulphamethoxazole resistant isolates (n=33), 27 (81.8%) were dhfrI, 1 (3.0%) was 
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dhfrVII, 2 (6.1%) were dhfrXII, 1 (3.0%) was dhfrXII and dhfrXIII together, and 2 
(6.1%) were dhfrIb and dfhrV together. Sixty-seven (58.8%) of the 114 
sulphamethoxazole resistant isolates were positive for at least 1 sulphonamide gene, 5 
(4.4%) were positive for at least 1 sulphonamide gene and 1 trimethoprim gene, and 33 
(28.9%) were positive for at least 1 sulphonamide gene, 1 trimethoprim gene, and were 
also phenotypically positive for trimethoprim-sulphamethoxazole.  
 
The majority of the chloramphenicol resistant isolates (n=30) were catI (n=21, 
70.0%) positive, 5 (16.7%) were floR positive, and 4 (13.3%) had no corresponding 
chloramphenicol resistance gene. 
 
The gentamicin resistant isolates (n=2) had resistance genes aac(3)-IV and ant(3’)-
Ia(aada1) together (n=1) and ant(3’)-Ia(aadA1) and aph(3’)-Ia together (n=1). The 31 
kanamycin resistant isolates had 14 (45.2%) with the aph(3’)-Ia resistance gene, 1 
(3.2%) with ant(3’)-Ia(aadA1), 15 (48.3%) with ant(3’)-Ia(aadA1) and aph(3’)-Ia 
together, and 1 (3.2%) with no associated resistance gene. Almost half of the 
streptomycin resistant isolates (n=41, 47.7%) did not have an associated streptomycin 
resistance gene, 14 (16.3%) had aph(3’)-Ia resistance gene, 9 (10.5%) had had ant(3’)-
Ia(aadA1), 20 (23.3%) had ant(3’)-Ia(aadA1) and aph(3’)-Ia together, 1 (1.1%) isolate 
had ant(3’)-Ia(aadA1) and ant(3’)-Ia(aadA6), and 1 (1.1%) had aac(3)-IV and ant(3’)-
Ia(aadA1) together. 
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7.3.5. Unconditional association between phenotypic antimicrobial susceptibility 
and identification of resistance genes 
 
Phenotypic resistance to a number of antimicrobials was associated with the presence 
of the aminoglycoside genes ant(3”)-Ia (aadA1) and aph(3’)-Ia (Table 7.6). Positive 
associations were detected between phenotypes streptomycin and kanamycin and their 
respective resistance genes, ant(3”)-Ia (aadA1)  and aph(3’)-Ia . Isolates with 
phenotypic ACKSSuT resistance were more likely to contain both the aadA1 and 
aph(3’)-Ia genes than isolates without this pattern (Table 7.6). 
 
Fewer unconditional associations were identified for the tetracycline genes than for 
the aminoglycoside genes (Table 7.7). Tetracycline resistance was not associated with 
the presence of the tetA gene, but was strongly associated with tetB. 
 
Chloramphenicol resistant isolates were 63 and 18 times more likely to be either catI 
gene or floR gene positive, respectively, than chloramphenicol susceptible isolates 
(Table 7.8). Several of the extended spectrum cephalosporins were associated with floR, 
but not with catI. Significant associations between other phenotypic resistance patterns 
of interest and these genes were also detected.  
 
Sulphamethoxazole resistance was associated with both sulI and sulII, but the 
association was much stronger for sulII (Table 7.9). Tetracycline resistance was 
strongly associated with both sulphonamide resistance genes. ACSSuT phenotype 
pattern was associated with sulI but not sulII. 
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Trimethoprim-sulphamethoxazole resistant isolates were associated with dhfrI, but 
not with dhfrXII (Table 7.10). Chloramphenicol resistant isolates were also associated 
with dhfrI, but not with dhfrXII. Associations with phenotypic patterns including 
ACSSuT, ACKSSuT, and A3C were also detected 
 
Ampicillin resistant isolates were 86 times more likely to be positive for blaTEM than 
ampicillin susceptible isolates (Table 7.11). ACSSuT and ACKSSuT resistant isolates 
were also more likely to be positive for blaTEM than isolates susceptible to the ACSSuT 
and ACKSSuT patterns of antimicrobials. 
 
Table 7.12 and Figure 7.3 summarize the associations between resistant phenotypes 
and the 6 antimicrobial families representing the 24 resistance genes investigated. The 
aminogylcoside gene ant(3”)-Ia (aadA1) and the trimethoprim gene dhfrI were 
associated with every antimicrobial investigated.  Resistance to ampicillin, kanamycin, 
streptomycin, sulphamethoxazole, and the ACSSuT pattern were associated with all 6 
families of resistance genes investigated. Tetracycline and trimethoprim resistance were 
associated with 5 of the families while chloramphenicol and the ACKSSuT pattern were 
associated with 4 of the 6 families. 
 
Isolates resistant to ≥1 antimicrobial were 74.3 (95% CI, 15.8-349, P<0.0001) times 
more likely to be positive for ≥1 of the resistance genes investigated than were 
susceptible isolates. Additionally, isolates resistant to ≥2 antimicrobials were 140 (95% 
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CI, 48.5-407, P<0.0001) times more likely to be positive for ≥2 resistance genes than 
isolates that were not resistant ≥2 antimicrobials. There was a increase of 1.2 (95% CI, 
1.2-1.3, P<0.0001) resistance genes identified for every additional antimicrobial to 
which an isolate was resistant. 
 
7.4. Discussion 
 
The objective of this study was to measure the associations between AMR 
phenotypes and resistance genes in fecal generic E. coli isolates obtained from a study 
of cow-calf herds. To the best of our knowledge this study provides some of the first 
available information describing AMR both phenotypically and genotypically in cow-
calf isolates.  Additionally, it took a novel approach to investigating statistical 
associations between AMR phenotype and genotype. These data demonstrate extensive 
associations between various phenotypes and unrelated resistance genes. They illustrate 
the complex nature of AMR and would be useful in targeting future research projects. 
 
Phenotypic resistance, as measured by microbroth dilution, was associated with the 
presence of at least one of the associated resistance genes for that antimicrobial. The 
relationship between isolates resistant to specific antimicrobials and related resistance 
genes was not unexpected, since a strong correlation between the phenotypic resistance 
pattern of a strain and the presence of resistance genes has previously been observed 
(van de Klundert et al., 1984, Shaw et al., 1991). In situations where a very strong 
association was detected between certain phenotypes and genotypes, the phenotypic 
expression of resistance to a particular antimicrobial may be a good indicator of the 
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underlying resistance gene for that antimicrobial especially in cases where the majority 
of resistance to those antimicrobials is caused by a single gene. Examples of such 
isolates from this population would include kanamycin and aph(3’)-Ia, chloramphenicol 
and catI, sulphamethoxazole and sulII,  trimethoprim-sulphamethoxazole and dhfrI, and  
ampicillin and blaTEM. 
 
On the other hand, there was a lack of association between tetracycline resistance 
and the tetA resistance gene. This lack of association is probably because tetA is less 
likely to be found in isolates positive for tetB and most of the tetracycline resistant 
isolates were tetB positive. Jones et al. (1992) suggested an incompatibility of plasmids 
carrying the tetracycline resistance determinants could explain the existence of the 
negative associations between tetA and tetB. There was also no association between 
trimethoprim-sulphamethoxazole and the dhfrXII resistance gene. Trimethoprim 
dihydrofolate reductase (dhfr) belongs to the dhfr protein family that includes the 
chromosomally encoded trimethoprim sensitive and resistant dhfr genes of bacteria 
(Hall and Collis, 1998). It has been found that dhfrXII and dhfrXIII are closely related 
to each other but not to other members of the subgroup (Hall and Collis, 1998). Since 
the majority of the trimethoprim-sulphamethoxazole isolates were positive to dhfrI, the 
lack of relatedness between dhfrI and dhfrXII may explain why dhfrXII was not 
associated with trimethoprim-sulphamethoxazole resistance. 
 
The associations between cefoxitin, ceftiofur, cephalothin and A3C, and the floR 
resistance gene may indicate some degree of gene linkage. If linkage is present and 
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there is selection for florfenicol resistance, there may also be selection for resistance to 
these other antimicrobials or at least for the presence of these resistance genes. Because 
extended spectrum cephalosporins are important in human medicine, anything 
perpetuating the presence of these resistance genes is undesirable. Florfenicol resistance 
is typically located on a large transferable plasmid (Meuner et al., 2003), but it can also 
reside on chromosomes or non-conjugative plasmids (Singer et al., 2000). If floR is 
being carried on a conjugative plasmid in these cow-calf isolates, the selection of the 
floR gene may ultimately result in co-selection of other resistance genes in the presence 
of florfenicol since plasmids often carry multiple resistance genes (Cloeckaert et al., 
2000). Thus, if resistance genes for extended-spectrum cephalosporins (ESCs) are 
linked to floR on such plasmids, ESC-resistance may be selected for by florfenicol use 
in cattle, even in the absence of ceftiofur use. This observation may therefore have 
important public health implications. Such plasmids have been found in porcine E. coli 
in Ontario (Travis et al., 2006). The MIC panel used in this study did not include 
florfenicol. Because florfenicol is approved for use in cattle in Canada and the presence 
of the floR gene was detected, the frequency of florfenicol resistance requires further 
investigation. 
 
For every additional antimicrobial to which phenotypic resistance was observed, 
another 1.2 resistance genes were detected. Phenotypic and genotypic characterization 
of the isolates demonstrated comparable patterns. Additionally, the most common drugs 
to which isolates demonstrated resistance were consistent with the most common 
resistance genes detected. Tetracycline, sulphamethoxazole, and streptomycin were the 
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top three drugs identified as being the most common for resistance measured either 
phenotypically or genotypically. The most commonly detected combinations of 
resistance phenotypes and resistance genes were also for sulphamethoxazole and 
tetracycline.   
 
In many instances the phenotype or the genotype alone would not accurately predict 
the other.  Molecular mechanisms underlying AMR are numerous and complex and the 
presence or absence of a specific gene corresponding to a particular phenotype does not 
necessarily imply that the particular strain is resistant or susceptible (Arrts, et al., 2006). 
DNA testing does not indicate whether an isolate is susceptible or resistant, but 
indicates if the gene is present or absent (Arrts et al 2006). Resistant phenotypes can 
emerge from many different genetic determinants and each determinant may present 
unique epidemiological features (Lanz et al., 2003). The divergence between genotype 
and phenotype could simply be explained by not testing for all possible resistance genes 
or by genes not being turned on within certain isolates. Examples of genes that were not 
tested for and that could account for the discrepancy between genotype and phenotype 
include strA/strB, sulIII, clmA, and blacmy2. One other explanation for the difference in 
phenotypic resistance and the presence of resistance genes could be that the breakpoint 
may be misplaced resulting in misclassification of isolates as susceptible and resistance. 
Finally, some resistance phenotypes may be caused by point mutations rather than gene 
acquisition; therefore, no associated resistance gene would be expected. The genotypic 
and phenotypic polymorphism in this study was also described by Blake et al. (2003).  
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This study did not investigate the presence of class I integrons. Although an integron 
probe was not included, the ant(3”)-1 (aadA1) probe was used. The ant(3”)-Ia (aadA1) 
gene along with several different dhfr genes and the sulI gene have been located as gene 
cassettes within integrons (Lévesque et al., 1995, Fluit and Shmitz, 1999, Carattoli, 
2001, Gestal et al., 2005). Despite not testing for integrons specifically, the strong 
associations along with the various patterns containing two or more of these genes may 
indicate the presence of integrons in this sample population. 
 
A description of the extended spectrum beta-lactamases would also have been useful 
in this population. Read et al. (2005) found that antimicrobials commonly used in 
feedlot practices in western Canada could contribute to the presence of the blaCMY-2 
gene in generic E. coli isolated from these animals. The presences of these genes are 
particularly important as this class of antimicrobials is important in human medicine.  
 
The A3C, ACSSuT, AKSSuT, and ACKSSuT resistance patterns were investigated 
for consistency with the reporting structure of the Canadian Integrated Program for 
Antimicrobial Resistance Surveillance or CIPARS (CIPARS, 2006). The spread of 
multi-drug resistant Salmonella Typhimurium DT104 (definitive type 104) by 
chromosomal integration of the genes encoding for resistance to ampicillin, 
chloramphenicol, streptomycin, sulphonamides, and tetracyclines (ACSSuT type) has 
been reported (Ihnot et al., 1998, Bolton et al., 1999, Casin et al., 1999, Schmieger and 
Schicklmaier, 1999). This is important because there is the ability for phylogenetically 
diverse gram negative clinical isolates to demonstrate similar patterns of resistance 
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(Rowe-Magnus, 2002). Also, since there is the ability for horizontal transfer of genetic 
material within and between microbial genera (Weldhagen, 2004) identifying analogous 
patterns to those of S. Typhimurium in commensal E. coli maybe relevant. Poppe et al. 
(2005) demonstrated the ability of resistance transfer between E. coli and Salmonella; 
therefore, the transfer of resistance from generic E. coli to zoonotic enteropathogens or 
vice versa is a concern. The relationship between the phenotype patterns and the 
resistance genes that make up these patterns indicate that there probably is an 
underlying molecular mechanism, such as plasmids or integrons that would explain the 
numerous associations between a phenotype and non-related resistance genes. To 
determine whether it is the same mechanism as found in Salmonella would require 
further molecular work.  
 
For the phenotypes and resistance genes investigated the study did demonstrate that a 
phenotype does not necessarily reflect the underlying genotype and that a resistance 
gene does not always have an expressed phenotype. The associations between 
phenotype and underlying resistance genes were numerous and complex illustrating the 
likelihood of molecular linkage of resistance genes in this population. This is important 
since often only phenotype is reported.  This information alone does not always provide 
a complete picture of what is happening at the molecular level.  By assessing phenotype 
and genotype together researchers may examine if MIC breakpoints are appropriate, if 
there are emerging novel resistance genes responsible for a phenotype, if unrelated and 
un-expressed genes may impact future AMR emergence and if the current theories on 
prudent use are appropriate with the apparent extensive co-selection.  
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Both methods of characterization help to improve our understanding of the 
epidemiology of AMR. Assessment of AMR at the genetic level is an important tool in 
the understanding and the control of AMR (Lanz et al., 2003). It is apparent that the 
relationship between phenotypic resistance and the presence of resistance genes is 
extremely complicated. The extensive number of relationships between individual 
resistances or phenotypic resistance patterns and individual resistance genes or families 
of resistance genes suggests that there could be extensive linkage, and that there is 
probably co-selection when one type of resistance is being perpetuated. The type of 
linkages may be secondary to the recognition that AMR selection is not an independent 
process due to the complex nature of the associations between individual antimicrobials 
and resistance genes. 
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Figure 7.1. Schematic of number of samples, number of isolates and number of farms for each age group of animals investigated 
 
  
Figure 7.2.  Minimum inhibitory concentration distribution for 207 isolates tested for antimicrobial susceptibility using Sensititre 2002 
NARMS CMV7CNCD plate configuration. Numbers are presented as a percentage of the total isolates (n=207) 
 
Roman numerals I-IV indicate the ranking of human importance, Veterinary drug directorate, Health Canada. The un-shaded fields indicate the range tested for 
each antimicrobial in the 2002 plate configuration. Vertical double bars indicate the breakpoints used for categorization into susceptible and resistant. Numbers in 
bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater than that range of dilutions. 
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Figure 7.3.  The complex nature of AMR phenotypes and families of resistance genes 
 
  
243
Table 7.1. Antimicrobial family, genetic marker, primer sequence, GenBank accession number and DNA source for resistance genes 
tested 
 
 
PCR primer sequence (5'-3') 
                        
Antimicrobial 
family 
Genetic marker 
Forward Reverse 
Amplicon 
size (bp) 
GenBank 
accession no. 
Source of 
DNA  
 
Beta-lactams blaTEM GAGTATTCAACATTTTCGT ACCAATGCTTAATCAGTGA 857 AF309824 R. C. Levesque 
 blaSHV TCGCCTGTGTATTATCTCCC CGCAGATAAATCACCACAATG 768 AF148850 R. C. Levesque 
Aminoglycosides aac(3)-IIa (aacC2) CGGAAGGCAATAACGGAG TCGAACAGGTAGCACTGAG 740 X54723 D. Sandvang 
 aac(3)-IV GTGTGCTGCTGGTCCACAGC AGTTGACCCAGGGCTGTCGC 627 X01385 J. Harel 
 aph(3')-Ia (aphA1) ATGGGCTCGCGATAATGTC CTCACCGAGGCAGTTCCAT 600 M18329 J. Harel 
 aph(3')-IIa (aphA2) GAACAAGATGGATTGCACGC GCTCTTCAGCAATATCACGG 680 V00618 J. Harel 
 ant(3”)-Ia(aadAI) CATCATGAGGGAAGCGGTG GACTACCTTGGTGATCTCG 786 DQ166553.1 J.Harel 
 ant(3”)-If (aadA6) GAGTAACGCAGTACCCGC CACTGGCATGGCACTAAGC 795 AY444814.1 J. Harel 
Tetracycline tet(A) GTGAAACCCAACATACCCC GAAGGCAAGCAGGATGTAG 888 X00006 J. Harel 
 tet(B) CCTTATCATGCCAGTCTTGC ACTGCCGTTTTTTCGCC 774 J01830 J. Harel 
 tet(C) ACTTGGAGCCACTATCGAC CTACAATCCATGCCAACCC 881 J01749 J. Harel 
Phenicols catI AGTTGCTCAATGTACCTATAA
CC 
TTGTAATTCATTAAGCATTCTG
CC 
547 M62822 J. Harel 
 floR CGCCGTCATTCCTCACCTTC GATCACGGGCCACGCTGTGTC 215 AF252855 D. G. White 
Trimethoprim dhfrI AAGAATGGAGTTATCGGGAA
TG 
GGGTAAAAACTGGCCTAAAAT
TG 
391 X00926 J. Harel 
 dhfr1b AGTATCATTGATAGCTGCG GTAGTGCGCGAAGCGAAC 517 DQ388123.1 J. Harel 
 dhfrV CTGCAAAAGCGAAAAACGG AGCAATAGTTAATGTTTGAGC
TAAAG 
432 X12868 O. Sköld 
 dhfrVII GGTAATGGCCCTGATATCCC TGTAGATTTGACCGCCACC 265 X58425 O. Sköld 
 dhfrIX TCTAAACATGATTGTCGCTGT
C 
TTGTTTTCAGTAATGGTCGGG 462 X57730 C. Wallen 
 dhfrXII GAACTCGGAATCAGTACGC ACGCGCATAAACGGAGTG 483 DQ157751.1 J. Harel 
 dhfrXIII CAGGTGAGCAGAAGATTTTT CCTCAAAGGTTTGATGTACC 294 Z50802 P. V. Adrian 
 dhfrXV GGGAACAATTACTCTTC GTCTTCAGATGATTTAGC 186 Z83311D P. V. Adrian 
Sulfonamides sulI TTCGGCATTCTGAATCTCAC ATGATCTAACCCTCGGTCTC 822 X12869 R. C. Levesque 
 sulII CGGCATCGTCAACATAACC GTGTGCGGATGAAGTCAG 722 M36657 J. Harel 
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Table 7.2. Investigation into the association between resistance phenotype and genotype 
included the following individual and groups of antimicrobials 
 
 
Response variables  
 
Risk factors for phenotype 
 
blaTEM  Ampicillin  
 
aph(3’)-Ia  
 
 
Cefoxitin  
tetA 
 
Ceftiofur  
tetB  
 
tetC 
Cephalothin 
 
Chloramphenicol 
 
catI  
 
floR 
Kanamycin 
 
Streptomycin  
 
dhfrI  
 
dhfrXII 
Tetracycline 
 
Sulphamethoxazole   
 
sulI  
 
sulII 
Trimethoprim/ 
Sulpha   
 
A3C 
   
 ACSSUT 
  
AKSSUT 
  
ACKSSUT 
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Table 7.3. Antimicrobial resistance phenotype and genotype prevalence (n=207) 
 
Antimicrobial Proportion %  
(# positive) 
Antimicrobial  
 
 
Resistance gene 
 
 
Proportion %  
(# positive) 
 
Amikacin 0.0 Ampicillin blaTEM 17.9 (37) 
Amox/Clav. 4.8 (10)  blaSHV 0.0 
Ampicillin 18.4 (38) Gentamicin aac(3)-IV 0.5 (1) 
Cefoxitin 4.8 (10)  ant(2")-Ia 0.0 
Ceftiofur 1.5 (3)  aac(3)-Iia 0.0 
Ceftriaxone 0.0 Neo/Kana aph(3')-Ia 17.9 (37) 
Cephalothin 4.8(10)  aph(3")-IIa 0.0 
Gentamicin 1.0 (2) Strep/spectinob ant(3”)-Ia(aadA1) 19.3 (40) 
Kanamycin 15.0 (31)  ant(3")_If (aadA6) 1.5 (3) 
Streptomycin 41.6 (86) Tetracycline tetA 13.0 (27) 
Chloramphenicol 14.5 (30)  tetB 45.4 (94) 
Ciprofloxacin 0.0  tetC 8.7 (18) 
Naladixic acid 0.0 Chloramphenicol  catI 13.0 (27) 
Sulphamethoxazole 55.1 (114)  floR 3.4 (7) 
Tetracycline 58.9 (122) Trimethoprim  dhfrI 16.9 (35) 
Trimethoprim/Sulpha 15.9 (33)  dhfrIb 1.0 (2) 
A3C 1.5 (3)  dhfrV 1.0 (2) 
ACSSUT 4.4 (9)  dhfrVII 0.5(1) 
AKSSUT 5.8 (12)  dhfrIX 0.5 (1) 
ACKSSUT 3.9 (8)  dhfrXII 1.9 (4) 
AMR +  64.7 (134)  dhfrXIII 0.5 (1) 
   dhfrXV 0.0 
  Sulphonamides  sulI 14.5 (30) 
   sulII 48.3 (100) 
  + for any gene  64.3 (133) 
aNeo/Kan=neomycin/kanamycin 
bStrep/Spectino=streptomycin/spectinomycin 
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Table 7.4.  Patterns of resistance genes present in isolates with susceptible phenotypes 
(n=8) and resistant phenotypes with no genotype (n=8) 
 
 
Resistance Genes Present 
 
 
# of isolates 
with this gene 
pattern and no 
phenotype 
Phenotype
aph(3’)-Ia / tetB / sulII 1 None 
blaTEM 1 None 
blaTEM / aph(3’)-Ia / ant(3”)Ia (aadA1)/ dhfrI / dhfrXII / sulII 1 None 
blaTEM / tetB 1 None 
dhfrIX 1 None 
tetA / tetC 1 None 
tetC 2 None 
Total number of isolates with no corresponding phenotype 8  
   
Phenotype Present # of isolates 
with this 
phenotype 
and no 
corresponding 
resistance 
genes 
Genotype 
Sulphamethoxazole 6 None 
Amoxicillin/clavulanic acid, ampicillin, cefoxitin 1 None 
Streptomycin, tetracycline, sulphamethoxazole 1 None 
Total number of isolates with no corresponding genotype 8 
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Table 7.5. Table 12: Resistance genes detected for each of the ACSSuT, AKSSuT, and 
ACKSSuT phenotype patterns where the phenotype and genotype did not match 
 
 
Phenotype 
Pattern 
#  of 
Isolates 
Mismatched resistance genes  
for each phenotype pattern 
ACSSuT 1 blaTEM ,aph(3')-Ia, ant(3")-Ia (aadA1), tetB,  dhfrI, sulII 
(n=3) 1 tetA,  tetC,  floR, sulI 
 1 blaTEM, aph(3')-Ia, ant(3")-Ia (aadA1), tetA,  floR,  dhfrI, 
dhfrXII, sulI, sulII 
   
AKSSuT 5 blaTEM ,aph(3')-Ia, tetB, sulI 
(n=7) 2 blaTEM,, aph(3')-Ia, tetA, dhfrIb, dhfrV  sulI, sulII 
   
   
ACKSSUT 1 floR, dhfrI,sulII 
(n=2) 1 aph(3')-Ia, ant(3")-Ia (aadA1), tetA, tetB,  dhfrXI, sulI 
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Table 7.6. Unconditional associations between being positive for individual or multiple 
AMR phenotypes and the antimicrobial gene ant(3")-Ia (aadA1) or aph(3')-Ia  (n=207) 
 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value 
ant(3”)-Ia (aadA1)  Ampicillin 9.4 4.2 21.2 0.0001 
 Chloramphenicol 24.3a 9.9 59.3 0.0001 
 Kanamycin 6.5 3.1 13.7 0.0001 
 Streptomycin 6.6 2.8 15.2 0.0001 
 Tetracycline 12.2 8.9 50.8 0.0006 
 Sulphamethoxazole 23.5 18.8 113 0.0001 
 Trimethoprim/sulpha 24.7 11.3 60.3 0.0001 
 ACSSuT 8.2 2.3 30.0 0.0015 
 ACKSSuT 30.6 3.2 291.4 0.0029 
      
aph(3')-Ia   Ampicillin 12.2 4.1 36.2 0.0001 
 Chloramphenicol 7.0 2.8 17.9 0.0001 
 Kanamycin 306 64.9 1440 0.0001 
 Streptomycin 26.4 8.1 86.1 0.0001 
 Tetracycline 11.1 2.9 42.5 0.0004 
 Sulphamethoxazole 12.7 3.8 42.7 0.0001 
 Trimethoprim/sulpha 14.4 6.2 33.5 0.0001 
 ACKSSuT 36.5 4.5 295.4 0.0007 
Only statistically significant (P<0.004) associations are reported. 
aExample interpretation: isolates that are positive for chloramphenicol resistance are 24.3 (95% 
CI, 9.9-59.3, P=0.0001) times more likely to be positive to aadA1 than isolates that are 
chloramphenicol susceptible. 
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Table 7.7. Unconditional associations between being positive for various individual or 
multiple AMR phenotypes and the AMR genes tetA or tetB (n=207) 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value
tetA Ampicillin 6.1 1.9 19.4 0.0023 
 Cefoxitin 4.9 1.7 13.8 0.0026 
 ACSSuT 27.7 3.9 198.0 0.0009 
      
tetB Kanamycin 5.1 1.8 13.8 0.0017 
 Streptomycin 7.3 3.5 15.3 0.0001 
 Tetracycline 29.2 11.1 76.6 0.0001 
 Sulphamethoxazole 18.1 8.0 40.8 0.0001 
Only statistically significant (P<0.004) associations are reported. 
No statistically significant associations for the tetC resistance gene 
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Table 7.8. Unconditional associations between being positive for various individual or 
multiple AMR phenotypes and the AMR genes catI or floR (n=207) 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value
catI Ampicillin 5.5 2.1 14.3 0.0005 
 Chloramphenicol 63.1 18.2 218.2 0.0001 
 Kanamycin 8.1 3.1 21.5 0.0001 
 Streptomycin 9.7 3.4 27.8 0.0001 
 Sulphamethoxazole 26.2 3.0 224.7 0.0029 
 Trimethoprim/sulpha 46.5 13.7 158.4 0.0001 
 ACKSSuT 24.6 3.7 166.4 0.001 
      
floR Cefoxitin 20.0 4.3 93.0 0.0001 
 Ceftiofur 78.2 6.0 1021.6 0.0009 
 Cephalothin 20.0 4.3 92.2 0.0001 
 Chloramphenicol 17.5 3.5 87.4 0.0005 
 A3C 78.2 6.0 1021.6 0.0009 
 ACSSuT 24.0 5.3 108.1 0.0001 
Only statistically significant (P<0.004) associations are reported. 
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Table 7.9. Unconditional associations between being positive for various individual or 
multiple AMR phenotypes and the AMR genes sulI or sulII (n=207) 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value
sulI Ampicillin 5.4 1.7 16.8 0.004 
 Chloramphenicol 21.9 8.3 58.0 0.0001 
 Kanamycin 6.3 2.0 20.1 0.0017 
 Streptomycin 6.1 2.1 17.6 0.0009 
 Tetracycline 26.2 2.9 235.6 0.0036 
 Sulphamethoxazole 33.8 3.2 356.4 0.0034 
 Trimethoprim/sulpha 20.3 6.6 62.6 0.0001 
 ACSSuT 8.3 2.0 34.0 0.0034 
      
sulII Kanamycin 13.6 2.8 66.0 0.0012 
 Streptomycin 18.7 7.1 49.4 0.0001 
 Tetracycline 38.9 12.5 121.0 0.0001 
 Sulphamethoxazole 125.4 41.5 378.4 0.0001 
Only statistically significant (P<0.004) associations are reported. 
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Table 7.10. Unconditional associations between being positive for various individual or 
multiple AMR phenotypes and the AMR gene dhfrI or dhfrXII (n=207) 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value
dhfrI Ampicillin 9.0 4.0 19.9 0.0001 
 Chloramphenicol 57.4 16.0 206.0 0.0001 
 Kanamycin 11.9 5.1 27.8 0.0001 
 Streptomycin 16.8 5.2 53.6 0.0001 
 Tetracycline 8.7 2.1 35.9 0.0028 
 Sulphamethoxazole 18.3 3.9 85.2 0.0002 
 Trimethoprim/sulpha 121.3 30.6 480.7 0.0001 
 ACSSuT 9.4 2.5 35.5 0.0009 
 ACKSSuT 35.3 5.1 242.6 0.0003 
      
dhfrXII Ceftiofur 24.9 3.6 171.5 0.0011 
 A3C 24.9 3.6 171.5 0.0011 
 ACSSuT 24.3 4.1 144.7 0.0005 
Only statistically significant (P<0.004) associations are reported. 
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Table 7.11.Unconditional associations between being positive for various individual or 
multiple AMR phenotypes and the AMR gene any blaTEM (n=207) 
 
   Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value 
blaTEM  Ampicillin 85.8 26.8 275.2 0.0001 
 Kanamycin 17.5 5.9 51.9 0.0001 
 Streptomycin 11.0 3.6 33.6 0.0001 
 Tetracycline 7.6 2.4 24.4 0.0006 
 Sulphamethoxazole 4.2 1.7 10.5 0.0019 
 Trimethoprim/sulpha 9.9 3.8 25.9 0.0001 
 ACSSuT 10.1 2.9 35.5 0.0003 
 ACKSSuT 14.7 3.3 66.1 0.0005 
Only statistically significant (P<0.004) associations are reported. 
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Table 7.12. Summary of associations between various antimicrobials and each family of resistance genes 
 
Antimicrobial 
 
Aminoglycoside gene + Tetracycline gene 
+ 
Phenicol gene + Sulphonamide  
gene + 
Trimethoprim gene + Ampicillin gene + 
        
 
 
ant(3”)-Ia (aadA1) aph(3’)-Ia tetA tetB catI floR sulI sulII dhfrI dhfrXII blaTEM 
Ampicillin + + + N + N + N + N + 
Chloramphenicol + + N N + + + N + N N 
Kanamycin + + N + + N + + + N + 
Streptomycin + + N + + N + + + N + 
Tetracycline + + N + N N + + + N + 
Sulphamethoxazole + + N + + N + + + N + 
Trimethoprim 
Sulphamethoxazole 
+ + N N + N + N + N + 
ACKSSuT + + N N + N N N + N + 
ACSSuT + N + N N + + N + + + 
+ association between the resistance gene and the phenotype 
N= no association between the resistance gene and the phenotype 
For more details about the above associations please refer to Tables 5 through 11 
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CHAPTER 8 
MOLECULAR CHARACTERIZATION OF AMR IN FECAL GENERIC 
ESCHERICHIA COLI ISOLATES FROM WESTERN CANADIAN COW-CALF 
HERDS: PART II ASSOCIATIONS BETWEEN RESISTANCE GENES 
 
8.1. Introduction 
 
Antimicrobial resistance (AMR) is an important issue in both human and veterinary 
medicine. Many studies have focused on organisms that are pathogenic for people 
including; Salmonella spp. (Wray et al., 1991), Campylobacter spp. (Gaunt and 
Piddock, 1996), or Escherichia coli O157 (Meng et al., 1998). Transmissible genetic 
elements encoding AMR can also be maintained in commensal bacteria (Shaw and 
Cabelli, 1980, Salyers and Shoemaker, 1996, Falagas and Siakavelllas, 2000). 
Resistance gene transmission from nonpathogenic to pathogenic organisms within the 
intestinal tract may be important for the development of AMR (Winokur et al., 2001). 
Escherichia coli have developed a number of elaborate methods for acquiring and 
disseminating genetic determinants and may serve as a reservoir for transmissible 
resistance (Neidhardt, 1996). Studying the molecular determinants of AMR in generic 
E. coli will increase our understanding of the significance of these bacteria in the 
development and transfer of AMR.  
 
Antimicrobial use (AMU) has an impact on the distribution of AMR phenotypes 
(McGowan and Gerding, 1996, Gaynes and Monnet, 1997, Aarestrup. 1999) and 
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resistance gene possession (Blake et al., 2003). As a result of varying AMU practices in 
different livestock species, describing AMR in one livestock class may not be 
representative of another. To date there is little information available on AMR in cow-
calf herds and no data for western Canada, although the western provinces of Alberta 
and Saskatchewan contain more than 65% of the beef cow, breeding heifer and calf 
populations in Canada (Statistics Canada, Accessed July 25, 2006; 
http://www.40.statcan.ca/101/cst01/prim50a.htm). Describing AMR throughout all 
phases of livestock production is vital to understanding the epidemiology of AMR.  
 
The spread of mobile genetic elements such as plasmids, transposons, or 
integron/gene cassettes (Hall and Collins, 1995, Bennett, 1999, Schwarz and Chaslus-
Dancla, 2001) may be responsible for the rapid dissemination multiple AMR genes 
(Kruse and Sorun, 1994, Salyers and Cuevas, 1997, Sandvang et al., 1997). Linked 
clusters of AMR on a single mobile element can also aggregate in such a way that 
antimicrobials of a different class or even non-antimicrobial substances like heavy 
metals or disinfectants can select for AMR bacteria (Recchia and Hall, 1997, Salyers et 
al., 2004). Exchange of resistance genes between pathogens and non-pathogens or 
between gram positive and negative bacteria has also been documented (Prescott, 2000, 
Salyers et al., 2004).  
 
Co-selection of resistance genes has a substantial impact on the implementation of 
prudent antimicrobial use guidelines.  Since resistance genes can be linked on mobile 
genetic elements use of a particular antimicrobial can select for resistance not only to 
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that antimicrobial but potentially to a variety of others.  This means that even if there is 
restricted use of certain antimicrobials, the resistance genes associated with these 
restricted antimicrobials could still be perpetuated through co-selection.  By 
understanding the associations between resistance genes the impact of certain prudent 
use guidelines can be considered. The objective of this study was to explore 
associations between genetic determinants of AMR in fecal generic E. coli isolates 
obtained from cow-calf herds in western Canada. 
 
8.2. Materials and methods 
 
As a part of a strategic research initiative to study AMR and AMU in cow-calf herds 
(Gow and Waldner, 2007, Gow et al., 2007a,b,c), this project was undertaken to 
compliment a project examining associations between AMR phenotype and resistance 
genes (Gow et al., 2007c). The focus of this paper is on associations between resistance 
genes to explore the potential for co-selection of AMR genetic determinants in 
commensal E. coli. 
 
Materials and methods have been described in detail elsewhere (Gow et al., 2007c).  
Briefly, the 207 isolates utilized for this study were a selected sub-set from a larger 
study investigating AMR in cow-calf herds. The isolates were divided into susceptible 
or resistant.  Since genetic determinants of AMR were of interest the majority of 
isolates (65%, 134/207) selected for this project were classified as resistant 
phenotypically.  From either the susceptible or resistant list, isolates were randomly 
selected ensuring that not ≥1isolate from the same animal was included. Fecal samples 
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were cultured for generic E. coli.  A minimum of three isolates per sample identified as 
E. coli were selected and stored at -80°C until susceptibility testing could be performed. 
Isolates were tested for susceptibility using a microbroth dilution technique (Sensititre®, 
TREK Diagnostic Systems Inc., Cleveland, Ohio) and the standard 2002 National 
Antimicrobial Resistance Monitoring System (NARMS) public health panel (CIPARS, 
2006). All testing was done in accordance with National Committee on Clinical 
Laboratory Standards (NCCLS) guidelines (NCCLS, 2000). DNA hybridization and 
PCR were used to test for 24 resistance genes from 6 antimicrobial families was done 
on the 207 isolates (Table 8.1).  Details on isolate phenotype have been described 
elsewhere (Gow et al., 2007c). 
 
8.2.1. Statistical analysis 
 
Descriptive analyses were completed and variables were recoded as necessary for 
statistical modeling using commercially available software programs (SPSS 11.0 for 
Windows, SPSS Inc., Chicago, Illinois). Initially all isolates were coded as to the 
presence or absence of each gene considered in the analysis. Isolates were further 
categorized for the presence or absence of at least one gene for each of the six families 
of antimicrobials considered in this study. For example; if an isolate contained any 
individual tet resistance gene or any combination of tet resistance genes it would have 
been classified as being positive for the appropriate individual genes, but it also would 
have been classified as being tetracycline gene positive as well.  Mulitple resistance was 
defined as an isolate with the presence of ≥2 resistance genes. 
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Outcome and response variables of interest included the individual resistance genes 
with a prevalence of greater than 1.5% that could contribute to specific AMR patterns 
as well as the resistance genes dhfrI and dhfrXII (Table 8.2).  Generalized estimating 
equations (GEE) were used to account for clustering of isolates sampled within herd 
(SAS v.8.2 for Windows (PROC GENMOD); SAS Institute, Cary, North Carolina, 
USA). Model specifications included a binomial distribution, logit link function, 
repeated statement with subject equal to herd, and an exchangeable correlation 
structure.  
 
Statistically significant associations were reported as odds ratios (OR) with 95% 
confidence limits. Odds ratios >1 indicate an increasing occurrence of the genotype 
being studied with the other genotype being measured (a positive association) while 
those <1 indicate a decreasing occurrence of the genotype being studied with increases 
in the other measured genotype (a negative association). Multiple comparisons were 
accounted for using a Bonferroni correction to provide a conservative estimate for the 
level of statistical significance (Dohoo et al., 2003) An association was significant if 
P<0.004 after correction for 12 comparisons (P < 0.05/k, k = number of comparisons) 
(Dohoo et al., 2003).  
 
8.3. Results 
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8.3.1. Description of sample population for genotyping study 
 
In the spring of 2002, samples (n=107) were collected from calves with a median age 
of 6 days and ranging in age from of 1 to 120 days. Dam age for these calves ranged 
from 2 to13 years with a median cow age of 5 years. Fifty-seven percent of the calves 
were male, and calves not currently showing clinical signs of disease accounted for 
91.2% (98/107) of the population sampled.  
 
Samples (n=50) were also collected from healthy cows that ranged in age from 2 to 
10 years with a median age of 5 years.  
 
The median age for calves sampled in the fall (n=50) was 204 days with a range of 
118 to 301. Median dam age for these calves was 6 years (range, 2 to 14 years). Fifty-
six percent of these calves were male and all calves were classified as healthy.  
 
8.3.2. Resistance genes detected in the selected isolates 
 
Resistance genes were detected in 64.3% of the isolates. The most common 
resistance genes detected included a gene for sulphonamide resistance, sulII, a gene for 
tetracycline resistance, tetB, and a gene for streptomycin resistance, ant(3”)-Ia (aadA1) 
(Table 8.3). No isolates carried the resistance genes blaSHV, ant(2”)-Ia, aac(3)-IIa, 
aph(3”)-IIa, and dhfrXV . Low levels of aac(3)-IV, ant(3”)-If (aadA6) and several 
resistance genes for trimethoprim were detected.  
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Sixteen different multiple resistance gene patterns were identified in 106 of the 
isolates. For the multi-resistance gene isolates, the median number of resistance genes 
was 2 with a maximum of 7. The most common pattern detected included sulII and tetB 
together (n=40, 19.8%). The next most common pattern (6 isolates) contained a 
grouping of blaTEM, aph(3’)-Ia, tetB and sulII (2.9%).  
 
8.3.3. Unconditional association between resistance genes 
 
Numerous associations were detected between the various resistance genes examined 
and the aminoglycoside genes (Table 8.4). At least one resistance gene in each family of 
antimicrobials considered was associated with the aminoglycoside gene ant(3”)-Ia 
(aadA1 (Table 4).  Both ant(3”)-Ia (aadA1 and aph(3’)-Ia were also strongly associated 
with each other. 
 
Fewer associations were identified among the various resistance genes examined and 
the tetracycline genes (Table 8.5) than for the aminoglycoside genes. TetA and tetC 
were significantly associated and were often found in the same isolate. However, tetA 
positive isolates were less likely to be tetB positive than isolates that were tetA negative 
(Table 8.5). There was no significant association between tetB and tetC.  
 
Phenicol genes catI and floR were not associated with each other. Two different 
resistance genes from the trimethoprim family had the strongest associations with either 
the cat1 or the floR genes (Table 8.6).  
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Of the resistance genes tested, chloramphenicol, tetracycline and streptomycin genes 
were the most strongly associated with sulphonamide genes (Table 8.7). Resistance 
genes sulI and sulIII were not associated with each other.  
 
Very strong associations were also detected between the phenicol resistance genes 
and the trimethoprim resistance genes (Table 8.8). Neither trimethoprim gene was 
associated with the other.  
 
Numerous associations between individual genes and blaTEM resistance genes were 
detected with the strongest association between (aph3’)-Ia and blaTEM (Table 8.9).  
 
Table 8.10 and Figure 8.1 summarize the associations between individual resistance 
genes at the antimicrobial family level. At least one resistance gene from every other 
family of antimicrobials was significantly associated with at least one resistance gene 
belonging to the aminoglycoside family.  
 
8.4. Discussion 
 
To gain a better understanding of the epidemiology and the implications of AMR in 
cow-calf herds, fecal generic E. coli isolates obtained from cow-calf herds were 
examined to describe the associations between resistance genes. The complex nature of 
AMR was demonstrated by the large number of associations of moderate to substantial 
magnitude that were detected between resistance genes.  
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Resistance genes are often associated with integrons or mobile DNA such as 
plasmids and transposons that facilitate resistance gene distribution (Jacoby, 1994, 
Tenover and Rasheed, 1998). The presence of resistance genes on plasmids or on 
bacterial chromosomes suggests that genes conferring multi-drug resistance can exist as 
complex configurations of physically linked elements (Carattoli, 2001). The large 
number of strong associations between genes is consistent with the hypothesis that there 
is linkage between many of these resistance genes. The exact mechanism of linkage 
cannot be determined by the current study, but further molecular investigation would 
demonstrate potential gene linkages and the location of gene clusters on mobile genetic 
elements.  
 
In addition to resistance acquisition, some of resistance genes and associations 
between resistance genes might be accounted for by common AMU on cow-calf farms. 
Direct use of antimicrobials can drive the co-selection of resistance genes. An example 
of this phenomenon was described by O’Conner et al., (2002) who determined that the 
use of injectable oxytetracycline in cattle receiving chlortetracycline in their feed was 
associated with an increase in the incidence of resistance to chloramphenicol and 
sulphasoxazole. Similar mechanisms might underlie the patterns demonstrated in these 
cow and calf isolates since different patterns of co-selection can be dependent on AMU 
patterns (Lanz et al, 2003).  
 
Antimicrobials commonly used in western Canadian cow-calf herds are 
tetracyclines, sulphonamides and trimethoprim/sulphonamides (Gow and Waldner, 
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2007). These antimicrobials are consistent with some of the most prevalent resistance 
genes demonstrated in this study. However, despite the ban of chloramphenicol use in 
food producing animals since 1985 (Gilmore, 1986), chloramphenicol resistance was 
expressed by these isolates. This may indicate that co-selection is contributing to the 
persistence of chloramphenicol resistance genes in the population (Travis et al., 2006). 
In this study, the chloramphenicol gene catI was associated with the presence of both a 
trimethoprim gene (dhfrI) and a sulphonamide gene (sulI). In beef cattle there may be 
co-selection for the chloramphenicol resistance gene resulting from selecting for 
trimethoprim or sulphamethoxazole resistance. Further investigation into the molecular 
relationship and the potential link to AMU is needed. 
 
There was a negative association between tetA and tetB resistance genes.  An 
incompatibility of plasmids carrying the tetracycline resistance determinants could 
explain the existence of the negative association between tetA and tetB (Jones et al., 
1992). No association was detected between sul1 and sulII. Potentially the plasmid 
incompatability and the strong association of tetA with sulI and tetB with sulII could 
account for this lack of association. The absence of an association between dhfrI and 
dhfrXII  was not unexpected because dhfrXII and dhfrXIII are closely related to each 
other but not to other members of the subgroup (Hall and Collis, 1998). 
 
This study did not investigate the presence of class I integrons or extended-spectrum 
beta-lactamases. Although an integron probe was not included, the ant(3”)-1 (aadA1) 
probe was used. The ant(3”)-Ia (aadA1)  gene, along with several different dhfr genes 
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and the sulI gene, have been located as gene cassettes within integrons (Lévesque et al., 
1995, Fluit and Shmitz, 1999, Carattoli, 2001, Gestal et al., 2005). When examining 
associations between these three genes they were all strongly associated with each other 
as well as with resistance genes blaTEM, cat1, aph(3’)-Ia. Despite not testing specifically 
for integrons, the various patterns containing two or more of these genes suggested the 
presence of integrons in this sample population.  
 
To understand the implication of the multiple associations detected between 
individual resistance genes, higher-level associations were examined between indicators 
of genetic resistance to families of antimicrobials. While the authors do recognize, 
particularly for the aminoglycoside family of antimicrobials, that resistance to one 
antimicrobial within this family does not confer resistance to the entire family (Salyers 
and Whitt, 2005), the goal of this investigation was simply to create an initial picture of 
complex nature of resistance between the families of antimicrobials used in cow-calf 
herds.  This exploration provided further insight into the complexity of the 
epidemiology of AMR. This network of associations also brings into question the 
definition of “prudent use” and the impact of these associations on developing policy 
and clinical practice guidelines to minimize AMR. The implication is that current 
attempts to limit the emergence or spread of AMR based on careful restriction of the 
choice of antimicrobials will not prevent selection for a number of unrelated AMR 
genes. Therefore, the assessment of AMR at the genetic level is a critical tool in the 
understanding and the potential control of AMR (Lanz et al., 2003). This research 
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provides a baseline of important resistance gene relationships that need to be considered 
when planning potential AMR control in cow-calf herds.   
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Figure 8.1. Resistance gene relationships between antimicrobial families. Each line 
represents one of the relationships detailed in Tables 4 to 9 
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Table 8.1. Antimicrobial family, genetic marker, primer sequence, GenBank accession number and DNA source for resistance genes 
tested 
PCR primer sequence (5'-3') 
                        
Antimicrobial family Genetic 
marker 
Forward Reverse 
Amplicon 
size (bp) 
GenBank 
accession no. 
 
Source of DNA 
Beta-lactams blaTEM GAGTATTCAACATTTTCGT ACCAATGCTTAATCAGTGA 857 AF309824 R. C. Levesque 
 blaSHV TCGCCTGTGTATTATCTCCC CGCAGATAAATCACCACAATG 768 AF148850 R. C. Levesque 
Aminoglycosides aac(3)-IIa 
(aacC2) 
CGGAAGGCAATAACGGAG TCGAACAGGTAGCACTGAG 740 X54723 D. Sandvang 
 aac(3)-IV GTGTGCTGCTGGTCCACAGC AGTTGACCCAGGGCTGTCGC 627 X01385 J. Harel 
 aph(3')-Ia 
(aphA1) 
ATGGGCTCGCGATAATGTC CTCACCGAGGCAGTTCCAT 600 M18329 J. Harel 
 aph(3')-IIa 
(aphA2) 
GAACAAGATGGATTGCACGC GCTCTTCAGCAATATCACGG 680 V00618 J. Harel 
 ant(3”)-
Ia(aadAI) 
CATCATGAGGGAAGCGGTG GACTACCTTGGTGATCTCG 786 DQ166553.1 J.Harel 
 ant(3”)-If 
(aadA6) 
GAGTAACGCAGTACCCGC CACTGGCATGGCACTAAGC 795 AY444814.1 J. Harel 
Tetracycline tet(A) GTGAAACCCAACATACCCC GAAGGCAAGCAGGATGTAG 888 X00006 J. Harel 
 tet(B) CCTTATCATGCCAGTCTTGC ACTGCCGTTTTTTCGCC 774 J01830 J. Harel 
 tet(C) ACTTGGAGCCACTATCGAC CTACAATCCATGCCAACCC 881 J01749 J. Harel 
Phenicols catI AGTTGCTCAATGTACCTATAACC TTGTAATTCATTAAGCATTCTGCC 547 M62822 J. Harel 
 floR CGCCGTCATTCCTCACCTTC GATCACGGGCCACGCTGTGTC 215 AF252855 D. G. White 
Trimethoprim dhfrI AAGAATGGAGTTATCGGGAATG GGGTAAAAACTGGCCTAAAATTG 391 X00926 J. Harel 
 dhfr1b AGTATCATTGATAGCTGCG GTAGTGCGCGAAGCGAAC 517 DQ388123.1 J. Harel 
 dhfrV CTGCAAAAGCGAAAAACGG AGCAATAGTTAATGTTTGAGCTAAAG 432 X12868 O. Sköld 
 dhfrVII GGTAATGGCCCTGATATCCC TGTAGATTTGACCGCCACC 265 X58425 O. Sköld 
 dhfrIX TCTAAACATGATTGTCGCTGTC TTGTTTTCAGTAATGGTCGGG 462 X57730 C. Wallen 
 dhfrXII GAACTCGGAATCAGTACGC ACGCGCATAAACGGAGTG 483 DQ157751.1 J. Harel 
 dhfrXIII CAGGTGAGCAGAAGATTTTT CCTCAAAGGTTTGATGTACC 294 Z50802 P. V. Adrian 
 dhfrXV GGGAACAATTACTCTTC GTCTTCAGATGATTTAGC 186 Z83311D P. V. Adrian 
Sulfonamides sulI TTCGGCATTCTGAATCTCAC ATGATCTAACCCTCGGTCTC 822 X12869 R. C. Levesque 
 sulII CGGCATCGTCAACATAACC GTGTGCGGATGAAGTCAG 722 M36657 J. Harel 
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Table 8.2. Investigation into the association between genotypes included the following 
individual and groups of antimicrobials. Each gene in the response variable column was 
individually tested for associations with each gene in the risk factors column 
 
 
Response variables  
 
Risk factors for genotype 
blaTEM blaTEM 
aph(3’)-Ia aph(3’)-Ia 
ant(3”)-Ia Ant(3”)-Ia 
tetA  tetA  
tetB tetB 
tetC tetC 
catI catI 
floR floR 
dhfrI  
dhfrXII 
sulI 
dhfrI  
dhfrXII 
sulI 
sulII sulII 
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Table 8.3. List of antimicrobial agents and the associated resistance genes investigated 
along with the resistance gene prevalence for 207 isolates from beef cattle
Antimicrobial  Resistance gene Prevalence  %  (# Positive) 
Ampicillin blaTEM 17.9 (37) 
 blaSHV 0.0 
Gentamicin aac(3)-IV 0.5 (1) 
 ant(2")-Ia 0.0 
 aac(3)-Iia 0.0 
Neomycin/ 
Kanamycin aph(3')-Ia 17.9 (37) 
 aph(3")-IIa 0.0 
Streptomycin/ 
Spectinomycin ant(3”)-Ia (aadA1) 19.3 (40) 
 ant(3")_If (aadA6) 1.5 (3) 
Tetracycline  tetA 13.0 (27) 
 tetB 45.4 (94) 
 tetC 8.7 (18) 
Chloramphenicol  cat1 13.0 (27) 
 floR 3.4 (7) 
Trimethoprim  dhfrI 16.9 (35) 
 dhfrIb 1.0 (2) 
 dhfrV 1.0 (2) 
 dhfrVII 0.5(1) 
 dhfrIX 0.5 (1) 
 dhfrXII 1.9 (4) 
 dhfrXIII 0.5 (1) 
 dhfrXV 0.0 
Sulphonamides  sulI 14.5 (30) 
 sulII 48.3 (100) 
Gene for AMR  
Yes/No  64.3 (133) 
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Table 8.4. Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial gene ant(3")Ia (aadA1) and aph(3')-Ia  (n=207) 
 
   
95% Confidence 
Interval  
Response 
Variable Risk Factor OR Lower Upper P-value 
ant(3”)-Ia 
(aadA1) 
blaTEM   
11.5 4.9 27.2 0.0001 
 cat1 53.9 13.2 221 0.0001 
 aph(3’)-Ia  10.0 4.5 22.4 0.0001 
 tetA 6.2 2.3 16.6 0.0003 
 su1I 52.3 11.7 233 0.0001 
 dhrfI 96.2a 30.2 306 0.0001 
     
aph(3’)-Ia  blaTEM   22.7 6.6 78.1 0.0001 
 cat1 9.0 3.5 22.7 0.0001 
 ant(3”)-Ia (aadA1) 10.7 4.7 24.5 0.0001 
 tetB 16.8 5.0 56.8 0.0001 
 su1I 5.9 2.3 15.1 0.0002 
 sulII 17.4 4.2 71.6 0.0001 
 dhfrI 18.2 7.1 47.2 0.0001 
Only statistically significant (P<0.004) associations are reported 
aExample interpretation: isolates that are positive for the resistance gene dhfrI are 96.2 (95% CI, 30.2-
306.3, P=0.0001) times more likely to be positive to aadA1 than isolates that are dhfrI negative isolates. 
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Table 8.5. Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial resistance genes tetA, tetB or tetC (n=207) 
 
   
95% Confidence 
Interval  
Response Variable Risk Factor OR Lower Upper P-value 
tetA ant(3”)-Ia (aadA1) 6.7 2.5 17.9 0.0001 
 tetB 0.2 0.1 0.5 0.0012 
 tetC 8.7 2.4 30.7 0.0008 
 sulI 15.0 5.6 40.0 0.0001 
      
tetB aph(3’)-Ia  9.5 3.3 27.1 0.0001 
 tetA 0.2 0.1 0.5 0.0008 
 sulII 25.7 12.0 54.8 0.0001 
      
tetC floR 17.8 3.9 80.8 0.0002 
 tetA 6.4 2.0 20.9 0.002 
Only statistically significant (P<0.004) associations are reported 
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Table 8.6. Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial resistance genes catI or floR (n=207) 
 
   
95% Confidence 
Interval  
Response 
Variable Risk Factor OR Lower Upper P-value 
cat1 blaTEM   7.0 2.8 17.8 0.0001 
 aph(3’)-Ia  8.9 3.6 22.0 0.0001 
 ant(3”)-Ia (aadA1) 56.8 12.2 266 0.0001 
 sulI 83.0 21.3 323 0.0001 
 dhfrI 214 46.3 989 0.0001 
      
floR tetC 17.4 3.3 92.4 0.0008 
 dhfrXII 39.4 7.8 200 0.0001 
Only statistically significant (P<0.004) associations are reported 
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Table 8.7. Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial resistance genes sulI and sulII (n=207) 
 
   
95% Confidence 
Interval  
Response Variable Risk Factor OR Lower Upper P-value 
sulI blaTEM 5.0 1.9 13.4 0.0012 
 cat1 96.9 23.4 401 0.0001 
 aph(3’)-Ia 6.2 2.4 16.4 0.0002 
 ant(3”)-Ia (aadA1) 79.3 14.3 441 0.0001 
 tetA 16.1 5.4 47.9 0.0001 
 dhfrI 27.4 9.9 75.4 0.0001 
      
sulII aph(3’)-Ia 16.5 3.1 87.2 0.0009 
 tetB 33.9 15.5 74.3 0.0001 
Only statistically significant (P<0.004) associations are reported 
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Table 8.8. Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial resistance gene dhfrI and dhfrXII(n=207) 
 
   95% Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value 
dhfrI blaTEM 13.2 4.5 39.1 0.0001 
 cat1 193 44.6 836 0.0001 
 aph(3’)-Ia 16.5 6.6 40.9 0.0001 
 ant(3”)-Ia (aadA1) 86.4 26.3 283 0.0001 
 sul1 23.2 8.4 63.7 0.0001 
      
dhfrXII   floR 32.4 6.5 162 0.0001 
Only statistically significant (P<0.004) associations are reported 
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Table 8.9.  Unconditional associations detected between being positive for individual 
resistant genes and the antimicrobial resistance gene blaTEM (n=207) 
 
   95% Confidence Interval  
Response Variable Risk Factor OR Lower Upper P-value
blaTEM cat1 7.2 2.7 18.9 0.0001 
 aph(3’)-Ia 22.9 6.7 77.7 0.0001 
 ant(3”)-Ia (aadA1) 12.3 5.1 29.7 0.0001 
 sulI 4.8 1.8 12.4 0.0013 
 dhfrI 14.6 4.7 44.9 0.0001 
Only statistically significant (P<0.004) associations are reported 
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Table 8.10.  Associations between individual resistance genes summarized at the 
antimicrobial family level 
 
 
Aminoglycoside 
gene + 
Tetracycline 
gene + 
Phenicol 
gene + 
Sulphonamide 
gene + 
Trimethoprim 
gene + 
Ampicillin 
gene + 
Aminoglycoside  
Gene+ 
+ + + + + + 
Tetracylcine 
Gene + 
+ + + + N N 
Phenicol gene + + + N + + + 
Sulphonamide 
gene + 
+ + + N + + 
Trimethoprim  
gene + 
+ N + + N + 
Ampicillin  
 gene + 
+ N + + + N 
+ indicates association detected 
N= indicates no association detected
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CHAPTER 9 
ANTIMICROBIAL RESISTANCE AND VIRULENCE FACTORS IN GENERIC 
ESCHERICHIA COLI ISOLATES FROM WESTERN CANADIAN COW-CALF 
HERDS 
 
9.1. Introduction 
 
Shiga toxin or verotoxin producing Escherichia coli (STEC/VTEC) are the most 
important recently emerged groups of foodborne pathogens (Remis et al., 1984, 
Karmali, 1989, Beutin et al., 1998, Paton and Paton, 1998, Beutin et al., 2002, Blanco et 
al., 2004, Mora et al., 2004). Major STEC associated outbreaks have been experienced 
in Canada, Japan, the United Kingdom, and the USA (Karmali, M., 1989, Beutin et al., 
1998, Paton and Paton, 1998, Willshaw, et al., 2001, Beutin et al., 2002). In people, 
these infections are associated with gastroenteritis that may be complicated by 
hemorrhagic colitis (HC) or hemolytic-uremic syndrome (HUS). Hemolytic uremic 
syndrome is a major cause of renal failure in children (Mora et al., 2004).  
 
Shiga-toxigenic E. coli produce either one or two cytotoxins called Shiga toxins (stx1 
and stx2) or verotoxins (vt1 and vt2) (Paton and Paton, 1998). Intimin is another 
virulence factor responsible for intimate attachment of STEC. It is encoded by 
chromosomal gene eae which is part of a large cluster of virulence genes on a 
pathogenicity island termed the locus for enterocyte effacement (LEE) (Kaper et al., 
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1998). Shiga-toxigenic E. coli carrying the eae gene have been closely associated with 
HC and HUS (Karmali, 1989).  
 
Antimicrobials are not commonly recommended for therapy of STEC infections 
because they can lyse cell walls leading to the release of the toxins (Waterspiel et al., 
1992, Wong et al., 2000). Additionally, antimicrobials are avoided because they can 
cause increased expression of the toxins in vivo (Zhang et al., 2000). Despite the limited 
use of antimicrobials to treat STEC infections, there have been recent reports suggesting 
that antimicrobial resistance (AMR) of STEC is increasing (Gonzalez et al., 1989, 
Farina et al., 1996, Meng et al., 1998, Galland et al., 2001, Willshaw et al., 2001, 
Schroeder et al., 2002). 
 
Virulence genes are either located in chromosomal gene clusters (pathogenicity 
islands) or harbored in mobile accessory genetic elements such as plasmids and phages 
(Groismann, 1996, Finlay and Falkow, 1997, Hacker et al., 1997). Resistance genes are 
also often associated with mobile DNA such as plasmids, transposons, and integrons 
(Jacoby, 1994, Tenover and Rasheed, 1998). Since AMR and virulence genes are 
carried in a similar fashion it is possible that they could be linked and then co-selected 
(Martinez and Baquero, 2002). Reported increases in AMR STEC isolates are of 
concern because antimicrobial use (AMU) could potentially enhance the selection of 
bacteria carrying virulence genes; ultimately accelerating the spread of virulence genes 
within bacterial populations (Boerlin et al., 2005).  
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Cattle, sheep, and goats have been implicated as the primary reservoirs for STEC 
(Blanco et al., 2001, 2003, 2004). AMR bacteria from livestock and farms pose a risk to 
public health through direct contact with livestock or production environments, and also 
through AMR food borne pathogens (van den Bogaard and Stobberingh, 2000, White et 
al., 2001). Non-pathogenic E. coli are also a potential problem because they can provide 
a pool of transferable resistance genes (Schmieger and Schicklmaier, 1999, Winokur et 
al., 2001).  
 
The current literature contains several articles describing AMR in STEC’s from a 
variety of animal populations (Gonzalez and Blanco, 1989, Galland et al., 2001, Zhao et 
al., 2001, Maidhof et al., 2002, Schroeder et al., 2002, Betteleheim et al., 2003, Mora et 
al., 2005). However, the current literature describing AMR in STEC does not always 
contain directly comparable information on the nature and extent of resistance in non-
STEC populations. The presence of AMR within a STEC positive isolate alone does not 
indicate whether or not STEC are more or less likely to be resistant to antimicrobials 
than non-STEC organisms, or conversely whether organisms that are resistant to 
antimicrobials are more or less likely to contain virulence genes than organisms that are 
susceptible. The primary objective of this study was to investigate if presence of AMR 
or the presence of AMR genes is associated with the presence of the virulence genes 
stx1, stx2, and eae in E. coli isolates from cow-calf herds.  
 
9.2. Materials and methods 
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9.2.1. General aspects of the study and sample collection 
 
Fecal samples were collected from 480 individually identified beef calves on 91 
privately owned cow-calf farms in Alberta and Saskatchewan that were accessible in the 
calving and nursery area (Figure 9.1). The farms were part of a larger survey for risk 
factors affecting calf health. Fecal samples were obtained either directly from the 
rectum or from the ground immediately after defecation. A separate disposable glove 
and container were used between samples. The majority of samples were collected from 
March until the end of May with a few herds having samples collected in June and early 
July.  
 
9.2.2. Laboratory methods 
 
9.2.2.1 Escherichia coli culture 
 
Fecal samples were sent on ice to a diagnostic laboratory (Prairie Diagnostic 
Services, Saskatoon, Saskatchewan) for culture. The samples were cultured onto 
MacConkey agar plates at 37◦C for 18 hours for isolation of E. coli. Each sample had at 
least three individual lactose fermenting colonies identified as E. coli using standard 
biochemical tests: indole, Triple Sugar Iron (TSI) slant, citrate and urea. If both dry and 
mucoid colonies were detected within a sample, then three isolates from each colony 
type were tested. In the case of one colony type, three isolates from that type were 
tested.  Individual E. coli isolates were stored in 50% glycerol and Luria-Bertani (LB) 
broth at -80ºC until sensitivity testing was performed.  
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9.2.2.2 Selection of isolates for further testing 
 
A total of 1677 isolates were identified and saved for further testing. Isolates were 
divided into sensitive and resistant based on the criteria listed under “Antimicrobial 
susceptibility testing”; 94 isolates resistant to at least one antimicrobial and 12 
susceptible isolates were randomly selected using a random number generator. This 
subset of 106 isolates was tested for the presence of resistance genes and virulence 
factors. No isolate replicates from the same fecal sample were included; therefore, this 
sub-set of isolates represents 106 animals from 57 farms. 
 
9.2.2.3. Susceptibility testing methodology 
 
E. coli isolates were tested for susceptibility (Alberta Agriculture, Food and Rural 
Development) using a microbroth dilution technique (Sensititre®, TREK Diagnostic 
Systems Inc., Cleveland, Ohio) and the standard 2002 National Antimicrobial 
Resistance Monitoring System (NARMS) CMV7CNCD gram negative public health 
panel  
 
Minimum inhibitory concentrations (MICs) for 16 antimicrobials were assessed for 
106 isolates (Figure 9.2). Breakpoints for susceptibility were used, as defined by the 
National Committee on Clinical Laboratory Standards (NCCLS 2000) (Figure 9.2). All 
isolates identified with intermediate susceptibility were classified as susceptible for the 
statistical analysis. Amikacin results > 4µg/mL were labeled not interpretable because 
 287 
the breakpoint is 4 dilutions beyond the range of the panel. The breakpoint used for 
streptomycin was 64µg/ml (CIPARS, 2006). 
 
9.2.2.4. Molecular testing methodology 
 
9.2.2.4.1. Bacterial strains and growth conditions 
 
DNA hybridization and PCR were used to test for 24 resistance genes from 6 
antimicrobial families (Département de Pathologie et Microbiologie, Faculté de 
Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec). The 
antimicrobial family, the genetic marker along with the PCR primer sequence, and 
source of DNA are summarized in Table 9.1. 
 
The 28 strains used as positive controls and templates for DNA amplification were 
obtained from different laboratories (Maynard et al., 2003, Maynard et al., 2004). These 
strains were stored at -80°C in tryptic soy broth medium containing 10% glycerol 
(vol/vol) and were propagated on Luria-Bertani broth or agar containing one of the 
following antimicrobial agents at the appropriate concentrations: ampicillin (50 µg/ml), 
gentamicin (30 µg/ml), kanamycin (50 µg/ml), tetracycline (10 µg/ml), chloramphenicol 
(10 µg/ml), trimethoprim (10 µg/ml), and sulfamethazine (200 µg/ml).  
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9.2.2.4.2. Detection of antimicrobial resistance genes 
 
Oligonucleotide primers for PCR amplification of antimicrobial resistance gene 
sequences are described in Maynard et al. (2003, 2004). Template DNA was prepared 
from bacterial cultures by the boiling method of Daigle et al. (1994). PCR reactions 
(total volume, 50 µl) contained 1x PCR buffer (10 mM Tris-HCl pH 9.0, 50 mM KCl, 
1.5 mM MgCl2) (Amersham Pharmacia Biotech Inc., Piscataway, N.J.), 200 µM each of 
the four deoxynucleoside triphosphates, 1 U of Taq DNA polymerase (Amersham 
Pharmacia Biotech Inc.), 25 pmol of each primer and 5 µL of template. DNA 
amplification was carried out in a GeneAmp PCR system 9700 (Perkin-Elmer, Foster 
City, Calif.) with the following conditions: 5 min at 94°C, followed by 30 cycles of 
94°C for 30 s, 50°C for 30 s, and 72°C for 1.5 min. An aliquot (3 µL) of each PCR 
reaction was resolved in a 1.2% agarose gel to confirm product size and purity. PCR 
products were labeled with [ -32P] dCTP by using Ready-To-Go DNA Labeling Beads 
(Amersham Pharmacia Biotech Inc.). Colony hybridizations were performed as 
described previously (Harel et al., 1991).  
 
9.2.2.4.3. Detection of virulence factor genes 
 
Isolates were provided to a commercial diagnostic lab for virulence factor detection 
(Prairie Diagnostic Services, Saskatoon, Saskatchewan). Two to four colonies of each 
E. coli isolate were randomly selected from blood agar plates and resuspended in 400 µl 
of D-Solution (4 M guanidine isothiocyanate, 25mM Na citrate at pH 8.0, 0.5% 
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sarcosyl, 0.1 M β-mercaptoehanol) (Sigma Aldrich Corporate Office St. Louis, 
Missouri, USA). TE-saturated phenol (100 µl) (Sigma Aldrich Corporate Office St. 
Louis, Missouri, USA) and 100 µl of chloroform were added to each tube, followed by 
mixing, incubation at -20°C for 10 minutes, centrifugation for 5 minutes at 4°C and 
15,000 x g and removal of the aqueous layer to a fresh tube. Phenol:chlorofom 
extractions were repeated until the interface was clear. Nucleic acids were precipitated 
by the addition of 500 µl of 95% salted ethanol (VWR International Inc. West Chester, 
Pennsylvania, USA) followed by incubation at -20°C and pelleted by centrifugation at 
15,000 x g for 15 min at 4°C. DNA pellets were dried for 5-10 minutes between 30 and 
35°C and dissolved in 80 to 100 µl of sterile water.  
 
Oligonucleotide primers used for the PCR detection of virulence associated genes are 
shown in Table 9.2. PCR reactions (50 µl total volume) contained 1x PCR buffer 
(Fermentas International Inc., Burlington, Ontario, Canada), 2mM MgCl2, 250 mM of 
each of the four dNTPs, 2.5 U Taq DNA polymerase (Fermentas International Inc., 
Burlington, Ontario, Canada), four primers (2 µl / primer, 20 pmol/µl) and 2 µl of 
template DNA. The thermocycler protocol consisted of 2 min at 94°C followed by 35 
cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds and a final 
extension at 72°C for 10 min. PCR products were visualized following electrophoresis 
on a 1.25% agarose gel.  
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9.2.5. Statistical analysis 
 
Descriptive analyses were completed using commercially available software (SPSS 
11.0 for Windows, SPSS Inc., Chicago, Illinois). All isolates were coded for the 
presence or absence of each resistance phenotype, resistance gene, or virulence gene 
considered in the analysis (Table 9.3). Summary categories for being positive for any 
virulence factor, for resistance to any antimicrobial, for any resistance gene, for 
resistance to multiple antimicrobials, or for multiple resistance genes were established. 
 
 Minimum inhibitory concentration results were classified according to the 
Veterinary Drug Directorate (VDD), Health Canada Guidelines (CIPARS, 2006). To 
facilitate consistent comparisons with the Canadian Integrated Program for 
Antimicrobial Resistance Surveillance (CIPARS) the same nomenclature for patterns of 
resistance were used (CIPARS, 2006). Multiple resistance was defined as resistance to 
≥2 antimicrobials. 
 
Unconditional associations for being positive for either phenotypic or genotypic 
AMR and the presence of the three virulence factors of interested were investigated 
using generalized estimating equations (GEE) to account for clustering within herd 
(SAS v.8.2 for Windows (PROC GENMOD); SAS Institute, Cary, North Carolina, 
USA). Model specifications included a binomial distribution, logit link function, 
repeated statement with subject equal to herd, and an exchangeable correlation 
structure. All variables investigated are listed in Table 9.3.  
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Multiple comparisons were accounted for using a Bonferroni correction to provide a 
conservative estimate for the level of statistical significance (Dohoo et al., 2003) An 
association was significant if P<0.003 after correction for 14 comparisons (P < 0.05/k, k 
= number of comparisons) (Dohoo et al., 2003).  
 
Because no statistically significant associations were identified, post hoc power was 
estimated to determine whether the sample size was adequate to detect an important 
association between tetracycline resistance and the presence of the stx2 and eae in these 
106 isolates (EPI Info 6 ver 6.04d, CDC, USA, Fleiss et al., 2003). 
 
9.3. Results 
 
9.3.1. Description of sample population examined in AMR and virulence study 
 
The median age of calves sampled for this study was 6 days with a range of 1 to 120 
days and the dams for these calves ranged from 2 to 13 years with a median of 5 years. 
Of the 106 calves sampled, 58% (61/106) were male and 92% (98/106) were healthy. 
 
9.3.2. Phenotypic antimicrobial susceptibility in the selected isolates 
 
Ranges of observed minimum inhibitory concentrations (MICs) for the 106 isolates 
selected for study are summarized for each antimicrobial in Figure 9.2. The individual 
antimicrobials to which resistance was most commonly observed were tetracycline, 
sulphamethoxazole, and streptomycin (Table 9.4). Twenty-seven different resistance 
 292 
patterns were represented in this sample. One isolate was resistant to 10 different 
antimicrobials. The most common AMR patterns detected included a grouping of 
streptomycin, sulphamethoxazole, and tetracycline (n=28, 27%) while the second most 
common grouping was sulphamethoxazole and tetracycline (n=14, 13%).  
 
9.3.3. Resistance Genes 
 
The most common resistance patterns detected phenotypically were also detected 
genotypically. Tetracycline resistance gene tetB, sulphonamide resistance gene sulII 
and streptomycin/spectinomycin gene aada1 were the most common resistance genes 
detected (Table 9.5). A total of 35 different multiple resistance gene combinations were 
identified.  For multi-resistance gene isolates, the median number of resistance genes in 
the observed patterns was 3 with a maximum of 11. The most common resistance gene 
combinations detected included both sulphonamides (sulII) and tetracycline (tetB) 
(n=30). The next most common pattern (7 isolates) contained a grouping of aph(3’)-Ia, 
ant (3”)Ia (aadA1), tetB, catI, dfri, sulI and sulII.  
 
9.3.4. Shiga-toxin producing E. coli (STEC) virulence genes 
 
Of the 106 isolates examined, about half contained at least one virulence gene of 
interest (Table 9.6).  The most common virulence gene detected was stx2. About a 
quarter of isolates (26.3%) contained all three virulence factors. 
 
 293 
9.3.5. Association between AMR and virulence factors 
 
Approximately half of the isolates were resistant to at least one antimicrobial and 
were also carrying at least one of the virulence genes examined (Table 9.7). Phenotypic 
resistance was not significantly associated with the presence of stx1, stx2, or eae 
(P>0.003) (Table 9.8).  
 
 About half of the isolates were positive for both virulence and resistance genes 
(Table 9.9), but the proportion of isolates containing specific virulence and resistance 
genes varied between 0 and 100%.The most common virulence gene detected in isolates 
with at least one resistance gene or with multiple (≥2) resistance genes was stx2.  No 
significant associations (P>0.003) were detected between any of the resistance genes 
and stx1, stx2, or eae (Table 9.10).  
 
9.3.6. Post hoc assessment of study power 
 
With the current data, a 2.5 fold difference between isolates with or with out 
tetracycline resistance that were stx2 positive, could have been detected with 95% 
confidence and >80% power. For eae, the minimum difference that could have been 
detected in the occurrence of eae positive isolates that were or were not resistant to 
tetracycline was 3.0 fold with 95% confidence and >80% power.  The actual difference 
was only 1.6 and 1.5 times respectively (Table 9.7), therefore study power was not 
sufficient to detect a significant difference if one was present at this low level but it was 
sufficient to detect a moderate difference. 
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9.4. Discussion 
 
The primary objective of this study was to assess the association between AMR and 
the occurrence of stx1, stx2 and eae in E. coli isolates collected from cow-calf herds. No 
significant associations were detected between any of the AMR phenotypes or 
genotypes and virulence factors in this population of healthy beef calves. Resistant 
isolates were no more likely to have STEC virulence factors than susceptible isolates. 
 
 Even though virulence genes and AMR can be transmitted in a similar fashion, and 
associations between certain virulence genes and AMR have been detected in isolates 
from swine samples (Boerlin et al., 2005), there was no significant association detected 
between AMR and the virulence genes examined in this study.  The lack of association 
might be due to how these virulence and resistance genes are transmitted.  Most stx 
genes are thought to be encoded on bacteriophage genomes integrated into the bacterial 
chromosome (O’Brien et al., 1984, Acheson et al., 1998, Neely and Freidman, 1998, 
Muneisa et al., 2000).  During transduction, DNA from a bacteriophage is interjected 
into a host cell where it can lead to the production of new phage particles (Schwartz et 
al., 2006). Subsequent replication of phage DNA and repackaging into new phage 
particles ultimately leads to the ability of these particles to be released (Schwartz et al., 
2006). The primary limitations of transduction are the amount of DNA that can be 
incorporated into a phage head and the requirement for a specific receptor for phage 
attachment (Schwartz et al., 2006). Specificity of bacteriophages results in this 
mechanism of AMR transfer being relatively unimportant (Prescott, 2000). Therefore, 
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the lack of association between AMR and the stx virulence genes is not unexpected. No 
significant association between the virulence gene eae and AMR is probably the result 
of eae being carried chromosomally (Kaper et al., 1998), while many of the resistance 
genes investigated are often located on plasmids (Schwartz et al., 2006). 
 
In contrast to our findings, where resistance was detected in equal proportions of 
STEC positive and STEC negative isolates, Bettleheim et al. (2003) reported higher 
levels of resistance in non-STEC than in STEC isolates, regardless of source. The main 
difference between these two studies was the sampling frame. The Bettleheim (2003) 
study included bovine, porcine, ovine, and human samples from both healthy and 
diseased animals and people, with the majority of AMR in non-STECs identified in 
porcine, symptomatic human and healthy baby samples. The bovine samples in the 
Betteleheim (2003) study that were both STEC positive and resistant were collected 
from diagnostic samples. Sick cattle have been reported to have higher levels of 
resistant STEC than healthy cattle (Gonzalez and Blanco, 1989, Bettleheim et al., 
2003). One possible reason for this is that sick animals are more likely to have been 
treated with antimicrobials, potentially creating an environment more favorable for 
resistant populations as a result of selection pressure. Additionally, some selective 
advantage might be provided to bacteria that are also carrying virulence genes. Further 
research is needed to assess if the association between virulence factors stx1, stx2 and 
eae and AMR are different in healthy and sick cattle.  
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Previous reports that primarily focus on the prevalence of AMR in STEC positive 
isolates (Galland et al., 2001, Zhao et al., 2001, Maidhof et al., 2002, Schroeder et al., 
2002, Mora et al., 2005) cannot be directly compared to the current study because 
isolates were selected for this study based on AMR status. The proportion of resistant 
isolates does not represent the background frequency in the source population. 
However, the primary objective of this study was not to describe the prevalence of 
AMR genotypes and phenotypes, but to address the relationship between AMR and 
stx1, stx2, and eae. Post hoc power calculations suggested there was sufficient power to 
detect important associations between the most common resistances and STEC 
virulence factors in this sample. 
 
The proportion of STEC gene positive isolates can be considered in relation to 
previous research since AMR and virulence are not related and, therefore, the 
proportion of virulence genes detected should not have been biased as a result of isolate 
selection. The proportion of STEC gene positive isolates is similar to what has been 
previously reported by researchers investigating STECs in healthy adult beef cattle in 
Brazil (53% STEC) (Cerqueira et al., 1999), in healthy dairy calves in Japan (46% 
STEC) (Koybayashi et al., 2001), and from both sick and healthy animals and people in 
Australia (48% STEC) (Bettleheim et al., 2003). Our results differ from studies on 
healthy calves in Spain (23% STEC) (Blanco et al, 1996), healthy cattle at slaughter in 
France (70%) (Rogerie, et al., 2001), and healthy bulls, dairy and beef cows in France 
(18% STEC) (Pradel et al, 2000). 
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The most prevalent of all of the virulence genes detected in the current study was 
stx2. Other studies have reported that stx2 and eae are more often associated with severe 
human disease than stx1 (Boerlin, et al., 1999).  Further investigation into the serotypes 
of these isolates would be important to determine their potential impact on human 
health. 
 
The STEC prevalence in cattle can be influenced by many factors including 
sampling and detection methods adopted (Caprioli et al., 2005), potentially accounting 
for the wide range of reported prevalences.  Additionally, the proportion of animals 
shedding stx genes also appears to vary with other factors including, animal age, and 
season (Cray and Moon, 1995, Chapman et al., 1997, Hancock et al., 1997, Hancock et 
al., 1998, Shinagawa et al., 2000, Paiba, et al., 2003). 
 
While the literature does contain information on the proportion of resistant STEC 
isolates from a variety of populations including samples from healthy and diseased 
cattle, sheep, pigs, people, and food  (Gonzalez and Blanco, 1989, Galland et al., 2001, 
Zhao et al., 2001, Maidhof et al., 2002, Schroeder et al., 2002, Betteleheim et al., 2003, 
Mora et al., 2005), we are unaware of other work that has investigated whether there is 
an association between AMR, measured both phenotypically and genotypically, and the 
virulence genes stx1, stx2, and eae.  This work demonstrates that AMR is not any more 
likely in STEC positive isolates than in STEC negative isolates in this population of 
health beef calves. 
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Figure 9.1.  Schematic of number of samples, number of isolates and number of farms 
for each age group of animals investigated  
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Figure 9.2.  Minimum inhibitory concentration distribution for 106 isolates tested for antimicrobial sensitivity using Sensititre 2002 
NARMS CMV7CNCD plate configuration. Numbers are presented as a percentage of the total isolates (n=106). 
 
Roman numerals I-IV indicate the ranking of human importance, VDD. The un-shaded fields indicate the range tested for each 
antimicrobial in the 2002 plate configuration. Vertical double bars indicate the breakpoints and highlighted cells locate the median. 
Numbers in bold font are the number of isolates with growth in all wells within the tested range, indicating the actual MIC is greater 
than that range of dilutions. 
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Table 9.1. Antimicrobial family, genetic marker, primer sequence, GenBank accession number and DNA source for resistance genes 
tested. 
 
PCR primer sequence (5'-3') 
 
Source of DNA Antimicrobial 
family 
Genetic marker 
Forward Reverse 
Amplicon 
size (bp) 
Positive 
control 
 
Beta-lactams blaTEM GAGTATTCAACATTTTCGT ACCAATGCTTAATCAGTGA 857  R. C. Levesque 
 blaSHV TCGCCTGTGTATTATCTCCC CGCAGATAAATCACCACAATG 768  R. C. Levesque 
Aminoglycosides aac(3)-Iia 
(aacC2) 
CGGAAGGCAATAACGGAG TCGAACAGGTAGCACTGAG 740  D. Sandvang 
 aac(3)-IV GTGTGCTGCTGGTCCACAGC AGTTGACCCAGGGCTGTCGC 627  J. Harel 
 aph(3')-Ia 
(aphA1) 
ATGGGCTCGCGATAATGTC CTCACCGAGGCAGTTCCAT 600  J. Harel 
 aph(3')-Iia 
(aphA2) 
GAACAAGATGGATTGCACGC GCTCTTCAGCAATATCACGG 680  J. Harel 
 Ant(3”)-
Ia(aadaI) 
     
 Ant(3”)-If 
(aada6) 
     
Tetracycline Tet(A) GTGAAACCCAACATACCCC GAAGGCAAGCAGGATGTAG 888  J. Harel 
 Tet(B) CCTTATCATGCCAGTCTTGC ACTGCCGTTTTTTCGCC 774  J. Harel 
 Tet(C) ACTTGGAGCCACTATCGAC CTACAATCCATGCCAACCC 881  J. Harel 
Phenicols catI AGTTGCTCAATGTACCTATAACC TTGTAATTCATTAAGCATTCTGCC 547  J. Harel 
 floR CGCCGTCATTCCTCACCTTC GATCACGGGCCACGCTGTGTC 215  D. G. White 
Trimethoprim dhfrI AAGAATGGAGTTATCGGGAATG GGGTAAAAACTGGCCTAAAATTG 391  J. Harel 
 Dhfr1b      
 dhfrV CTGCAAAAGCGAAAAACGG AGCAATAGTTAATGTTTGAGCTAAAG 432  O. Sköld 
 dhfrVII GGTAATGGCCCTGATATCCC TGTAGATTTGACCGCCACC 265  O. Sköld 
 dhfrIX TCTAAACATGATTGTCGCTGTC TTGTTTTCAGTAATGGTCGGG 462  C. Wallen 
 dhfrXII      
 dhfrXIII CAGGTGAGCAGAAGATTTTT CCTCAAAGGTTTGATGTACC 294  P. V. Adrian 
 dhfrXV      
Sulphonamides sulI TTCGGCATTCTGAATCTCAC ATGATCTAACCCTCGGTCTC 822  R. C. Levesque 
 sulII CGGCATCGTCAACATAACC GTGTGCGGATGAAGTCAG 722  J. Harel 
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Table 9.2.  Primer name, primer sequence, length, positive controls used and the reference for each virulence factor tested 
 
 PCR primer sequence (5'-3')    
Virulence 
factor 
 
Forward Reverse 
Amplicon  
Size (bpa) 
E. coli 
+ control Reference 
eae ATCTTCTGCGTACTGCGTTCA CATTATGGAACGGCAGAGGT 790 STJ348/O157:H7 Beudry (1996) 
stx1 TTAGACTTCTCGACTGCAAAG TGTTGTACGAAATCCCCTCTG 530 STJ348/O157:H7 Woodward (1992) 
stx2 CTATATCTGCGCCGGGTCTG AGACGAAGATGGTCAAAACG 327 STJ348/O157:H7 Woodward (1992) 
abp =base pairs 
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Table 9.3. Investigation into the association between AMR phenotypes and virulence factors and between AMR resistance 
genes and virulence factors  
 
 
Response variables  
 
Risk factors for phenotype 
 
 
Risk factors for genotype 
Eae Ampicillin blaTEM  
stx1 and stx2 Amoxicilln/Clavulanic Acid aph(3’)-Ia  
stx2 Cefoxitin  ant(3”)Ia (aada1)  
+ for any virulence factor Cephalothin  tetA, tetB, tetC 
 Chloramphenicol  catI, floR  
 Kanamycin   dhfrI, dhfrXII 
 Streptomycin  sul1, sul2  
 Tetracycline  AMR gene + 
 Sulphamethoxazole  Multiple AMR gene + (≥2 genes) 
 Trimethoprim/Sulpha    
 AMR +   
 Multiple AMR + (≥2 antimicrobials)  
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Table 9.4.  Prevalence of AMR phenotypes in the study samples (n=106) 
 
Antimicrobial 
 
% Positive 
(# positive / total isolates) 
Amikacin 0 
Amox/Clav. 6.6 (7/106) 
Ampicillin 32.1 (34/106) 
Cefoxitin 6.6 (7/106) 
Ceftiofur 1.9 (2/106) 
Ceftriaxone 0 
Cephalothin 7.5 (8/106) 
Gentamicin 1.9 (2/106) 
Kanamycin 28.3 (30/106) 
Streptomycin 67.0 (71/106) 
Chloramphenicol 25.5 (27/106) 
Ciprofloxacin 0 
Naladixic acid 0 
Sulphamethoxazole 82.1 (87/106) 
Tetracycline 86.7 (92/106) 
Trimethoprim/Sulpha 29.2 (31/106) 
AMR +  88.7 (94/106) 
Multiple AMR + 
(≥2 antimicrobials) 85.8 (91/106) 
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Table 9.5. Prevalence of AMR genotypes in the study sample (n=106) 
 
Antimicrobial  
 
Resistance genes 
 
 % Positive   
(# positive/total isolates)  
Ampicillin blaTEM 32.1 (34/106) 
 blaSHV 0  
Gentamicin aac(3)-IV 0.9 (1/106) 
 ant(2")-Ia 0 
 aac(3)-Iia 0 
Neomycin/Kanamycin aph(3')-Ia 34.0 (36/106) 
 aph(3")-Iia 0 
Streptomycin/spectinomycin ant(3")Ia (aadA1) 34.9 (37/106)
 ant(3")If (aadA6) 0 
Tetracycline (tet) tetA 17.9 (19/106) 
 tetB 72.6 (77/106) 
 tetC 2.8 (3/106) 
Chloramphenicol  catI 24.5 (26/106) 
 floR 4.7 (5/106) 
Trimethoprim (TMP) dhfrI 31.1 (33/106) 
 dhfrIb 1.9 (2/106) 
 dhfrV 1.9 (2/106) 
 dhfrVII 0.9 (1/106) 
 dhfrIX 0 
 dhfrXII 3.8 (4/106) 
 dhfrXIII 0.9 (1/106) 
 dhfrXV 0 
Sulphonamides (sulpha) sulII 25.5 (27/106) 
 sulII 75.5 (80/106) 
Gene + AMR   89.6 (95/106) 
Multi-gene + (≥2 genes)  84.9 (90/106) 
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Table 9.6. Crude prevalence of virulence factors in the study samples and prevalence adjusted for clustering at the herd level  
with the 95% CI (n=106) 
 
   95 % CI    
Virulence Factor Prevalence (%) (# positive/total)
Predicted 
prevalence  
adjusted 
for clustering 
 
Lower 
 
 
Upper 
 
eae 
 (%) 
stx2  
(%) 
stx1and stx2 
(%) 
eae 17.9 (19/106) 18.0 11.3 27.3 19 (100.0) 10 (52.6) 5 (26.3) 
stx2 41.5 (44/106) 38.9 28.9 50.0 10 (22.7) 44 (100.0) 19 (43.2) 
stx1/stx2 17.9 (19/106) 17.2 10.7 26.5 5 (26.3) 19 (100.0) 19 (100.0) 
Virulence factor + 50.0 (53/106) 48.1 37.7 58.7 19 (35.8) 44 (83.0) 19 (35.8) 
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Table 9.7. The number of isolates resistant to each antimicrobial investigated and the number (percent) of isolates resistant and 
positive for each virulence factor (n=106) 
 
` 
 # of isolates resistant 
to each  
antimicrobial 
eae  
(%) stx2 (%) Stx1 and stx2 (%) 
Virulence  
factor + 
Amikacin 0 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Amox/Clav. 7 2 (28.6) 5 (71.4) 3 (42.9) 5 (71.4) 
Ampicillin 34 6(17.6) 15 (44.1) 9 (26.5) 15 (44.1) 
Cefoxitin 7 2 (28.6) 4 (57.1) 3 (42.9) 4 (57.1) 
Ceftiofur 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Ceftriaxone 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Cephalothin 8 2 (25.0) 4 (50.0) 3 (37.5) 4 (50) 
Gentamicin 2 1 (50.0) 2 (100.0) 0 (0.0) 2 (100.0) 
Kanamycin 30 5 (16.7) 12 (40.0) 6 (20.0) 13 (43.3) 
Streptomycin 71 15 (21.1) 32 (45.1) 14 (19.7) 38 (53.5) 
Chloramphenicol 27 5 (18.5) 14 (51.9) 6 (22.2) 15 (55.6) 
Ciprofloxacin 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Naldixic Acid 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Sulphamethoxazole 87 16 (18.4) 40 (46.0) 16 (18.4) 46 (52.9) 
Tetracycline 92 17 (18.5) 40 (43.5) 17 (18.5) 47 (51.1) 
Trimethoprim/Sulphamethoxazole 31 4 (12.9) 14 (45.2) 6 (19.4) 15 (48.4) 
AMR + 94 17 (18.1) 41 (43.6) 17 (18.1) 48 (51.1) 
Multi AMR + (≥2 antimicrobials) 91 91 (17.6) 40 (44.0) 16 (17.6) 46 (50.5) 
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Table 9.8.  Unconditional associations between AMR phenotypes and virulence factors eae, stx1 and stx2 together, and stx2 (n=106) 
 
 
eae 
 
stx1 and stx2 
 
stx2 
 
  95% CI   95% CI   95% CI  
Antimicrobial OR Lower Upper P-value OR Lower Upper P-value OR Lower Upper P-value 
Ampicillin 0.98 0.36 2.71 0.97 1.91 0.67 5.45 0.23 1.04 0.41 2.61 0.94 
Cefoxitin 1.97 0.43 8.93 0.38 4.52 1.08 18.91 0.04 2.37 0.62 9.05 0.21 
Ceftiofur - - - - - - - - - - - - 
Ceftriaxone - - - - - - - - - - - - 
Cephalothin 1.70 0.41 7.00 0.46 2.86 0.55 14.84 0.21 1.33 0.28 6.32 0.72 
Gentamicin - - - - - - - - - - - - 
Kanamycin 0.91 0.32 2.57 0.86 1.11 0.33 3.76 0.87 0.84 0.36 1.95 0.69 
Streptomycin 2.36 0.89 6.28 0.09 1.28 0.37 4.47 0.70 1.39 0.62 3.11 0.43 
Chloramphenicol 1.01 0.32 3.15 0.99 1.25 0.38 4.06 0.72 1.43 0.58 3.52 0.43 
Sulphamethoxazole 1.41 0.42 4.69 0.57 1.14 0.32 4.12 0.84 3.10 1.11 8.70 0.03 
Tetracycline 1.50 0.38 5.92 0.56 1.01 0.22 4.73 0.99 1.62 0.52 5.07 0.41 
Trimethoprim/Sulpha 0.60 0.18 1.98 0.40 1.03 0.34 3.10 0.96 1.05 0.44 2.53 0.92 
AMR + 1.22 0.31 4.83 0.77 0.79 0.17 3.70 0.77 1.92 0.55 6.68 0.31 
Multiple AMR + 
(≥2 antimicrobials) 0.95 0.31 2.92 0.92 0.68 0.19 2.44 0.56 1.82 0.62 5.29 0.27 
- would not converge 
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Table 9.9.  The number of isolates positive for each resistance gene and the number 
(percent) of isolates positive for the resistance gene and the virulence factor (n=106) 
 
Antimicrobial Family Resistance Genes 
Isolates 
positive 
for each 
gene  
Eae  
(%) 
stx2 
(%) 
stx1 and 
stx2 
(%) 
positive  
for any 
virulence 
factor 
(%) 
β-lactams blaTEM 34 5 (14.7) 15 (44.1) 7(20.6) 15 (44.1) 
Gentamicin aac(3)-IV 
 
1 
 
1 (100.0) 1 (100.0) 0  (0.0) 1 (100.0) 
Neomycin aph(3')-Ia 36 6  (16.7) 15 (41.7) 7 (19.4) 16 (44.4) 
Streptomycin aadA1  37 5  (13.5) 19 (51.4) 9 (24.3) 20 (54.1) 
Tetracycline tetA 19 3  (15.8) 12  (63.2) 6 (31.6) 12 (63.2) 
 tetB 77 15 (19.5) 31 (40.3) 13 (16.9) 37 (48.1) 
 tetC 3 0 (0.0) 2 (66.7) 0 (0.0) 2 (66.7) 
Chloramphenicol catI 26 2 (7.7) 12 (46.2) 4 (15.4) 13 (50.0) 
 floR 5 1 (20.0) 3 (60.0) 0 (0.0) 3  (60.0) 
Trimethoprim dhfrI 33 4 (12.1) 15 (45.5) 6 (18.2) 16 (48.5) 
 dhfrIb 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 dhfrV 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 dhfrVII 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 dhfrXII 4 2 (50.0) 2 (50.0) 1 (25.0) 2 (50.0) 
 dhfrXIII 1 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0) 
Sulphonamides sulI 27 2 (7.4) 13 (48.1) 4 (14.8) 14 (51.9) 
 sulII 80 16 (20.0) 33 (41.3) 12 (15.0) 39 (48.8) 
Gene + for AMR  95 17 (17.9) 40 (42.1) 17 (17.9) 47 (49.5) 
Multi-gene + for AMR 
(≥2 genes)  90 16 (17.8) 38 (42.2) 15 (16.7) 44 (48.9) 
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Table 9.10. Unconditional associations between AMR genotypes and virulence factors eae, stx1 and stx2 together, and stx2 (n=106) 
 
 
 eae stx1 and stx2 stx2 
  
 
95% CI   95% CI   95% CI  
AMR gene OR Lower Upper P-value OR Lower Upper P-value OR Lower Upper P-value 
Blatem 0.39 0.25 2.09 0.55 1.14 0.40 3.24 0.81 1.06 0.47 2.39 0.89 
cat1      0.28 0.06 1.25 0.10 0.66 0.14 3.04 0.59 1.01 0.36 2.84 0.99 
floR      1.05 0.09 11.9 0.97 - - - - 2.33 0.29 19.0 0.43 
aph(3’)-Ia      0.90 0.34 2.38 0.83 1.20 0.41 3.46 0.74 0.99 0.50 1.97 0.99 
Aada1   0.59 0.19 1.83 0.36 1.88 0.67 5.25 0.22 1.77 0.77 4.04 0.18 
tetA 0.84 0.21 3.41 0.81 2.53 0.80 8.01 0.11 3.02 0.97 9.42 0.06 
tetB       1.67 0.44 6.33 0.45 0.76 0.23 2.52 0.66 0.76 0.31 1.88 0.55 
tetC - - - - - - - - 3.98 0.26 60.1 0.32 
sulI 0.27 0.06 1.28 0.10 0.64 0.13 3.04 0.57 1.16 0.44 3.06 0.77 
sulII      2.09 0.64 6.86 0.23 0.51 0.17 1.60 0.25 1.07 0.46 2.50 0.88 
dhfr1 0.54 0.17 1.70 0.29 0.94 0.31 2.91 0.92 1.10 0.47 2.59 0.83 
dhfrxII      5.02 1.05 23.9 0.04 1.49 0.25 8.74 0.66 1.61 0.32 7.99 0.56 
AMR gene + 1.02 0.28 3.78 0.97 0.80 0.14 4.46 0.80 0.98 0.31 3.04 0.97 
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CHAPTER 10 
SUMMARY AND CONCLUSIONS 
 
10.1 Introduction 
 
Despite the continued focus on the importance of antimicrobial resistance (AMR) 
and antimicrobial use (AMU) by the scientific community and the general public, there 
is still a need for more information. Although there have been strides in developing a 
greater understanding of this complex subject, especially with the introduction of 
molecular techniques, there are still many unanswered questions. In an attempt to fill in 
some of the gaps surrounding the issue of AMR in agriculture, a study of AMR and 
AMU in western Canadian cow-calf herds was launched. This investigation had three 
primary hypotheses. First, that AMR would be infrequently detected in fecal generic 
Escherichia coli isolates from cow-calf herds because these animals are extensively 
managed relative to most other livestock commodities. Second, routine AMU is 
uncommon in most cow-calf operations and that AMR would be associated with AMU. 
Third, associations between AMR genes would support evidence of co-selection of 
unrelated resistance genes and virulence factors. Specific objectives were then designed 
to address these questions. 
 
The study was successful in fulfilling its objectives; specifically it describes 
prevalence and patterns of AMR in the different age groups commonly found on cow-
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calf farms, it identifies some of the risk factors associated with AMR development in 
calves, it describes common reasons for treatment and the types of antimicrobials used 
on cow-calf farms, it provides an initial description of  the relationships between AMR 
phenotype and AMR genes, between AMR genes, and between AMR and specific 
virulence factors.  
 
10.2 Summary of highlights from each chapter 
 
10.2.1. Antimicrobial use study 
 
This AMU study provides some of the first documentation of AMU and reason for 
treatment in extensively managed cow-calf herds during calving season. At least 86% of 
the herds treated one or more calves or cows during the study period; however, the 
overall proportion of both calves and cows reported as treated was less than 14% for 
calves and 3% for cows.  This relatively small proportion of treated animals is 
consistent with the finding that the majority of antimicrobials reported as used in cow-
calf operations were for individual therapeutic use rather than prophylaxis, 
metaphylaxis, or growth promotion.  
 
Although some oral antimicrobials were used; injectable formulations were the most 
commonly reported method of antimicrobial administration on cow-calf farms. In feed 
AMU was uncommon, ionophores were incorporated into the feed of cows and/or 
heifers on 25% (58/203) of the farms but no other in-feed AMU was reported in these 
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herds. This varies from poultry, feedlot or swine operations where in feed use plays a 
larger role in antimicrobial delivery (McEwen and Fedorka-Cray, 2002, Rajic, 2006).  
 
The most commonly used products in cows were long acting injectable 
oxytetracyclines and penicillins. Injectable and oral sulphonamides, injectable 
florfenicol, and injectable oxytetracyclines were the primary drugs selected for 
treatment of calves. Of these products, oxytetracyclines, penicillins, and sulphonamides 
are readily available over the counter from farm supply outlets, and local feed 
companies as well as from the veterinarian. Ease of access and the relatively low cost of 
these products may be the reasons why these are the most commonly used 
antimicrobials in cow-calf herds.  Alternatively, some producers reported the use of 
antimicrobials not specifically formulated or registered for use in cattle and/or the 
administration of drugs registered for use in cattle for purposes other than that for which 
they were registered.  
 
Calves were more likely to be reported as treated than cows and heifers (13.5% vs 
2.7%), and the primary reason reported for calf treatment was diarrhea. When 
considering risk factors associated with whether a calf was ever treated, male calves 
were more likely to be treated than female calves, and calves for which manipulation or 
traction was applied during calving were more likely to be reported as treated than 
calves that did not require assistance. The odds of calf treatment also increased with 
increased reports of cow treatment in the same herd. 
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In the cows and bred heifers the primary reported reason for treatment from January 
to June was metritis followed closely by interdigital necrobacillosis. Cows and bred 
heifers were more likely to be treated if they were assisted at the time of calving, or if 
they experienced post calving problems such as uterine prolapse, retained fetal 
membranes, or metritis. Cows and bred heifers for which manipulation, traction, or 
caesarian section were reported at calving were more likely to be treated than cows and 
bred heifers that did not require assistance at calving.  
 
10.2.2. Prevalence study 
 
In order to study the prevalence of AMR in cattle from western Canadian cow-calf 
herds, fecal samples were collected from calves in the spring and fall of 2002, from 
cows in the spring of 2002, and from cow-calf pairs in the spring of 2003. E. coli was 
used as an indicator organism. Resistance to drugs classified as very important to 
human medicine by the Veterinary Drug Directorate were infrequent in all age classes 
at all sampling points. From this sampling frame it was apparent that, while younger 
animals were much more likely to be positive for AMR, isolates from all age classes 
demonstrated the most resistance to the same group of antimicrobials. The data also 
indicated that the cow-calf pair relationship was not an important factor in transfer of 
AMR. 
 
Resistance to most of the newer generation antimicrobials was infrequent. 
Resistances to drugs that are classified as very important in human medicine, by the 
Veterinary Drug Directorate, Health Canada, were detected in less than 1% of the 
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isolates. Additionally for the majority of drugs tested, the median MICs were well 
below the breakpoint for resistance for all age groups of animals investigated. Median 
MICs that are several dilutions below the breakpoint indicate that at the time of testing, 
most of the E. coli population in these animals were highly sensitive to those particular 
drugs.  
 
Increased prevalence of AMR in young calves has also been described by other 
researchers (Brophy et al., 1977, Hinton et al., 1984, Hinton, 1985, Mathew et al., 1999, 
Khachatryan et al., 2004). The prevalence of AMR differed significantly among the age 
groups sampled. When comparing the prevalence of resistance to any antimicrobial, 
young calves sampled in the spring of 2002 were almost 10 times more likely to have 
AMR isolates than older calves sampled in the fall of the year. A comparable trend was 
detected for the cow and young calf data. Young calves were 7 to 10 times more likely 
to be resistant to any antimicrobial than were cows. However, there was no difference 
detected in AMR prevalence between cows sampled in the spring 2002 and calves 
sampled in the fall of 2002. 
 
Despite differences in the magnitude of AMR in the different age groups, the three 
most common resistances detected were to tetracycline, sulphamethoxazole, and 
streptomycin. This is similar to what others have reported for E. coli isolates collected 
from dairy cattle as well as for a variety of other animal species (Kijima-Tanaka et al., 
2003, Bywater et al., 2004, Khachatryan et al., 2004). For all other drugs tested, isolates 
had varying degrees of resistance depending on the age group from which they were 
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collected. Despite the ban of chloramphenicol use in livestock in Canada, 
chloramphenicol resistance was still consistently detected in all of the age groups 
examined.  
 
The cow-calf pair relationship was not a significant determinant of transmission of 
resistance to the calf (P=0.36). AMR was detected in both the cow and the calf in only 5 
(4.8%) pairs, of the 105 examined. While the pair relationship did not seem to be an 
important determinant of AMR in the calf population the presence of AMR in the cow 
herd was associated with AMR in the calves.  For the herds that had both cow and calf 
samples collected in the spring of 2002, the odds that that calves would be resistant to 
sulphamethoxazole or tetracycline increased with the proportion of cows that were 
resistant to sulphamethoxazole (OR, 7.5, P=0.02) or to tetracycline (OR, 6.1; P=0.01) 
respectively. These findings indicate that the individual cow is not the primary 
determinant of the AMR status of her calf, but that the frequency of common types of 
resistance in the calves is associated with exposure from the cow herd or from 
contamination of the environment by the cow herd. 
 
10.2.3. Risk factor study 
 
Vaccination practices and the use of most antimicrobials in these herds was not 
significantly associated with the frequency of AMR in commensal E. coli isolated from 
calves. Herd use of sulbactum:ampicillin and gentamicin were, however, identified as 
risk factors for the incidence of antimicrobial resistance for several unrelated 
 324 
antimicrobials. These findings suggested the need to explore the potential importance of 
co-selection at the molecular level in these isolates. 
 
10.2.4. Molecular studies 
 
Assessment AMR at the genetic level is an important tool in the understanding and 
the control of AMR (Lanz et al., 2003). This study demonstrated the importance of 
characterizing resistance in generic E. coli using both phenotypic and genotypic 
methods. It is apparent that the relationships between phenotypes and resistance genes 
are extremely complicated. The extensive number of relationships between individual 
AMR phenotypes or specific resistance patterns and individual resistance genes or gene 
families suggests that there must be extensive linkage, and that there is a high 
probability of co-selection when one type of resistance is perpetuated. The type of 
linkages may be secondary to bringing attention to the message that AMR selection is 
not an independent process, but that there are numerous associations between resistance 
to individual antimicrobials and resistance genes and among resistance genes. 
 
In addition to the expected associations between phenotypic resistance to specific 
antimicrobials and their respective resistance genes, numerous other associations were 
detected. Some of the strongest associations were observed between ceftiofur and floR 
chloramphenicol and dhfrI, trimethoprim sulfamethoxazole and catI, and tetracycline 
and sulII. Each type of phenotypic resistance examined was associated with genetic 
resistance to an average of five families of antimicrobials. Phenotypic resistance to 
streptomycin, tetracycline, and sulphamethoxazole were each associated with the 
 325 
presence of resistance genes from all six of the families of antimicrobials examined in 
this study. The strong association between phenotypic resistance and resistance genes 
from different families of antimicrobials may indicate gene linkage. 
 
The complex nature of AMR was also demonstrated by the large number of 
associations of moderate to substantial magnitude that were detected between resistance 
genes. Some of the strongest associations were between tetB and sulII, sulI and catI, 
sulI and aadA1, aadA1 and dhfrI, and catI and dhfrI. The streptomycin gene, aadA1, 
was significantly associated with at least one gene from all six families of 
antimicrobials investigated. SulII and tetB were strongly associated with each other, 
while sulI was strongly associated with both cat1 and aadA1. These associations may 
help indicate why certain phenotypic resistance patterns are seen within commensal E. 
coli and may warrant further molecular studies. 
 
10.2.5. Virulence and AMR 
 
The primary objective of this study was to assess the association between AMR 
measured by the presence both phenotype and genotype and the occurrence of stx1, stx2 
and eae in E. coli isolates collected from cow-calf herds in Western Canada. No 
significant associations were detected between any of the antimicrobial resistant 
phenotypes or genotypes and the virulence factors of interest. Resistant isolates were no 
more likely to have STEC virulence factors than sensitive isolates. 
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10.3. Study limitations 
 
A review of the limitations of this project suggested some areas where changes might 
be considered for future studies in cow-calf herds. The first limitation was that herd and 
individual animal selection was not random. Enrolled herds were a volunteer, 
convenience sub-set of herds already participating in a larger health and productivity 
study. Individual animal samples collected were also convenience samples. The lack of 
random selection for both herds and individual animals could result in selection bias 
and potentially affect the generalizability of the study. However, participant cooperation 
was necessary for the collection of quality data. The logistics of sampling specific 
animals, given the need for additional animal handling and significant time 
contributions from the producers, would not have been tolerated by the herd owners 
during calving season. For these reasons it would be difficult to implement a true 
random selection of either the herds or individual animals without considerable 
additional resources for personnel and incentives to the participants.  
 
From the Agriculture census in 2001, Statistics Canada reported that the average beef 
size for Canada was 53.  In Saskatchewan and Alberta the average herd sizes were 58 
and 74 beef cows per herd with 15 and 20 replacement heifers respectively.   The 
average study herd size of 180 is larger than that reported by Statistics Canada.  
Because herds were enrolled in the productivity study based on their ability to provide 
the required data, these herds probably represent some of the more progressive, 
commercially viable, and intensively managed herds in western Canada. The herds 
providing data for this thesis therefore represent the prevalence of AMR and AMU in 
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this sector of the industry. The prevalence of AMR and AMU may be different in the 
few very large cow-calf herds that receive little or no treatment interventions or the very 
small herds present on some mixed or hobby farms. 
 
The initial AMU data collected from the cow-calf herds in this study were limited. 
First, only treatment records from January until June were included in the analysis. The 
reason for limiting the records to this time frame was that this period covers the months 
that the herds would have been relatively confined and under observation for calving. 
The AMU records during this period were, therefore, more likely to be accurate and 
complete than records outside of this time frame. The time around calving also 
represents the period when the majority of AMU occurs in cow-calf herds and 
potentially the highest risk period for the development of AMR. The information 
reported can not be directly extrapolated outside the study period because risks and 
treatment practices differ at other times in the production cycle. For example, animals 
are much less likely to be treated for infectious bovine keratoconjunctivitis (pinkeye) 
during the winter months than during the summer and are very unlikely to be treated for 
metritis or other calving complications while on summer pasture.  
 
Although individual animal records were available for this period, details on the 
specific antimicrobials used and the dose given were not reported by most herd owners. 
The data collection forms were designed for a separate study and were not intended to 
be used for this purpose. The lack of specific AMU data precluded investigation into the 
relationship between specific antimicrobials and resistances in individual animals. This 
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limitation could be over come in future cow-calf studies with the careful design of 
treatment data capture instruments.  
 
Under-reporting is another potential issue in AMU data collection. In this project 
under-reporting of individual animal treatments was unknown, but data collection 
personnel estimated at least 20% of participating herd owners did not consistently 
complete individual treatment records. Under reporting could have resulted in 
misclassification of some treated animals as not treated. This would likely have biased 
the association between individual animal treatment and AMR towards the null. To 
supplement the individual treatment record information, an attempt was made to collect 
additional data on the type of antimicrobials used by administering a questionnaire at 
the end of calving season where producers reported the frequency of use of specific 
products for each herd. However, retrospective data collection as done here has the 
potential for recall bias.  
 
The risk factor paper was also limited by the manner in which the AMU data were 
collected. Because the proportion of calves treated and AMU data were summarized for 
the entire period and not relative to the time of sample collection on that farm, there is 
also the potential for misclassification bias of exposure relative to the time the outcome 
of interest was measured. The herd might have been considered exposed to a certain 
antimicrobial or antimicrobials, but that exposure may have been subsequent to the 
sample collection. To assess the effect of these limitations on the study, animal 
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exposure could be measured through individual treatment records that included the type 
of antimicrobial used, the date of use, and potentially the volume.  
 
The molecular aspects of this work were intended as an initial exploration of the 
utility of these methods to examining the question of co-selection in cow-calf herds.  
This part of the project was not intended to be exhaustive or to provide definitive 
answers on this problem. Isolate selection was based on resistance status to maximize 
study power to address association between phenotypic and genotypic resistance. The 
proportion of resistant isolates therefore does not represent the background frequency in 
the source population.  
 
The second limitation of the genetic study was that the diagnostic lab did not test for 
integrons or extended spectrum beta-lactamases. The latter would have been 
informative in light of findings by Read et al. (2005) in a recent feedlot study. Read et 
al. (2005) reported the presence of extended spectrum beta-lactamases carrying the 
blacmy2 beta-lactamase gene. This gene was associated with therapeutic use of 
florfenicol, oxytetracycline or tilmicosin at entry into the feedlot.  
 
From the genetic work and the risk factor analysis in the spring calves, co-selection 
of AMR appears to be a contributor to AMR patterns in cow-calf herds. Investigation 
into the presence of certain plasmids would therefore be useful.  
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Testing for hemolysin in addition to the other virulence factors would be interesting 
because the hemolysin virulence gene may be carried on plasmids with AMR genes. 
These additional molecular components should be included in any future studies of 
cow-calf herds. 
 
10.4. Conclusions 
 
Cow-calf herds are not a significant reservoir for AMR to antimicrobials classified as 
very important to human medicine such as ceftiofur. This is worth mentioning as cow-
calf farms are the most common type of livestock operation in western Canada. Finding 
limited resistance to antimicrobials of very high importance in human medicine 
indicates that at this time cow-calf herds do not pose a significant risk to human health. 
However, since there can also be the co-selection of underlying AMR genes, there is the 
possibility of AMR genes being perpetuated despite no phenotypic evidence of 
resistance.  Continued monitoring of both the phenotype and the underlying AMR genes 
would be needed to see if this pattern changes over time and with the availability of new 
antimicrobials. 
 
These data indicate that young calves have the highest prevalence resistant generic 
fecal E. coli in cow-calf herds. Since young calves shed the highest percentage of 
resistant organisms control should consider them as a source of AMR organisms. 
However, it is also important to recognize that while cows may shed a lower proportion 
of resistant isolates they also contribute more manure to the environment than do 
calves; therefore, they can not be ignored in developing on farm AMR control 
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programs. Additionally, given the similarity in the patterns of AMR observed across age 
groups, and the relationship between AMR in the cow herd and AMR in the calf 
population the cow herd is likely a reservoir of exposure for calves to resistant 
organisms. In order to develop a plan for AMR control, continued research is needed to 
understand why AMR is higher in very young calves and how the E. coli population 
changes after the spring and during the summer pasture season prior to weaning.  
 
Despite the limitations, this study does provide the first available documentation of 
the proportion of calves, heifers, and cows reported as treated during the calving season 
and the types of conditions most often treated for in a large number of western 
Canadian cow-calf herds. The study also provides some initial information about AMU 
practices in these herds which can be used to help address issues such as extra-label 
drug use, prophylactic treatment of entire calf crops, and the importance of minimizing 
dystocia in reducing the need for treatment of either cows or calves. 
 
Aside from the molecular interest in understanding AMR at the gene level, we can 
also consider the broader implications of the extensive number of associations detected 
between families of antimicrobials. The relationships between resistance genes allow us 
to begin to comprehend the magnitude and the complexity of the epidemiology of 
AMR.  The demonstration of this network of associations also brings into question the 
definition of “prudent use” and the impact of these associations on developing policy 
and clinical practice guidelines to minimize AMR. The implication is that current 
attempts to limit the emergence or spread of AMR based on careful restriction of the 
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choice of antimicrobials will not prevent selection for a number of unrelated AMR 
genes. Therefore, the assessment of AMR at the genetic level is a critical tool in the 
understanding and the potential control of AMR (Lanz et al., 2003). 
 
In addition to the antimicrobial selection pressure itself there are hundreds of 
bacterial genera and species interacting and adapting to many variables within an 
animal production system and, therefore, understanding the complete effects of AMR 
and AMU in these production systems is extremely complex (White and McDermott, 
2001). This study does provide insight into the farm-level treatment factors that can 
influence AMR found in cattle in cow-calf operations.  
   
This project demonstrated the level and type of resistance encountered on cow-calf 
farms as well as common risk factors for the presence of AMR. It also examined 
reasons for AMU in these herds. These data can be used by veterinarians and producers 
to incorporate specific interventions designed to minimize the need for AMU and to 
understand how certain practices may lead to increased AMR.  
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